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There is an urgent need for new antimicrobial agents as a result of the rapid rate 
of resistance emergence to available therapies, as well as to combat new and 
emerging diseases.  Natural products still provide a largely untapped resource of 
chemical entities with the potential for development into useful pharmaceuticals.   
On this basis, an investigation into the antimicrobial activities of South African 
lichens, desiccation-tolerant plants and the medicinal tree, Warburgia salutaris, 
was undertaken with the aim of investigating in vitro bioactivity.  Furthermore, this 
project aimed to evaluate in vivo pharmacokinetic profiles of the most bioactive 
constituents, as well as to investigate a method for determining lead-like 
properties earlier on in the drug development process.   
 
The crude acetone extract of the lichen, Teloschistes chrysophthalmum, 
exhibited the most potent activity against any organism, namely S. aureus (IC50 
of 1.1µg/ml).  The lichen metabolite , usnic acid, was identified in several extracts 
and was shown to have moderate antimalarial activity (IC50 of 15.1µg/ml).  Two 
anti-Staphylococcal compounds, L17-1 and L17-3, were isolated from T. 
chrysophthalmum  with IC50’s of 1.1 and 0.7µg/ml respectively against drug-
sensitive S. aureus and 11.1 and 11.4µg/ml against MRSA.  These compounds 
displayed very little cytotoxicity against the CHO cell line, with IC50’s of 81.0 and 
greater than 100µg/ml for L17-1 and L17-3 respectively and resultant favourable 
selectivity indices of 73.6 and greater than 142.9 respectively. 
 
Only two of the thirty extracts of the desiccation-tolerant plants inhibited organism 
growth at 125µg/ml or less.    The methanol extract of M. flabellifolius exhibited 
variable activity against C. albicans, initially as potent (<7.8µg/ml), but with a 
subsequent loss of activity.  Exhaustive fractionation failed to yield an active 
component.  Sequential extracts prepared from various parts of commercially 













exhibited potent antifungal and moderate antimycobacterial activity.  The most 
active extract, the DCM extract of the bark with an IC50 of 4.2µg/ml against C. 
albicans, was further fractionated, leading to the isolation of 19 pure or semi-pure 
compounds, three of which were identified as muzigadial, warburganal and 
ugandensidial.  These compounds and fractions displayed potent cytotoxicity, 
despite promising activity against C. albicans, making them unsuitable for further 
pharmacological investigation.   
 
The most promising hit compounds from in vitro testing were L17-1 and L17-3 
from the lichen, T. chrysophthalmum.  These two compounds were administered 
to mice together at 10mg/kg each, orally and subcutaneously, to determine which 
compound presented the best in vivo pharmacokinetic profile.  A method was 
developed for the detection of both compounds in a single assay from 10µl of 
mouse whole blood using sensitive LC-MS/MS technology, with the lowest level 
of detection being 24ng/ml.  The results of the initial in vivo testing revealed that 
L17-3 achieved greater levels in vivo, with a good Cmax concentration of 
14.5µg/ml after oral administration.  Subsequent administration of L17-3 alone at 
5mg/kg orally, subcutaneously and intravenously revealed that this compound 
has 40.7 and 41.7% oral and subcutaneous bioavailability respectively.  Oral 
administration of L17-3 resulted in a Cmax of 2.78µg/ml at a Tmax of 3.4 hours, with 
a resultant half-life of 2.98 hours.  No signs of in vivo toxicity were observed after 
oral or subcutaneous administration at either 5mg/kg or 10mg/kg.  L17-3 is an 
orally bioavailable compound, capable of reaching in vitro MIC levels (15.6µg/ml) 
in vivo, without toxicity,  with the distinct potential to clear a systemic S. aureus 
infection in vivo.  This project has emphasised the pharmacological potential of 
the largely unstudied lichen-derived compounds.   Furthermore, a method has 
been suggested for the selection of bioavailable natural product-derived 
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1.1 Infectious diseases and the need for new drugs 
Infectious diseases are responsible for an enormous amount of global morbidity 
and mortality.  Infection with the human immunodeficiency virus (HIV) has had a 
major impact on the occurrence and treatment of infectious diseases, particularly 
in southern Africa (Fauci, 2001; Madhi et al., 2000).  Compounding this problem 
has been the emergence of drug resistance, particularly in developing countries 
with high rates of infectious diseases and large populations living in crowded and 
unhygienic environments (Kunin, 1993).  In the case of respiratory infections, the 
organisms most frequently responsible are Mycobacterium tuberculosis, 
Moraxella catarrhalis, Haemophilus influenzae, Streptococcus pneumoniae and 
Staphylococcus aureus, Mycoplasma pneumoniae, Bordetella pertussis, 
Klebsiella pneumoniae, Pseudomonas aeruginosa and Proteus mirabilis 
(Ehrhardt and Russo, 2001; Porras, 1996). 
 
Infectious diseases are still regarded as neglected diseases, as there is still a 
lack of safe, affordable and effective treatments available. Drug companies no 
longer invest as much money into antibacterial drug development due to poor 
profit margins in comparison to chronic medication (Talbot et al., 2006; Projan, 
2003).  Furthermore, for most bacterial diseases, more than one type of drug is 
available for treatment in the case of drug resistance, and few organisms have 
become resistant to all the available drugs.  Nowadays, for a drug to be 
approved, it needs to show improved efficacy over currently available therapies, 
but this could be dangerous if the disease-causing organisms become resistant 
to a broad range of drugs thereby reducing the number of potential second-line 













1983 to 1987, the approval of new antibiotics by the Federal Drug Administration 
(FDA) decreased by 56% from 1998 to 2002 (Spellberg et al., 2004).   
Trouiller et al. (2002) found that of the 1393 new chemical entities marketed 
between 1975 and 1999, only sixteen were for tropical diseases and   
tuberculosis, all with public sector involvement.  These chemicals have all been 
included in the World Health Organization (WHO) Essential Drug List as they 
represent a definite therapeutic benefit. A further impediment to the development 
of a new antimicrobial drug is the prohibitive cost, which is estimated to be about 
US$403 million, and if taken to the point of marketing approval, those costs rise 
to US$802 million (DiMasi et al., 2003).  
 
There is an urgent need for new antimicrobial agents, due to the emergence of 
multi-drug resistance in common pathogens, the rapid emergence of new 
infections and the possibility that these organisms may be used in a military 
capacity (Spellberg et al., 2004; Bradley et al., 2007).  Emerging resistance to 
currently available antimicrobial agents is a growing problem as the laboratory 
detection of emerging phenotypes is difficult and empiric therapies need to be 
altered by clinicians.  Drug resistance also leads to longer and more expensive 
treatment and increased morbidity and mortality (Mulvey and Simor, 2009). 
Several factors contributing to increasing antimicrobial resistance are misuse of 
antibiotics, more immunocompromised hosts, poor hygiene and a greater 
number of invasive procedures (File, 1999; Owens and Rice., 2006; Kunin, 
1993).  There is a direct link between the rate at which organisms become 
resistant and exposure to the drug (Tenover, 2001).   
 
A review by Andersson (2003) shows that if high levels of resistant organisms 
are present within the community they are likely to remain there for some time.  A 
contributor to the evolution of antibiotic resistant organisms in man is the use of 
antibiotics in agricultural animal feed over the last four decades as growth 
promoters and prophylactically for disease-prevention.  This can create a serious 













used in human-based therapy (Wegener, 2003; File, 1999; Tenover and Hughes, 
1996).  Compounding this problem is the fact that human (and animal) 
commensal gut anaerobic bacteria have developed the ability to acquire and 
disseminate a broad range of mobile deoxyribonucleic acid (DNA) transfer 
factors, including genes encoding resistance to antibiotics.  This horizontal DNA 
transfer has been shown to occur between unrelated bacterial species (between 
Gram-positive and Gram-negative bacteria) (Vedantum and Hecht, 2003). 
 
Figure 1: A schematic of antibiotic sites of action and potential bacterial resistance mechanisms 




Researchers have come to realise that the development of antibiotic resistant 
organisms is inevitable.  Bacteria have evolved several ways in which to survive 
inhibition or killing by antibiotics, as shown in Figure 1.  These include enzymatic 
inactivation of the agent, active removal of the agent from the cell by efflux 













decreasing the uptake of antibiotics (Singh and Barrett, 2006; File, 1999; Mulvey 
and Simor, 2009; Piddock, 2006; Paulsen, 2003).  Furthermore, the emergence 
and dispersion of resistant strains are likely to result from antibiotic selection 
pressure (Mulvey and Simor, 2009), as shown in Figure 2. 
   




With regards to the development of new antibiotics, efforts have largely been 
focused on improving the efficacy of existing classes of drugs, as well as agents 
that when co-administered with current antibiotics, reverse the organism 
resistance (for example, ß-lactamase inhibitors such as clavulanic acid) (Singh 
and Barrett, 2006).  Apart from the need for new antibiotics, measures need to be 
put in place for the prudent use of currently available and new drugs to increase 
the lifespan of the available drugs (Andersson, 2003; File, 1999; Owens and 
Rice., 2006; Fendrick et al., 2001; Murray, 1994).  Disease-causing pathogens 
have the ability to evade established treatments which means that not only are 
new classes of antimicrobials required, but a better understanding of host-
microbe interactions (Courvalin and Davies, 2003).    With the rate at which 
international travel is increasing, one can expect the spread of drug resistant 
bacteria to spread as well.  Constant and efficient surveillance is required to 













resistance and the mechanisms of resistance development (Verhoef and Fluit, 
2006).   
 
For the purpose of this project, early drug discovery was aimed at four classes of 
pathogenic organisms, namely mycobacteria, Gram-positive bacteria, Gram-
negative bacteria and yeast.  The representative organisms in each class are 
Mycobacterium tuberculosis, Staphylococcus aureus, Klebsiella pneumoniae and 
Candida albicans.   
1.1.1 Mycobacterium tuberculosis 
The WHO reported that tuberculosis (TB), the cause of much morbidity and 
mortality globally, was responsible for 9.2 million new cases and 1.6 million 
deaths in 2006 (WHO, 2008).  Tuberculosis is diagnosed by sputum smear 
microscopy, a rapid and low cost method for detecting acid-fast bacilli (AFB) in 
sputum (Trébucq, 2004).  Current treatment regimens are based on a six to eight 
month course of multi-drug therapy, which leads to high rates of patient 
nonadherence and subsequent increases in mortality and development of drug 
resistant strains (O’Brien and Nunn, 2001). Multi-drug resistant TB (MDR-TB) is 
classified as TB resistant to at least two of the front-line drugs, rifampicin and 
isoniazid.  Extensively drug resistant TB (XDR-TB) is MDR-TB that is also 
resistant to at least three of the six classes of second-line drugs, therefore 
making it more expensive and difficult to treat and it is subsequently associated 
with very high mortality rates (Duncan, 2003; WHO, 2008).  45 countries have 
reported XDR-TB cases, as is represented in Figure 3.  The only prevention 
against TB infection has been the BCG (bacilli Calmette-Guérin) vaccine, the 
effectiveness of which is controversial (Maes, 1999).   
 
HIV infection has had a major impact on TB.  The WHO (2008) estimates that in 
2006, 0.7 million cases and 0.2 million deaths resulting from TB were in HIV-
positive people.  In South Africa alone, 44% of people with TB are also HIV-













confirmed TB infection were HIV positive and these patients often had irregular 
chest X-ray presentations and negative sputum smears, despite testing culture 
positive for TB (Elliott et al., 1990). Furthermore, simultaneous infection with HIV 
and TB is associated with increased mortality and drug toxicity (Wallis et al., 
1996). 
 
Figure 3: Countries that have reported XDR-TB cases (WHO, 2008) 
 
 
The complete genome sequence of M. tuberculosis H37Rv shows that the 
organism differs substantially from other bacteria in that many genes are directed 
towards the production of enzymes involved in lipogenesis and lipolysis as well 
as proteins that may allow antigenic variation (Cole et al., 1998).  The 
mycobacterial cell wall plays a large role in its intrinsic resistance to antibiotic 
agents.  Its low permeability can be attributed to the few porins in the cell wall 
slowing down the movement of hydrophilic agents across the cell wall and the 
thick lipid bilayer also hinders the movement of lipophilic agents (Jarlier and 
Nikaido, 1994).  This complex cell wall structure unique to mycobacteria is 
viewed as a major target for novel drug development (Chatterjee, 1997; Wheeler 













responsible for fatty acid synthesis, some of which form precursors for the 
mycolic acids in the cell wall.  The FAS II system in particular is unique to 
microbes (Mdluli and Spigelman, 2006).  Apart from this permeability barrier 
which slows down the movement of antibiotic agents into the cell, the organism 
also uses efflux pumps, antibiotic modifying, degrading and target-modifying 
enzymes to nullify the effects of some antibiotics.   
 
Despite the resemblance to Gram-negative bacteria in its ability to provide 
selective permeability and sharing of orthologous genes for energy production 
(Fu and Fu-Liu, 2002), mycobacteria do not appear to gain antibiotic resistance 
by means of transmissible genetic elements, such as plasmids (Nguyen and 
Thompson, 2006).  Furthermore, outside of the cell wall and plasma membrane 
is a capsule composed primarily of polysaccharide and protein.  This layer has 
been shown to aid in the organism’s adhesion to and penetration of host cells, 
contain toxic lipids and contact-dependent lytic substance, as well as providing a 
passive barrier to diffusion of molecules, thereby aiding the pathogenicity of the 
organism (Daffé and Etienne, 1999).   
 
No new novel compound for the treatment of TB has been developed in many 
years, particularly due to the high cost of new drug development in comparison to 
the TB market size.  Furthermore, the price at which these drugs can be sold 
needs to be kept low to accommodate their use in poor countries (O’Brien and 
Nunn, 2001). The TB Structural Genomics Consortium was established to obtain 
more structural and functional information on proteins produced by M. 
tuberculosis that are essential to its growth and virulence.  This information can 
further be applied to the identification of new drug targets and the development of 
new anti-tuberculosis agents (Goulding et al., 2002).  As a result of the 
elucidation of the complete genome sequence of M. tuberculosis, new drug 
targets have been identified and high throughput screening needs to be 
employed, together with rational drug design, followed by optimization of the 














Most anti-tuberculosis drug development has been based on the production of 
derivatives of existing drugs.  An example is the rifamycin derivative, KRM-1648, 
which inhibits bacterial RNA polymerase (Fujii et al., 1995).  An ethambutol 
analogue, SQ109, developed from a combinatorial approach, displays similar 
activity to INH in vitro, and promising in vivo activity with good tissue distribution, 
despite its low oral bioavailability (Jia et al., 2005; Hampton, 2005). The 
introduction of the rifampicin derivative, rifapentine, into treatment regimens can 
enable an increase in the dosing interval as a result of its long half life compared 
to rifampicin.  Its use in the treatment of MDR-TB, however, is limited, due to 
cross resistance with rifampicin-resistant strains (Chaulet, 1998; Tam, 1998).   
 
Ballell et al. (2005) reviewed small synthetic molecules with antimycobacterial 
activity, of which the most promising tuberculosis-specific leads appeared to be 
the diarylquinolones R207910 and PA-824.  The diarylquinolones represent a 
new class of compounds potentially effective against TB.  In particular, R207910, 
has been shown to be particularly potent and specific to mycobacteria, with in 
vitro MIC’s of 0.03 to 0.12µg/ml against reference and antibiotic susceptible 
strains of M. tuberculosis.  This compound appears to have a unique mode of 
action, ensuring that cross resistance with current anti-TB drugs should not be a 
problem.  Furthermore, this compound has been shown to have more potent in 
vivo bactericidal activity than INH or rifampicin.  In vivo murine and human 
pharmacokinetic studies have shown good oral absorption, long plasma half-life, 
high penetration into the tissues associated with TB infection and lack of obvious 
toxicity (Andries et al., 2005).  Several fluoroquinolones, particularly gatifloxacin 
and moxifloxacin, are also currently in various stages of clinical evaluation 
(O’Brien, 2003).     
 
A series of nitroimidazopyran compounds have also shown potent bactericidal 
activity against actively growing and dormant TB bacilli, as well as MDR-TB.  













cell wall mycolates.  Furthermore, these small molecules are orally bioavailable 
and can be easily manufactured on a large-scale, making them an ideal drug 
candidate for further clinical trials (Stover et al., 2000). The genome sequence of 
M. tuberculosis led to the cloning, expression and purification of MT CYP51, a 
protein that is similar to the drug targets, CYP51 isozymes, in fungi.  The authors 
subsequently demonstrated the antimycobacterial activity of several anti-mycotic 
azole drugs against M. bovis and M. smegmatis after showing that they bind to 
MT CYP51 with high affinity (Guardiola-Diaz et al., 2001).   
 
A new class of antituberculosis drug should ideally be able to shorten the 
duration of treatment, be able to treat latent TB, and be effective against drug 
resistant strains (O’Brien and Nunn, 2001; Duncan, 2003; Iseman, 2002; Ballell 
et al., 2005).  However, there is agreement among researchers that any new 
agent, however effective, introduced into a poorly managed treatment 
programme will still result in the development of drug resistant strains.   
     
1.1.2 Klebsiella pneumoniae 
The Gram-negative bacteria, K. pneumoniae, is responsible for a variety of 
infections, including meningitis in patients that have undergone neurosurgery (Lu 
et al., 1999), complicated skin and soft tissue infections of the extremities in 
patients with diabetes mellitus (Chang et al., 2008), urinary, biliary and 
gastrointestinal tract infections, as well as wounds arising from trauma (Talbot et 
al., 2006).  K. pneumoniae infections are associated with high mortality rates if 
untreated (Lu et al., 1999) as well as longer hospital stay prior to infection, 
treatment with newer antibiotics as well as hospitalization in an intensive care 
unit (Vatopoulos et al., 1996). Furthermore, these organisms have increased 
their spectrum of antibiotic resistance and the problem is exacerbated by the lack 
of potential drugs with novel modes of action in the development pipeline (Talbot 














In response to the development and use of successive generations of ß-lactam 
antibiotics over the last 60 years, Gram-negative organisms are gaining a 
broader spectrum of resistance characteristics and are progressively becoming 
more difficult to treat with subsequent high mortality rates (Paterson et al., 2003).  
The major concerns in the Enterobacteriaceae are the CTX-M extended-
spectrum ß-lactamases, plasmid-mediated AmpC ß-lactamases and KPC 
carbapenemases (Livermore and Woodford, 2006).  In members of the Gram-
negative bacteria, the most important mechanism by which they display 
resistance to ß-lactam antibiotics (penicillins) is the presence of plasmid-encoded 
ß-lactamase enzymes.  Further resistance to all ß-lactam antibiotics is conferred 
by the extended-spectrum ß-lactamase (ESBL) enzymes.  Several studies have 
shown the prevalence of ESBL-producing clinical strains to be between 13 and 
52% (Bell et al., 2002; Marra et al., 2006; Paterson et al., 2003; Bratu et al., 
2005a).  Cases have also been reported of single strains containing multiple 
different ß-lactamases (Essack et al., 2004; Giakouppi et al., 2008; Moland et al., 
2007).  It also appears as though the presence of these enzymes is becoming 
widespread in the family of Enterobacteriaceae (Hanson et al., 2001). 
 
Carbapenems have been used to treat ESBL-containing isolates of K. 
pneumoniae and resistance to the drug has been unusual in the past.  However, 
there are increasing reports of resistance to carbapenems (Nordmann et al., 
2009; Mulvey and Simor, 2009; Bratu et al., 2005a; Bratu et al., 2005b) as is 
demonstrated in Figure 4, leaving colistin as the only available course of 
treatment (Mulvey and Simor, 2009). Carbapenem resistance in Klebsiella 
species and other members of Enterobacteriaceae is mediated by the KPC ß-
lactamases (Bratu et al., 2005a). These strains are virtually resistant to all 
antibiotics and further compounding the problem is the fact that the 
microbiological detection of these strains is difficult and requires precise 
inoculum strengths (Bratu et al., 2005a; Nordmann et al., 2009).  There have 













acquiring resistance to ertapenem during the course of treatment by means of a 
porin loss (Elliott et al., 2006). 
 




Quinolone resistance in Gram-negative organisms is also a growing concern and 
appears to have arisen from multiple mechanisms including chromosomal 
mutations and plasmid-mediated resistance.  A further concern is that quinolone 
resistance is typically associated with resistance to a wide range of other agents 
(Robicsek et al., 2006; Strahelivits et al., 2007).  Increases in resistance to third-
generation cephalosporins have also been reported (Lu et al., 1999). Multi-drug 
resistant Gram-negative bacilli, defined as being resistant to more than two 
classes of antibiotics, are typically resistant to penicillins, cephalosporins, 
fluoroquinolones, trimethoprim-sulfamethoxazole and aminoglycosides (Mulvey 














1.1.3 Staphylococcus aureus 
S. aureus is a serious human pathogen capable of causing a diverse variety of 
infections (Zetola et al., 2005), an example of which is shown in Figure 5.  These 
infections were originally mainly rampant in hospital settings, such as in surgical 
patients (Talbot et al., 2006; Verhoef and Fluit, 2006) but are more frequently 
being identified in community-associated infections  (Von Köckritz-Blickwede et 
al., 2008; Zetola et al., 2005).  Estimates suggest S. aureus involvement in 
between 11 to 38% of all cases of bacteraemia (Von Köckritz-Blickwede et al., 
2008).  A serious complication of infection with S. aureus is multiple organ failure 
and vascular damage as a result of sepsis and toxic shock syndrome (Von 
Köckritz-Blickwede et al., 2008).  The first-line treatment of severe 
staphylococcal infections is vancomycin and second-line drugs include linezolid, 
daptomycin, clindamycine, tetracycline and co-trimoxazole (Zetola et al., 2005).  
 
Figure 5: Furuncle near the knee caused by S. aureus infection (Zetola et al., 2005) 
 
 
The emergence of S. aureus strains with resistance to initially methicillin and now 
vancomycin (Hiramatsu, 2001), the gold-standard therapy,  as well as other 
newer drugs, has left a dire need for new anti-staphylococcal drugs, particularly 
those that are orally administered (Talbot et al., 2006).  There has been an 
increase in community-acquired MRSA infection, primarily skin furunculosis, with 
new virulence characteristics in relatively young, healthy people, associated with 













that MRSA prevalence rates per 100 000 was 11.4 and 14.0 in North and South 
Ireland respectively in 1999. Resistance is even emerging against topical 
antibiotics, such as mupirocin and fucidic acid, used to treat superficial 
staphylococcal infections, such as in dermatitis and traumatic lesions (Critchley 
and Ochsner, 2008).  Currently, no vaccination exists for the prevention of 
staphylococcal disease, although various veterinary and clinical trials have 
investigated the use of various live and attenuated S. aureus preparations (Hu et 
al., 2009).  Several new oxazolidinone derivatives are under investigation after 
the FDA approval of linezolid (Hilliard et al., 2009; Barman et al., 2009; Takhi et 
al., 2008).    
 
1.1.4 Candida albicans 
The incidence of invasive fungal infections has increased substantially over the 
last twenty years.  Candida infections have been identified as a common 
bloodstream pathogen with associated high mortality rates and increased 
hospital stays and treatment costs, particularly for the immunocompromised host.  
Furthermore, the incidence of new and emerging fungal pathogens, such as 
Zygomecetes and Fusarium species, which are difficult to treat, has increasingly 
been reported (Petrikkos and Skiada, 2007; Weig and Brown, 2007).  There are 
currently no vaccines available to combat invasive fungal infections (Thevissen et 
al., 2007). 
 
The publication of the genomes of several Candida species, although not leading 
directly to the development of an effective antifungal drug, has provided 
information on how the pathogen interacts with its host environment during the 
disease process.  This information is envisaged to aid research into novel drug 
targets, such as genes necessary for virulence and viability, and diagnostic 
markers, as well as mapping the emergence and molecular basis of resistance 
(Weig and Brown, 2007; De Backer and Van Dijck, 2003).   C. albicans, the 













2007), has displayed an ability to alter its phenotype and become resistant in the 
presence of a drug, but can revert back to its susceptible phenotype once the 
drug pressure has been removed, known as epigenetic resistance (White et al., 
1998).  Various other cellular mechanisms of resistance are associated with 
fungi.  Many of these organisms occur commensally in the host and become 
pathogenic when the host becomes immunocompromised.  Some of these fungi 
are intrinsically resistant to antifungals, and in the presence of antifungal 
treatment, there can be replacement of the endogenous infection with a strain 
that has greater drug resistance.  A similar pattern can occur between strains of 
the same organism (White et al., 1998).  Andes et al. (2006) also showed that in 
vivo dosing regimens involving the more frequent administration of drugs prevent 
the emergence of drug resistant C. albicans, whereas regimens resulting in sub-
MIC (minimum inhibitory concentration) levels of drugs over prolonged periods 
tend to result in the emergence of drug resistant phenotypes.   
 
C. albicans biofilm formation on biomaterials, such as intravenous and urinary 
catheters, contributes largely to hospital acquired infections as they are largely 
protected from the host immune system on the device surface (White et al., 
1998; Andes et al., 2004).  Andes et al. (2004) developed an in vivo C. albicans 
biofilm model and demonstrated a thick bilayered structure, with yeast cells 
embedded in an extracellular matrix close to the catheter surface, and yeast and 
hyphal forms close to the outer surface.  These biofilms are also associated with 
hyper drug resistance.   
 
In the past, treatment of Candida infections has been made difficult by the lack of 
suitable antifungal therapies (Rex et al., 1995a).  Polyenes are a class of 
antifungals including amphotericin B and nystatin that target ergosterol-
containing membranes.  Ergosterol is the predominant sterol found in fungal 
plasma membranes.  These drugs have hydrophilic and hydrophobic sides, 
making them amphipathic, and are thought to disrupt the fungal membrane 













be the ‘gold standard’ for antifungal drug therapy for many years (White et al., 
1998; Petrikkos and Skiada, 2007).  It has, however, been associated with 
various toxicities and requires intravenous administration.  Recently, new lipid 
preparations of this drug with decreased toxicity have been introduced (Petrikkos 
and Skiada, 2007). 
 
Included in the class of ergosterol biosynthesis inhibitors are the allylamines, 
thiocarbamates, azoles and morpholine .  Fluconazole and itraconazole are first 
generation triazoles, but widespread-use of the former due to its good oral 
bioavailability and effective treatment of Candida infections led to the selection of 
fungal species with cross-resistance to other antifungals (Rex et al., 1995b; 
Petrikkos and Skiada, 2007).  A newer extended spectrum azole is voriconazole, 
a product of fluconazole, used to treat invasive aspergillosis, oesophageal 
candidiasis, disseminated skin Candida infections, as well as infections caused 
by Scedosporium apoispermum and Fusarium  species (Maschmeyer and 
Ruhnke, 2004; Petrikkos and Skiada, 2007; Weig and Brown, 2007).  Another 
second-line azole is the orally-administered posaconazole , a derivative of 
itraconazole , which gained FDA-approval in 2006 for treating invasive Aspergillus 
and Candida infections.  The investigational azole, ravuconazole, was being 
evaluated in 2007 in phase II clinical trials, showing good in vitro activity against 
a wide range of fungi, including those with fluconazole-resistance (Petrikkos and 
Skiada, 2007; Weig and Brown, 2007).  
 
Echinocandins represent another class of antifungal, with a unique mode of 
action in that they inhibit (1,3)-ß-D-glucan synthase, responsible for the 
production of a cell wall component in fungi.  Drugs belonging to this class 
include caspofungin which gained FDA approval in 2001 for, amongst others, the 
treatment of invasive aspergillosis and oesophageal candidiasis and is as active 
as amphotericin B but better tolerated (Maschmeyer and Ruhnke, 2004; 
Petrikkos and Skiada, 2007; Weig and Brown, 2007); micafungin, which was 













prophylaxis for stem cell transplant patients; and anidulafungin, which was 
approved in 2006 for the treatment of oesophageal candidiasis, candidaemia, 
peritonitis and abdominal abscesses resulting from Candida species (Petrikkos 
and Skiada, 2007; Weig and Brown, 2007). These drugs are useful in the 
treatment of severe candidiasis due to their effectiveness against Candida 
species in biofilms (Weig and Brown, 2007).  Another antifungal class, with an 
entirely different mechanism of action are the fluorinated pyrimidines, including 5-
flucytosine, which inhibits fungal DNA and RNA synthesis, although it is often 
associated with haematological toxicity (White et al., 1998; Rex et al., 1995a).   
 
The introduction of new antifungal drugs has provided alternative , less toxic 
treatments to the previous gold standard, AmBD.  Furthermore, the antifungal 
resources now consist of various drug classes with different modes of action, 
allowing for the possibility of combination therapy (Petrikkos and Skiada, 2007; 
Weig and Brown, 2007).  Despite these advances, the current armourment of 
antifungal drugs are hampered by a limited spectrum of activity, are associated 
with rapid resistance development and  many are fungistatic as opposed to 
fungicidal (Thevissen et al., 2007).  There is a continuous need for new 
antifungal agents, preferably with a unique mode of action to avoid cross-
resistance with currently available drugs.   Drug development should be focused 
on processes specifically involved in fungal cell wall biosynthesis (Weig and 
Brown, 2007).The fungal multi-drug efflux pumps could also be a good target for 
drug development as inhibiting their action could help the accumulation of drugs 
that would otherwise be rendered inactive.  History has shown that antifungal 
drug discovery needs to be an ongoing process as fungi will continually develop 
resistance properties to available agents (White et al., 1998). 
 
1.2 Natural products and drug discovery 
Natural products are typically secondary metabolites produced by living 













a third to half of commercially available drugs are derived from natural products 
(Clark, 1996; Strohl, 2000). Several reviews have shown how natural products 
have contributed to the discovery of drugs such as lovastatin, cyclosporin A, 
paclitaxel, erythromycin, amphotericin, digoxin, penicillin, vincristine and 
vinblastine (Clark, 1996; Cordell, 2000; Strohl, 2000; Newman et al., 2003).  For 
the period from 1989 to 1995, Cragg et al. (1997) showed that over 60% of 
anticancer and anti-infective approved drugs and pre-New Drug Application 
agents were of natural product origin, while Newman et al. (2003) showed that 
from 1981 to 2002, an average of 62% of new anti-cancer chemical entities were 
non-synthetic. Several natural product-derived drugs were ranked amongst the 
top 35 selling ethical drugs between 2000 and 2002 internationally (40% in 2000, 
24% in 2001 and 26% in 2002).  Between 2000 and 2003, 15 new natural 
product-derived drugs were launched, 14 of which can be produced semi- or 
synthetically.  In the same time period, another 15 compounds were in Phase III 
clinical studies or registration, of which ten are produced by semi-synthesis and 
four by total synthesis (Butler, 2004).   
 
Figure 6: A timeline depicting the discovery of novel classes of antibiotics and introduction to the 
market place.  Compounds listed in normal fonts are natural-product derived while those in italics 















Sources of natural products include marine macro-organisms, terrestrial plants, 
lichens and microbes (Singh and Barrett, 2006).  The latter have been shown to 
provide a valuable and largely untapped source of potential drugs, but difficulties 
in culturing these microbes have limited investigations into many ecosystems, as 
variations in growth conditions can lead to the production of substantially different 
metabolites from the same organism (Knight et al., 2003; Peláez, 2006).  Higher 
plants have to date not yielded any clinically relevant antibiotics (Singh and 
Barrett, 2006), although numerous authors have shown their potential in yielding 
compounds with antimicrobial properties (Cowan, 1999).  As shown in Figure 6, 
all but three classes of antibiotics originate from natural products.   The naturally-
derived products typically have complex structures and many functional groups, 
a combination which often leads to their being very specific to the pathogen as 
opposed to the host (Singh and Barrett, 2006). 
 
Drug discovery is generally based on three different principles, namely 
traditional, empirical and molecular.  The traditional system is based on cultural 
knowledge of products used in traditional medicines, the empirical approach is 
based on knowledge of physiological processes and may involve further 
development of natural product-derived leads, while the molecular approach is 
based on knowledge of a molecular target for the therapeutic agent (Harvey, 
1999).  Natural products are an attractive source for the discovery of new drugs 
for several reasons.  They are structurally diverse, many have drug-like 
properties and many are isolated as a family of homologues allowing for 
structure-activity studies.  When one considers the percentage of natural 
biodiversity that has been investigated for potential medicinal properties, it would 
seem as though this field would remain attractive for the continued search of 
drug-like compounds (Harvey, 1999; Pieters and Vlietinck, 2005).   
 
There is, however, declining interest in drug discovery from natural products by 
pharmaceutical companies for many reasons, including a move to high 













combinatorial chemistry, improvements in molecular and cellular biology leading 
to an increase in the number of molecular targets and a decreased interest in 
infectious disease therapies (Koehn and Carter, 2005; Butler, 2004; Patel and 
Gordon, 1996).    With the genomes of many pathogenic organisms, such as M. 
tuberculosis, now completed, there is an expectation that with the use of 
molecular technology and combinatorial chemistry, new cellular targets for 
effective drugs will result in the next generation of novel drugs, as well as 
speeding up the development of vaccines and effective diagnostic tools (Barry et 
al., 2000; Cole, 2002; Warner and Mizrahi, 2004).  However, this trend may be 
changing as these strategies are not delivering the expected outcomes. Natural 
products are still a good source of leads due to their chemical diversity and 
biochemical specificity. Furthermore, they have gone through the process of 
evolutionary pressure which has enabled these compounds to interact with 
specific biological targets and proteins, as proven by the large number of natural 
product-derived drugs in use today (Koehn and Carter, 2005). 
 
A disadvantage of drug discovery from natural products is the lengthy time and 
the more complicated drug development process (Balunas and Kinghorn, 2005; 
Koehn and Carter, 2005).  However, improvements in the technologies 
associated with the isolation and identification of compounds, such as 
automation of fraction collectors attached to high pressure liquid chromatography 
(HPLC) instruments, ability of mass spectrometry (MS) technology to identify 
known compounds, new liquid chromatography (LC) columns enabling better 
separation and improved sensitivity of nuclear magnetic resonance (NMR) with 
smaller samples have the ability to streamline the lead discovery process 
(Harvey, 1999; Butler, 2004).  The subsequent development and optimization of 
hyphenated techniques, such as LC-UV-MS (liquid chromatography-ultraviolet-
mass spectrometry) and LC-NMR, has also allowed the fractionation of crude 
plant extracts prior to compound isolation to avoid isolating known constituents, 
as well as enabling partial or complete on-line compound identification within a 













fractionation and immediate biological testing of the identified peaks using a 
method such as bio-autography, followed by the large-scale isolation of the 
active, unknown constituents (Wolfender et al., 2005; Clarkson et al., 2006). 
Furthermore, advances in molecular biology now aid the drug discovery process 
by enabling researchers to determine the mechanism of action of new 
compounds (Drews, 2000; Balunas and Kinghorn, 2005).  
 
Several authors emphasize the need to determine suitable drug-like properties 
early on in the screening process (Koehn and Carter, 2005; Butler, 2004). 
Drug discovery from natural products faces several challenges, including the cost 
of high throughput screening, the ability of early assays to determine drug-like 
properties, complications from testing complex natural product extracts in 
assays, delays in complicated structure elucidation and supply of large amounts 
of natural products to obtain enough pure compound for biological evaluation 
(Butler, 2004).  Unfortunately, high throughput screening does not have the 
ability to predict the oral bioavailability and permeability of a compound, and 
compounds generated in this manner are typically more lipophilic and less 
soluble.  Mechanisms by which the chemical and physical properties of a 
compound can lead to an immediate prediction of oral bioactivity early on during 
the drug discovery process would be enormously useful (Lipinski et al., 2001).   
Once a compound has been shown to have in vitro activity and no toxicity, it 
does not necessarily infer in vivo activity or safety as the compound may be 
metabolized into inactive metabolites or result in unexpected neurotoxicity.  
Despite the advances in the field of high-throughput screening and isolation 
procedures, available pharmacological methods are not able to accurately predict 
clinical efficacy and safety (Taylor et al., 2001).  Graz et al. (2007) argue that it 
could be more cost effective to perform clinical trials on human subjects involving 
crude extracts of traditional medicines that are currently in use as a means of 
focusing on meaningful clinical results.  This would in turn give an immediate 
indication of the effectiveness or potential toxicity of the treatment.  In the case of 













further, more sophisticated laboratory investigation.  Some researchers have also 
provided scientific evidence that natural products in the form of extracts or 
mixtures of compounds (‘natureceuticals’) could be as effective as single 
compounds (‘monoceuticals’) (Núñez-Sellés et al., 2007). 
 
1.3 Traditional medicine in drug discovery 
Natural products have been used for many centuries by humans as a source of 
medicine and have resulted in the development of many drugs used today 
(Newman et al., 2000) or bioactive leads which have been developed into 
prospective drugs (Rates, 2001).  Ethnopharmacology involves the research of 
traditional medicines that have been safely used for ages by cultural groups 
leading to the potential discovery of lead bioactive compounds with structurally 
diverse properties (Clark, 1996).  This approach has been relatively successful 
as shown in a review by Fabricant and Farnsworth (2001) where 80% of the 
commercially available plant-derived drugs had uses the same as or similar to 
their ethnomedical origins.   
 
Phytomedicines are still used by many people in the developing world due to lack 
of access to conventional western medicines.  Plant medicines can be 
administered in many forms, including infusions, tinctures, powders and capsules 
(Rates, 2001).  Not only is traditional medicine utilised as a primary means of 
treatment in developing countries, but it is widely recognised that many people in 
industrialised nations use traditional medicine in conjunction with western 
medicine (Bodeker, 2001).  In South Africa, it is estimated that more than 80% of 
the population consult with the approximately 200 000 traditional healers who are 
now largely regulated by the government (Baleta, 1998; Kale, 1995).  People 
consult with traditional healers for the treatment of various ailments, as well as 
for their personal well-being (Kale, 1995; Jäger, 2005; Cocks and Møller, 2002). 
Unfortunately these remedies are poorly controlled with very little safety data 













primary consultation with traditional healers might cause dangerous delays in 
seeking effective treatment for life -threatening illnesses (Smyth et al., 1995).   
 
Due to the rich natural biodiversity of South Africa, many investigations have 
been undertaken on the potential of local traditional medicines as bioactive leads 
in the drug development process (Van Vuuren, 2008).  McGaw et al. (2008) have 
reviewed research performed on South African medicinal plants used to treat the 
symptoms associated with TB.  One of the most famous South African traditional 
medicines, Umckaloabo®, originating from Pelargonium reniforme and 
Pelargonium sidoides, was originally used by the Englishman, Charles Stevens, 
for the treatment of tuberculosis.  This remedy gained widespread reputation in 
Europe in the early 1900’s for its ability to heal tuberculosis sufferers (Bladt and 
Wagner, 2007). Urbanisation has lead to a large trade in medicinal plants in 
South Africa, the end result being that many of these plants are now endangered 
species.  Very few of these plants are known to be commercially cultivated, with 
the exception of Warburgia salutaris and Siphonochilus aethiopicus amongst 
others (Coetzee et al., 1999).  The use of many of these medicinal plants 
harvested from the wild is therefore not sustainable (Coetzee et al., 1999). 
Currently, there is a lack of clinical evidence to support the use of these 
traditional medicines, but randomised trials might not be suited for testing the 
safety and efficacy of these treatments (Chaudhury, 2001). 
 
1.4 Lichens as a source of antimicrobials 
Lichens are formed from the symbiotic partnership of a fungus (mycobiont) and 
an algae and/or cyanobacteria (photobiont), capable of photosynthesis (Nash, 
1996).  Fossil evidence shows that lichen-like organisms have been around for 
millions of years (Yuan et al., 2005) and occur across the globe (Galloway, 1996) 
in a variety of habitats, including marine environments (Kahng et al., 2004), often 
existing in extreme conditions.  Kranner et al. (2005) hypothesise that this 













and enables them to survive desiccation and the accompanying increase in 
oxidative stress due to the unique antioxidant compounds produced in the 
lichenized state.  Benko et al. (2002) have demonstrated the desiccation-
tolerance of two Cladonia species which were able to recover their metabolic 
activity after four months of desiccation.  Lichens are also very successful at 
utilizing water sources other than rain, such as fog and dew (Nash, 2006).  
Various lichen species have adapted structurally according to the environments 
in which they grow (Prinzing, 1999; Shirtcliffe et al., 2006).  For example, 
Lecanora conizaeoides, is super-hydrophobic, allowing rainwater to run off its 
surface easily and this, together with gas channels, allows this lichen to 
photosynthesize when other species are waterlogged (Shirtcliffe et al., 2006). 
 
Lichens are broadly used for a wide range of purposes, including food to reindeer 
in Eurasia and caribou in North America during the winter months when plant 
material is not available.  They are also used as a food-source by people in the 
Northern Hemisphere with Umbilicaria esculenta being sold commercially in 
Japan.  Furthermore, lichens are widely used in traditional medicines globally, 
especially as laxatives (Dixon, 2005; Malhotra et al. 2008; Ingolfsdottir et al., 
1997; Podterob, 2008; Boustie and Grube, 2005).  The lichen most widely used 
as an herbal remedy to treat ailments including tuberculosis, bronchitis and 
diarrhoea, is Cetraria islandica (Podterob, 2008).  Very little published data on 
their use in traditional medicines in South Africa is available.  Madomombe and 
Afolayan (2003) report that Usnea barbata is used in rural parts of the Eastern 
Cape Province to treat wounds in humans and mastitis in cattle.  Furthermore, 
there have been reports of a community in the Richtersveld of the country 
utilizing various lichen species as herbal remedies (Prof. Timm Hoffman, 
University of Cape Town, personal communication) . Lichens also provide raw 
materials for the perfume industry, in dyes and are a means for dating rock 
surfaces (Dixon, 2005) and monitoring environmental pollution (Baptista et al., 














Lichen secondary metabolites are of fungal origin, however most of these 
compounds are unique to the lichenized state and are deposited on the walls of 
the fungal hyphae (Nash, 996).  Lichen metabolites can be aliphatic, 
cycloaliphatic, aromatic and terpenic compounds, all of which have displayed a 
plethora of biological activities (Huneck, 1999).  Lichen metabolites are classified 
into four groups, depending on the biochemical pathway responsible for 
synthesis, namely, polyketide path, shikimic acid path, mevalonic acid path and 
the photosynthetic production of the photobiont (Huneck, 1999).  These 
compounds are produced to afford the lichens protection from microbes, to 
increase the permeability of the cell walls of the phycobionts, to protect the  
organism from dangerous irradiation, to provide minerals from the substrate, as 
stress compounds in extreme conditions, to allow gaseous and water exchange 
(Huneck, 1999) and to deter predators (Gauslaa, 2005; Huneck, 1999; Boustie 
and Grube, 2005).    Lichens have also been known to form depsides and 
depsidones (polyketide-derived aromatic compounds) through the esterification 
of aromatic carboxylic acid units (Kristmundosdóttir et al., 2005).  
 
There have been several literature reports on the in vitro bioactivity, primarily 
antimicrobial, antioxidant and antiviral, of extracts of various lichen species 
(Esimone and Adikwu, 1999; Gulluce et al., 2006; Burkholder and Evans, 1945; 
Behera et al., 2006a; Türk et al., 2003; Madamombe and Afolayan, 2003; Paudel 
et al., 2008; Perry et al., 1999).  Furthermore, several compounds with in vitro 
bioactive properties have been isolated (Campanella et al., 2002; Choudhary et 
al., 2005; De Carvalho et al. 2005; Kristmundosdóttir et al. 2005; Lauterwein et 
al., 1995; Ingolfsdottir et al., 1997, Haroldsdóttir et al., 2004; Müller, 2001; Kumar 
and Müller, 1999a; Kumar and Müller, 1999b; Perry et al., 1999).  The structures 
of several lichen metabolites are illustrated in Figure 7.  The most well-known 
lichen-derived compound, the dibenzofuran derivative, usnic acid, has been 
shown to display a wide range of bioactivities, including antibacterial (Lauterwein 
et al., 1995; Francolini et al., 2004), including against drug-resistant strains of E. 













1998), antiviral (Campanella et al., 2002), antitrypanosomal (De Carvalho et al., 
2005), antiproliferative (Kumar and Müller, 1999a) and anticancer activity 
(Kristmundosdóttir et al., 2005;  Bézivin et al., 2004).  It is sold in Germany, 
Finland and Russia for the treatment of lupus, ringworm and athlete’s foot (Dixon, 
2005) and is widely used in various dietary supplements, including LipoKinetix 
(Syntrax, Cape Girardau, Missouri).  However, the consumption of this specific 
capsule has been associated with severe hepatotoxicity (Favreau et al., 2002).  
Even the crude extract of Usnea species are included in capsules which claim to 
‘promote a healthy urinary system’ (www.gaiaherbs.com), although not being 
FDA-approved.  It has also been shown that usnic acid can be produced in the 
laboratory by culturing the fungal component of usnic acid-containing lichens 
(Yamamoto et al., 1985; Behera et al., 2006b).  Despite the fact that the fungal 
constituent can be cultured in vitro, it has been found that the growth of these 
fungi is slow and there is a variation in the levels and types of compounds 
produced when compared to that of the naturally-occurring lichen (Yamamoto et 
al., 1993). 
 






































Lecanoric acid Pulvinic dilactone Thelephoric acid 
 
Over 800 compounds have been identified from lichens, but the pharmacological 













yet poorly studied (Kokubun et al., 2007; Boustie and Grube, 2005).  It is evident 
that South African lichens hold much promise as a relatively unstudied resource 
in the search for novel classes of antimicrobial drugs.  Despite the fact that most 
of the secondary metabolites of lichens are of fungal origin and originate from 
fairly well-defined biochemical pathways dictated by a relatively small amount of 
genetic material, chemical variation within the same genus, and even species, 
has been reported in lichens, typically as a result of geographic and 
environmental variation (Fiscus, 1972; Hesbacher et al., 1996; Culberson, 1967; 
Culberson et al., 1973; Culberson, 1969).   
 
1.5 Desiccation-tolerant plants as a source of antimicrobials 
Almost all plant species have a phase of their life cycle that is either partially or 
completely tolerant of desiccation, such as seeds.  However, there is a group of 
plants known as resurrection plants, making up less than 0.2% of total flora, 
which have the ability to cope with drought by being desiccation-tolerant and 
entering a quiescent state which can last for up to eleven years in some species 
(Scott, 2000; Benko et al., 2002; Proctor and Tuba, 2002).  Unlike other plants, 
resurrection plants have the ability to protect their vegetative tissues during 
drought stress.  On addition of water, the plant immediately resumes growth and 
reproduction (Scott, 2000).  These plants are often found in arid environments 
growing on rocky outcrops which can broaden the water catchment surface and 
allow any rainfall to accumulate in pools (Scott, 2000; Proctor and Tuba, 2002).  
Furthermore, these unique plants possess mechanisms that allow them to deal 
with various environmental stresses other than drought (Scott, 2000).  The most 
notable metabolic change that occurs in the desiccated state is the accumulation 
of carbohydrates, particularly sucrose (Scott, 2000; Whittaker et al., 2001; 
Pinheiro et al., 2001; Illing et al., 2005; Proctor and Tuba, 2002).  Various authors 
have also reported mechanisms by which the plants protect themselves against 
oxidative damage during the desiccated state by means of antioxidants (Mowla 













The most important property for a desiccation-tolerant plant to survive is the 
ability to promptly protect itself in response to rapidly changing environmental 
conditions (Scott, 2000).  An early study of the tissue survival of South African 
desiccation-tolerant flowering plants by Gaff (1971) included the plants 
Xerophyta retinervis Baker (Family Velloziaceae) and Myrothamnus flabellifolius 
(Family Myrothamnaceae), the mature foliage of which were found to have no 
relative humidity.  Proctor and Tuba (2002) supply a comprehensive list of 
genera containing desiccation-tolerant species which include Selaginella and 
Cheilanthes (Pteridophytes), as well as Xerophyta and Myrothamnus 
(Angiosperms), the four species investigated in this study. 
 
The desiccation-tolerant plant, M. flabellifolius, has various uses in southern 
African traditional medicine, including infusions taken to treat colds and 
respiratory ailments, decoctions for kidney problems and backache, decoctions 
and powdered leaves applied to external abrasions and wounds and the 
inhalation of smoke to treat asthma (Hutchings et al., 1996; Van Wyk et al., 
2002).  Viljoen et al. (2002) found that the essential oil of Myrothamnus 
flabellifolius exhibited antibacterial and antifungal activity.  The major 
components of the essential oil were pinocarvone and trans-pinocarveol.  The 
authors speculate that the traditional use of this medicinal plant may arise from 
the presence of this potent essential oil. Other compounds isolated from this 
plant include camphor, eucalyptol and a -pinene (Van Wyk et al., 2002), although 
none of these are associated with antimicrobial activity.  Sherwin et al. (1998) 
examined the woody stem of M. flabellifolius, a characteristic that makes it 
unique from other desiccation-tolerant plants.  They found that unusual knob-like 
structures of unknown chemical composition formed on the walls of the xylem 
vessels and that the mechanism applied for drought survival of this plant involves 
desiccation tolerance of the cellular constituents.   
 
In southern Africa, the roots of Xerophyta retinervis have reportedly been 












inflammatory and to treat general aches and pains (Hutchings et al., 1996; Van 
Wyk et al., 2002).  Furthermore, an unspecified species is reportedly used in Zulu 
traditional medicine, although further details are not supplied (Hutchings et al., 
1996).  Flavonoids have been isolated from this genus, such as amentoflavone 
(Van Wyk et al., 2002).   
 
In southern Africa, Selaginella caffrorum is reportedly smoked with Lycopodium 
species to treat headaches.  Other members of the family Selaginaceae are 
reportedly used to treat venereal diseases (Hutchings et al., 1996).   In India, 
Selaginella species are used for longevity, warding off infections, external ulcers 
and to treat urinary tract infections.  One species, namely S. involvens, has been 
shown to exhibit immunomodulatory and antioxidant properties (Gayathri et al., 
2005).  A flavonoid, 6-(2-hydroxy-5-acetylphenyl)-apigenin, was isolated from the 
medicinal plant Selaginella tamariscina in China (Liu et al., 2009).  Several 
Cheilanthes species (Family Adiantaceae) are used in medicinal remedies in 
southern Africa.  C. hirta is used as an antihelminthic, to treat colds and sore 
throats, as well as a reported cure for cancer.  C. viridis is a household remedy 
used by the Zulu people to treat sores and skin ailments, and is applied to burn 
wounds by other culture groups of South Africa (Hutchings et al., 1996).   
 
Multicellular organisms produce protective compounds as a means of controlling 
their environmental microflora or to protect themselves against infection by 
microbial pathogens.  These pathogens may infect organisms belonging to 
different biological kingdoms and it stands to reason that defence components 
produced by members of one kingdom may be effective against microbial 
pathogens of another kingdom (Thevissen et al., 2007).  The ability of 
desiccation-tolerant plants to survive in a quiescent state for prolonged periods of 
time suggests the presence of compounds other than those involved in the 
desiccation-mechanism itself, which afford a certain amount of protection to the 
plant from herbivores and infective agents.  Furthermore, when considering the 













that there could be an antimicrobial basis to all the remedies, which to date is 
largely unstudied.   
 
1.6 The medicinal plant Warburgia salutaris 
Warburgia species belong to the Family Canellaceae and are used throughout 
Africa as medicinal plants.  Warburgia salutaris is widely used in southern Africa 
to treat various ailments.  The Zulu people mix the powdered bark in water or 
alternatively smoke it to treat coughing.  The cooked roots are also taken to treat 
coughs, while the bark is reportedly mixed with fat as an ointment for genital 
irritation/infection (Hutchings, 1996).  Further uses in southern Africa include 
using primarily the bark for coughs, chest complaints, colds, venereal diseases, 
toothaches, backache, skin complaints, stomach ulcers, aphrodisiacs, 
constipation, influenza, fevers, pains, gastro-intestinal disorders, rheumatism and 
malaria (Hutchings et al., 1996; Van Wyk et al., 2002).   
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The bio-activity of Warburgia species throughout Africa has been well-studied.  
Extracts from W. stuhlmanii have exhibited antimalarial activity (Muthaura et al., 
2007) while those of W. salutaris have shown 5-lipoxygenase, antioxidant and 
molluscidal activity (Frum and Viljoen, 2006; Muchuweti et al., 2006; Clark and 
Appleton, 1997).  The extracts of various parts of W. ugandensis showed 
cytotoxic and antileishmanial activity (Olila et al., 2002; Ngure et al., 2009).  
Numerous compounds have been isolated from the genus Warburgia, as shown 
in Figure 8.  Many of these compounds are drimane sesquiterpenoids.  
Unsaturated aldehydes are widespread in nature as defence mechanisms for 
various organisms, including higher plants, liverworts, fungi, termites and 
molluscs.  These compounds display a wide variety of bioactivities as 
summarised in Table 1, including antibacterial, antimycobacterial, antifungal and 
army worm antifeedant activity (Olila et al., 2001a and b; Kubo and Taniguchi, 
1988; Rabe and van Staden, 2000; Wube et al., 2005; Clarkson et al., 2007; 
Madikane et al., 2007; Mashimbye, 1999; Kubo et al., 1976; Forsby and Walum, 
1996; Taniguchi et al., 1988; Lunde and Kubo, 2000).  Due to the popularity of 
W. salutaris bark in South African and African traditional medicine, the trees have 
become endangered.  Drewes et al. (2001) have shown that some of the active 
sesquiterpenoid constituents are also found in the leaves of the plant, providing 
evidence for the substitution of bark for leaves in traditional remedies and the 
subsequent sustainable use of this plant in folk medicine.   
 
Due to the fact that the medicinal plant, Warburgia salutaris, is so widely used 
and well-studied, it is envisaged that it could aid in the development of a method 
to study oral bioavailability of a group of natural product-derived compounds in a 
complex mixture to narrow the research focus onto those compounds with 
promising pharmacokinetic properties.  This research has been made possible by 
the availability of W. salutaris material cultivated on a sustainable basis to supply 













Table 1: Compounds with bioactivity isolated from various Warburgia species 
Compound Plant extract Biological activity Author 
7a-hydroxy-8-drimen-11,12-olide W. ugandensis bark DCM MIC of 128µg/ml against M. aurum and M. fortuitum Wube et al., 2005 
7ß-hydroxy-4(13),8-coloratadien-
11,12-olide W. ugandensis bark DCM MIC of 128µg/ml against M. fortuitum Wube et al., 2005 
4(13),7-coloratadien-12,11-olide W. ugandensis bark DCM MIC of 128µg/ml against M. aurum, M. fortuitum and M. smegmatis Wube et al., 2005 
11a-hydroxycinnamosmolide W. salutaris  bark DCM Inhibits mycobacterial arylamine N-acetyltransferase 
Clarkson et al., 2007; Madikane 
et al., 2007 
11a-hydroxymuzigadiolide W. ugandensis bark DCM  Wube et al., 2005 
3-hydroxymuzigadial W. salutaris  bark DCM Component of antimycobacterial fraction Clarkson et al., 2007 
3?, 9a,11a-trihydroxymuzigadiolide W. salutaris  bark DCM Component of antimycobacterial fraction Clarkson et al., 2007 
6a,9a,11a-trihydroxycinnamolide W. salutaris  bark DCM Component of antimycobacterial fraction Clarkson et al., 2007 
6a,9a-dihydroxy4(13),7-coloratadien-
11,12-dial 
W. ugandensis and W. salutaris 
bark DCM Component of antimycobacterial fraction 
Wube et al., 2005; Clarkson et al., 
2007 
6ß,9a,11a -trihydroxycinnamolide W. salutaris  bark DCM Component of antimycobacterial fraction Clarkson et al., 2007 
Bemadienolide W. stuhlmanii bark 60% methanol extract  Kubo et al., 1976 
Cinnamodial W. salutaris  bark DCM  Madikane et al., 2007 
Cinnamolide 
W. ugandensis bark DCM; W. 
stuhlmanii bark 60% methanol 
extract 
 Wube et al., 2005; Kubo et al., 1976 
Cinnamolide-3ß-acetate W. ugandensis bark DCM  Wube et al., 2005 
Isopolygodial W. salutaris  bark DCM  Mashimbye et al., 1999 
Linoleic acid W. ugandensis bark DCM 
MIC of 4µg/ml against M. aurum and M. phlei; MIC 
of 8 and 16µg/ml against M. fortuitum and M. 
smegmatis respectively. 
Wube et al., 2005 
Mukaadial W. ugandensis  and W. salutaris bark DCM Component of antimycobacterial fraction 
Clarkson et al., 2007; Mashimbye 
et al., 1999; Wube et al., 2005 
Muzigadial 
W. salutaris bark ethyl acetate; 
W. ugandensis bark DCM and 
ethanol 
MIC of 12.5µg/ml against S. aureus and B. 
subtilis; MIC of 50µg/ml against M. luteus; MIC of 
100µg/ml against E. coli and S. epidermis; inactive 
against K. pneumoniae; MIC of 16 and 32µg/ml 
against M. fortuitum and M. aurum respectively; 
MIC of 64µg/ml against M. phlei and M. 
smegmatis.  Anti-trypanosomal activity; Toxic in 
Rabe and Van Staden, 2000; 














brine shrimp assay 
Muzigadiolide W. ugandensis bark DCM MIC of 64µg/ml against M. phlei; MIC of 128µg/ml against M. aurum, M. fortuitum and M. smegmatis. Wube et al., 2005 
Polygodial 
W. salutaris  bark DCM; W. 
stuhlmanii and W. ugandesis 
bark 60% methanol extract 
African army worm antifeedant activity; Induces 
inositol phosphate mobilization in a concentration 
dependent manner; Potent fungicidal activity by 
damaging cell membranes or affection 
mitochondrial ATP synthase – MIC of 1.56µg/ml 
against Candida utilis and 0.78µg/ml to 3.13 
against Saccharomyces cerevisiae. 
Mashimbye et al., 1999; Kubo et 
al., 1976; Forsby and Walum, 
1996; Taniguchi et al., 1988; 
Lunde and Kubo, 2000 
Salutarisolide W. salutaris  bark DCM  Mashimbye et al., 1999 
Ugandensidial 
W. ugandensis  and W. salutaris 
bark DCM; W. stuhlmanii and W. 
ugandesis bark 60% methanol 
extract 
Component of antimycobacterial fraction; MIC of 
128µg/ml against M. fortuitum; African army worm 
antifeedant activity 
Clarkson et al., 2007; Wube et al., 
2005; Kubo et al., 1976 
Ugandensolide W. ugandensis bark DCM  Wube et al., 2005 
Warburganal 
W. salutaris  bark DCM; W. 
stuhlmanii and W. ugandesis 
bark 60% methanol extract 
African army worm antifeedant activity Mashimbye et al., 1999; Kubo et 
al., 1976 














1.7 Aims and objectives 
A hit compound is defined as a nonreactive compound derived from high-
throughput screening with in vitro activity of less than 20µM, while a lead 
compound is one that apart from its potency, shows selective activity and 
favourable pharmacokinetic properties (including distribution, metabolism, 
excretion, toxicity) for its eventual development into a small-molecule drug 
(Wunberg et al., 2006).  There is an increasing trend in the field of drug discovery 
to determine the physiochemical and pharmacological information of potential 
lead compounds earlier in the drug development process.  One of the problems 
associated with novel compounds in preclinical drug development is the 
uncertain absorption of the compound across the gastro-intestinal tract (Gruppo 
et al., 2006).  
 
A further drawback associated with drug discovery from natural products is the 
length of time required to accumulate large enough quantities of material for 
identification, in vitro bioactivity testing and eventually in vivo efficacy and 
bioavailability studies.  An objective of this project is to evaluate the feasibility of 
determining lead-like candidates earlier in the drug discovery process with the 
help of sensitive LC-MS/MS technology.  Prospective ‘hit’ compounds within a 
fraction, as identified by in vitro bioactivity assaying, will be assessed for in vivo 
bioavailability in a small animal model, requiring as little as 10µl of blood per 
sampling time point.  This will provide information on which compounds have the 
most favourable toxicity and oral bioavailability profiles, enabling the researcher 
to focus only on those compounds with good lead-like potential.  Many 
compounds with good in vitro activity will be poorly bioavailable in vivo.  These 
methods will therefore also eliminate the unnecessary efficacy testing in animal 















The specific aims of this project are: 
 
• To investigate the antimicrobial activity of ten South African lichens 
• To investigate the antimicrobial activity of four South African desiccation-
tolerant plants 
• To investigate the antimicrobial activity of the cultivated South African 
medicinal plant, Warburgia salutaris 
• To isolate  and identify compounds responsible for observed activity 
• To test the cytotoxicity of the active compounds 
• To evaluate the pharmacokinetics of ‘hit’ compounds 
• To develop a model for the pharmacokinetic evaluation of multiple 


















 Very little work has been performed on the antimicrobial properties of South 
African lichens due to a lack of local experts capable of identifying the species 
and difficulty in accumulating sufficient quantities of active secondary metabolites 
for bioactivity studies.  There has been a report on the antimicrobial extracts of 
local Usnea barbata, rurally used for the treatment of wounds in humans and 
mastitis in cattle (Madamombe and Afolayan, 2003).  These natural products 
could represent a locally untapped reservoir of promising antimicrobial leads.   
 
2.2 Results 
Ten lichen specimens were collected from the Eastern and Western Cape 
provinces of South Africa.  Of these, only eight were positively identified by 
means of genetic sequencing performed in Germany (Appendix Figures 90 to 
99), as well as with the aid of electron microscope pictures, illustrated in Figure 9.  
In Figure A and B of these pictures, its is possible to see the flat thalli of the two 
Xanthoparmelia species, as well as the cup-like reproductive structures known as 
apothecia in Figure B.  Figure D shows the finger-like isidia of the 
Xanthoparmelia species while Figure E depicts the stratified nature of lichen 
















Figure 9: Electron microscopy pictures of (A) Xanthoparmelia notata, (B) Xanthoparmelia 
semiviridis, (C) unknown lichen from Eastern Cape (L14), (D) Xanthoparmelia semiviridis from 
Eastern Cape, (E) Flavoparmelia soredicans  and (F) Teloschistes chrysophthalmum. 
       
           
 
 





















mountain bare rock, granite 
33°44’24”S 
18°56’58” E 

















































































*Genetic sequence does not match any known species.   
#Tentative visual identification made by Dr E. Timdal. 
Abbreviations: GPS - global positioning system 
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Unknown lichen L14  
 














Six of the species originate from the Western Cape, while the remainder were 
collected in the Eastern Cape, as shown in Table 2.  Seven of the lichens were 













lichens were located in a running stream attached to the base rock, and one 
species was found growing on the bark of a tree.  Photographs of the lichen 
specimens are illustrated in Figure 10.   
 
2.2.1 Bioactivity testing of crude acetone extracts 
Due to small sample quantities, acetone extracts were prepared from ten lichen 
species in an attempt to extract the greatest quantity of compounds available 
using one solvent, as recommended by Eloff (1998b).  The extract yields are 
tabulated in the Appendix, Table 33.  These acetone extracts were subsequently 
tested against M. aurum A+, K. pneumoniae ATCC 13883, S. aureus 
ATCC12600 and C. albicans ATCC 90028 using the broth micro-dilution method 
as described in Section 7.2 .  The results are displayed in Table 3.    
 
For crude extracts exhibiting MIC’s of 125µg/ml or less, IC 50 values were 
determined as specified under the criteria for active extracts in Chapter 7.2.  The 
acetone extract of Teloschistes chrysophthalmum demonstrated the greatest 
activity against S. aureus with an IC50 value of 1.1µg/ml, while none of the 
extracts showed activity at less than 1mg/ml against K. pneumoniae.  One lichen 
species, the unknown foliose lichen species L18, showed activity at less than 
500µg/ml against C. albicans.  Five lichen species, namely Xanthoparmelia 
notata, Xanthoparmelia semiviridis (Eastern Cape), Flavoparmelia soredicans, 
Thamnolia subuliforme and Usnea rubrotincta displayed activity against M. 
aurum at 125 to 250µg/ml.  It is interesting to note the differences in activity 
between the two X. semiviridis lichen species collected from the Eastern and 
Western Cape Provinces of South Africa.  The former displayed greater activity 
against S. aureus with an MIC ranging from 62.5-125µg/ml, while the latter had 














Table 3: The in vitro antimicrobial activities of ten lichen acetone extracts in µg/ml.  The results are expressed in terms of MIC’s followed by IC50 
values, for extracts with activity of 125µg/ml or less. 
 Lichen / Control drug S. aureus K. pneumoniae M. aurum C. albicans 
L1 Xanthoria parietina =2000 >2000 1000 2000 
L8 Xanthoparmelia notata 125-250, 31.0±0.92 2000 250 1000 
L11 Xanthoparmelia semiviridis (WC) 1000 4000 500 >500 
L14 Unkown1 (Parmotrema sp.) 250 1000 1000 1000 
L15 Xanthoparmelia semiviridis (EC) 62.5-125, 46.1±8.06 2000 250 1000 
L16 Flavoparmelia soredicans 125-250, 36.3±1.34 1000 250 1000 
L17 Teloschistes chrysophthalmum 15.6-31.3, 1.1±0.73 >1600 400 1000 
L18 Unknown 2 187.5-375 2000 500 250 
L19 Thamnolia subuliforme 1000 >2000 188 >2000 
L20 Usnea rubrotincta 62.5-125, 63.4±9.9 >2000 125, 56.8±5.9 >2000 
 Dimethylsulfoxide 25, 10.6±1.6% 12.5, 6.9±0.3% 12.5, 4.9±1.0% 12.5, 8.6±1.8% 
 Ciprafloxacin 0.313, 0.2±0.05 0.08, 0.042±0.002 n/a n/a 
 Nystatin n/a n/a n/a 3.1, 1.5±0.4 
 Isoniazid n/a n/a 0.08-0.16, 
0.061±0.005 
n/a 














2.2.2 Bioactivity testing and profiling of usnic acid 
The common lichen metabolite, usnic acid, was also evaluated for its 
antimicrobial activity, as shown in Table 4.  This compound is known to be 
present in many lichen species and is often responsible for observed 
antimicrobial activity.  Usnic acid (C18H16O7, Mw = 344) is a granular yellow 
powder which fluoresces at 232 and 282nm (Roach et al., 2006).  This 
compound was also tested for antimalarial activity as described in Section 7.4, as 
no record of such testing could be found in the literature and the assay was 
available in the Division of Pharmacology, University of Cape Town.  
 
Table 4: The antimicrobial activity of usnic acid and antimicrobial control drugs.   The results are 
expressed in µg/ml as an MIC, followed by the IC50 value, if appropriate, except for P. falciparum, 
where the result is expressed as an IC50 value. 






n/a n/a n/a 




C. albicans >1000 n/a 3.13, 1.7±0.04 n/a n/a 




P. falciparum 15.1±3.4 n/a n/a n/a 0.015±0.002 
Abbreviations: n/a - not applicable; MIC - minimum inhibitory concentration; INH - isoniazid; Nys - 
nystatin; Cip - ciprofloxacin; CLQ - chloroquine 
 
Usnic acid proved to be completely inactive against C. albicans and K. 
pneumoniae at the highest concentration tested, namely 1mg/ml.  It did, 
however, exhibit weak activity against S. aureus with an MIC value of 500µg/ml.  
Similarly, usnic acid showed poor activity against P. falciparum with an IC50 value 
of 15.1µg/ml, a thousand times less active than chloroquine, as shown in Table 
4.  This is the first report of the antimalarial activity of usnic acid.  The most 














The extract exhibiting the most potent activity against M. aurum is that of Usnea 
rubrotincta, with an IC50 value of 56.8µg/ml.  The secondary metabolite, usnic 
acid, is commonly found in Usnea species (Nash, 1996) and for this reason the 
extract was evaluated for the presence of usnic acid.  An HPLC chromatogram of 
the acetone extract (Figure 12) was compared to that of pure usnic acid (Figure 
11).  The chromatogram in Figure 12 shows the presence of large quantities of 
usnic acid in the acetone extract of U. rubrotincta , to which the observed 
antimicrobial activity can be attributed.  Due to the large wealth of knowledge 
already available on this lichen metabolite and its antimycobacterial activity, no 
further research was performed on this extract.  
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Figure 12: An HPLC chromatogram of the acetone extract of Usnea rubrotincta at 248.1nm 
































































2.2.3 Antimicrobial activity of extracts of Xanthoparmelia  semiviridis 
(Eastern Cape) 
The acetone extract of X. semiviridis (L15) from the Eastern Cape exhibited 
activity against S. aureus (IC50 value of 46.1µg/ml) and M. aurum (MIC of 
250µg/ml) as shown in Table 3.  Due to the large quantity of lichen material 
collected from the roof tiles of a house, sequential extracts were prepared of this 
lichen, the yields of which are depicted in the Appendix, Table 34.  During the 
extraction process, precipitates formed in several of the samples.  These were 
collected and tested separately, together with the crude extracts, against M. 
aurum A+, C. albicans ATCC 90028, S. aureus ATCC 12600 and K. pneumoniae 
ATCC 13883, and the results are shown in Table 5. 
 
Table 5: The activity of Xanthoparmelia semiviridis (Eastern Cape) extracts and precipitates 
against four organisms.  The results are described as MIC’s in µg/ml followed by IC50 values, if 
applicable. 
Extract M. aurum C. albicans S. aureus K. pneumoniae 
Petroleum ether 125, 84.4±14.5 >2000 250-500 >2000 
Dichloromethane 250 2000 2000 >2000 
Dichloromethane 
precipitate 
250 >2000 125, 93.0±6.65 >2000 
Ethyl acetate 250-500 2000 500-1000 =2000 
Ethyl acetate 
precipitate 
1000-2000 2000 =2000 =2000 
Methanol 250-500 1000 1000-2000 >2000 
Methanol precipitate 500-1000 2000 =2000 >2000 
Water >2000 2000 >2000 >2000 
Cip, Nys, INH 0.08-0.16 ± 0.057 1.6 ± 0.11 0.625 ± 0.007 0.042 ± 0.002 
 
In Table 5 it is evident that only two extracts display activity at 125µg/ml or less, 
namely the petroleum ether extract with an MIC of 125µg/ml against M. aurum 
and the dichloromethane precipitate with an MIC of 125µg/ml against S. aureus.  
From the HPLC profiles of the petroleum ether (PE) extract and dichloromethane 
(DCM) precipitate displayed in Figures 13 and 14 respectively, together with the 













usnic acid.  The DCM precipitate consisted almost entirely of this common lichen 
metabolite (86.4%).  The observed bioactivity corresponds to the reported activity 
of pure usnic acid described in Table 4.   Due to the wealth of literature reports 
available on the bioactivities of usnic acid, no further work was carried out on 
these samples. 
 
Figure 13: An HPLC chromatogram of the petroleum ether extract of Xanthoparmelia semiviridis 
from the Eastern Cape at 233.1nm with the individual compound absorbance displayed in the 















Figure 14: An HPLC chromatogram of the dichloromethane precipitate of Xanthoparmelia 
semiviridis from the Eastern Cape at 254nm with the individual compound absorbances displayed 










































































2.2.4 Isolation of compounds from Teloschistes chrysophthalmum 
The potent anti-Staphylococcal activity of the acetone extract of T. 
chrysophthalmum , as depicted in Table 2, prompted an investigation into its 
active metabolites. 
2.2.4.1 Bioactivity testing of fractions and compounds from Teloschistes 
chrysophthalmum  
 A liquid-liquid separation of the acetone extract of T. chrysophthalmum yielded 
an acetonitrile (ACN) and a PE fraction as described in Section 7.7.6.1.  The 
ACN fraction was further fractionated into its individual constituents by means of 
reversed-phase HPLC, as illustrated in Figure 15.  Three peaks were collected, 
eluting at 11.0, 14.6 and 16.7 minutes.  Peak 1 (L17-1) had a prominent 
absorbance at 269.8nm, peak 2 (L17-2) at 223.9nm and peak 3 (L17-3) at 267.5.  
Peak 2 had a distinctive orange colour. 
 
Figure 15: A chromatogram of the ACN fraction of the acetone extract of Teloschistes 



























These three compounds, L17-1 to L17-3, together with the ACN and PE 
fractions, were tested for activity against drug sensitive (Figure 16) and 
methicillin-resistant (MRSA) (Figure 17) S. aureus, as well as for cytotoxicity to 


































selectivity indices (SI) for each compound, defined as the quotient of the 
cytotoxicity and the activity, have also been calculated. 
 
From the data in Table 6, it is evident that the ACN and PE fractions of the 
acetone extract of Teloschistes chrysophthalmum had very similar activity 
against drug-sensitive S. aureus, although the ACN fraction displayed greater 
activity against MRSA.  Subsequent isolation and testing of the three primary 
constituents of the ACN fraction indicated that compounds L17-1 and L17-3 have 
moderate MIC values of 31.3 and 15.6µg/ml respectively, but good IC50 values of 
1.1 and 0.7µg/ml respectively against the drug-sensitive reference strain of S. 
aureus (Figure 16).  Both compounds exhibit weaker activity against the 
reference strain of MRSA, with IC50 values of 11.1 and 11.4µg/ml respectively 
(Figure 17).  Furthermore, this activity has been shown to be bactericidal against 
both the drug-sensitive and –resistant strains of S. aureus.  These compounds 
exhibit almost no in vitro cytotoxicity (IC50’s of 81 and >100µg/ml respectively; 
Figure 18) in comparison to the emetine drug control, which displays an IC50 of 
25ng/ml.  L17-3 in particular has very low cytotoxicity, with no negative effect 
being observed at the highest tested concentration, namely 100µg/ml, and an SI 
value of greater than or equal to 142.9, while L17-1 displayed an SI value of 
73.6.  A value of ten or greater would indicate a compound worth investigating as 















Table 6: The activity of fractions and pure compounds originating from the lichen Teloschistes chrysophthalmum against drug-sensitive and –
resistant reference strains of Staphylococcus aureus, as well as the toxicity of the two active compounds against CHO cells. Results are described 








 IC50 MIC IC50 MBC SI MIC IC50 MBC SI 
ACN fraction n/a 19.5-39.1 1.3±0.76 n/a n/a 31.25 13.7±2.3 n/a n/a 
PE fraction n/a 39.1 3.1±2.6 n/a n/a 
62.5-
125 
32.6±3.1 n/a n/a 
L17-1 81.0±17.8 31.3 1.1±0.8 31.3 73.6 31.3 11.1±4.8 31.3 7.3 
L17-2 n/a >250 n/a n/a n/a >250 n/a n/a n/a 






11.4±3.2 62.5 >8.8 
Ciprafloxacin n/a 0.3 
0.236± 
0.01 







n/a n/a n/a n/a n/a n/a n/a n/a 
Abbreviations: SI - selectivity index (IC50 cytotoxicity/IC50 antimicrobial activity), CHO - Chinese hamster ovarian cells, DMSO - dimethylsulfoxide, 














Figure 16: The dose response curves of (A) the acetone extract, (B) the ACN fraction, (C) the PE 
fraction, (D) L17-1 and (E) L17-3 from Teloschistes chrysophthalmum against drug sensitive S. 
aureus ATCC 12600.  Figure F represents the effect of ciprofloxacin.  Each data point represents 
the average of at least four replicates from two separate experiments and the results are 
expressed as the percentage organism viability across the log concentration range in µg/ml. 
A










































































































































Figure 17: The dose response curves of (A) the ACN fraction, (B) the PE fraction, (C) L17-1 and 
(D) L17-3 from Teloschistes chrysophthalmum against methicillin-resistant S. aureus ATCC 
43300.  Figure E represents the effect of ciprofloxacin.  Each data point represents the average of 
at least four replicates from two separate experiments and the results are expressed as the 
percentage organism viability across the log concentration range in µg/ml. 
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  Figure 18: The dose-response curves depicting the effect of L17-1 (A) and L17-3 (B) from 
Teloschistes chrysophthalmum and the drug control, emetine (C) on CHO cells. Each data point 
represents the average of at least four replicates from two separate experiments and the results 
are expressed as the percentage organism viability across the log concentration range in µg/ml. 
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2.2.4.2 Comparison of the constituents of the PE and ACN fractions of 
Teloschistes chrysophthalmum to those of the acetone extract 
of the growth substrate 
 A comparison of the fractions originating from the acetone extract of T. 
chrysophthalmum  and the roof tile substrate on which the lichen was found 
growing was performed to ensure that the active constituents did not originate 
from the substrate, but were in fact lichen metabolites.  The HPLC chromatogram 
of the acetone extract of the roof tiles is depicted in Figure 19, while those of the 
ACN and PE fractions of the acetone extract of the lichen are shown in Figures 















Figure 19: An HPLC chromatogram of the acetone extract of the roof tiles at 242.3nm with the 
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The chromatogram above of the acetone extract of the roof tile substrate on 
which the lichen was found growing, shows three prominent peaks at 14.5, 26.8 
and 31.9 minutes.  These three peaks have prominent absorbances at 239.2 and 
311.3, 269.8 and 365.8, and 233.3 and 282.8nm respectively. 
 
Figure 20: An HPLC chromatogram of the acetonitrile fraction of the acetone extract of 














5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00 45.00 50.00
 






































































Figure 21: An HPLC chromatogram of the petroleum ether fraction of the acetone extract of 
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The chromatograms of the ACN and PE fractions of the acetone extract of T. 
chrysophthalmum (Figure 20 and 21 respectively) indicate that these two 
fractions contain the same primary peaks eluting at 28.8, 30.8 and 31.3 minutes.  
Furthermore, these peaks appear to have the same absorbance spectra as 
indicated by the PDA spectral inserts in the chromatograms.  It is clear, however, 
that these fractions do not share any similar constituents with the acetone extract 
of the roof tiles, indicating that the isolated active compounds are of lichen origin.  
 
2.2.4.3 Identification of active compounds from Teloschistes 
chrysophthalmum  
The active constituents of the acetone extract of the lichen, T. chrysophthalmum, 
were subjected to NMR analysis on 600 MHz and 900 MHz instruments as 
described in Section 7.7.6.3, as well as tandem mass spectrometry (LC-MS/MS) 
and high-resolution mass spectrometry (HR-MS) as described in 7.7.6.4 in an 
effort to identify their molecular structures.  The 1H and 13C spectra of L17-1 are 

































Figure 22: The 1H NMR spectrum of L17-1solated from Teloschistes chrysophthalmum. 
L17_1_H1.ESP































































Figure 23: The 13C spectrum of L17-1 isolated from Teloschistes chrysophthalmum obtained on a 
Varian 600 MHz instrument 
L17-1_C13





























































































From the 1H spectrum of L17-1 illustrated in Figure 22 and the two-dimensional 
spectra shown in the Appendix, Figures 61 to 65, the presence of a single 
aromatic proton is detected at a chemical shift of 6.72 bonded to the carbon 
resonating at 101.8 and within two to three bonds of the carbon resonating at a 
chemical shift of 153.1 (Table 7).  This suggests that the aromatic ring/s is/are 
fully substituted with the exception of a single protonated carbon.   
 
Table 7: The NMR chemical shift values and two-dimensional correlations for L17-1 
1H (d) 13C (GHSQC) (d) GHMBC (d) DEPT 
2.53 18.8 139.8, 119.7, 116.2 CH3 
2.65 15.2 143.0, 131.0, 119.7 CH3 
3.87 56.6 153.1 CH3 
6.72 101.8 153.1, 143.0, 142.5, 119.7 CH 
 
Furthermore, the strong resonance on the 1H spectrum at a chemical shift of 3.87 
is associated with a carbon with a chemical shift of 56.6 within two to three bonds 
of the carbon with a resonance typical of that associated with a methoxy group 
(d=153.1).  From the DEPT spectrum, it is evident that there are a further two 
methyl groups at 18.8 and 15.2 with the associated protons resonating at a 
chemical shift of 2.53 and 2.65 respectively. Both of these methyl groups are 
within two to three bonds of the carbon resonating at 119.7, as is the aromatic 
proton at d = 6.72.  The 13C spectrum suggests the potential presence of two 
carbonyl groups resonating at a chemical shift of 161.64 and 157.04.  However, 
without X-ray crystallographic information, it is not possible at this stage to 
determine the exact location of the substituents on the molecular structure.   
 
















































The aromatic ring of L17-1 shares the same NMR characteristics as those 
reported by Mahandru and Gilbert (1979) for the aromatic ring of the depsidone, 
fulgidin, illustrated in Figure 24.  Briefly, the aromatic rings contains two methyl 
groups (1H d2.50 and 2.56), an aromatic methoxy group (1H d 3.97), two 
chlorine atoms and an aromatic proton (1H d 6.57).  As illustrated by the mass 
spectrum in Figure 25, L17-1 has an accurate mass of 386.9383 with molecular 
ions of 386.9, 388.9, 390.9 and 392.9 at a ratio of 21.3:21.3:7.3:1 in the negative 
ion mode.  Similarly, fulgidin has molecular ions at 388, 390, 392 and 394 at a 
ratio of 27:27:9:1, typical of a compound containing three chlorine atoms 
(molecular formula C16H11Cl3O3).  However, the mass differences suggest the 
absence of one proton on L17-1, potentially with regards to the hydroxyl group, 
as no hydroxy-associated proton resonances are apparent for L17-1. 
 




Figure 25 resulting from HR-MS, suggests a likely molecular formula of L17-1 to 
be C19H6O3Cl3.  The most promising predicted elemental composition suggested 













spectrum suggests the presence of chlorine isotopes, with the characteristic 
variation of two mass units.  The most abundant product ions were shown to 
have masses of 328 and 308, as shown in Figure 26. Initial losses of three 
masses of 15 suggest the loss of methyl groups (353 ?  338 ?  308). 
 
Figure 26: The product ions of L17-1 
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The 1H and 13C spectra obtained for L17-3 are depicted in Figures 27 and 28 
respectively, while the 900 MHz and two-dimensional NMR spectral data are 
illustrated in the Appendix Figures 66 to 79.  L17-3 appears to be closely related 
to L17-1, with the exception of the absence of a proton on the aromatic ring, 
which appears to be fully substituted, as well as an extra methyl group. As shown 
in Table 8, the strong resonance at 3.79 on the 1H spectrum could indicate either 
the presence of chlorine atoms or the protons of a methoxy group bonded to a 
carbon with a chemical shift value of 60.4.    
 
The methoxy group is attached to the carbon on the aromatic ring with a 
chemical shift value of 152.4.  The proton resonances at 2.32 and 2.44 which are 













group, the protons of which are separated from the aromatic carbon at d152.4 by 
two to three bonds.  The DEPT spectrum indicates the presence of a further two 
methyl groups (13C d15.1 and 18.9).  As with L17-1, the 13C spectrum suggests 
the presence of two carbonyl groups (d161 and 156).  As with L17-1, it is not 
possible to determine the exact location of the substituents without X-ray 
crystallographic information. 
 
Table 8: The NMR chemical shift values and two-dimensional correlations for L17-3 
1H (d) 13C (GHSQC) (d) GHMBC(d) COSY(d) DEPT 
2.32 10.5 122.6, 141.4, 152.4, 10.5 2.52, 2.62 CH3 
2.44 10.5 114.4, 153.6, 161.5, 18.9  CH3 
2.52 18.9 125.8, 127.7, 146.1, 10.5 2.32 CH3 
2.54 18.9 116.3, 119.8, 139.8, 15.1  CH3 
2.62 15.1 125.8, 127.7, 146, 18.9 2.32 OCH3 
3.79 60.4 152.4  CH3 
 
 
Figure 27: The 1H NMR spectrum of L17-3 isolated from Teloschistes chrysophthalmum obtained 
on a Varian 600 MHz instrument 
L17_3_H1_2ND





























































































Figure 28: The 13C NMR spectrum of L17-3 isolated from Teloschistes chrysophthalmum 
obtained on a Varian 600 MHz instrument 
L17_3_C13_2ND























































































































Figure 29 illustrates the high resolution mass spectrum of L17-3, the accurate 
mass of which was determined to be 400.9541.  Molecular ions at 400.95, 
402.95, 404.95 and 405.95 at a ratio of 12.8:12.8:4:1 once again indicates the 
presence of chlorine atoms with the characteristic two mass unit variation.  A 
likely elemental composition of this compound is predicted to be C20H8O3Cl3, as 
is shown in Figure 29.  The most prominent product ions of L17-3 have masses 
of 350.0, 342.0, 322 and 278.0, as depicted in Figure 30.  The loss of a chlorine 
atom explains the loss of 35 mass units from 400 ?  365, while a loss of 15 could 
account for the loss of a methyl group from a mass of 365 ?  350.  The further 




Figure 30: The product ions of L17-3  
TK3
m/z















































































Very little work has been performed on the pharmacological usefulness of lichens 
to medicine, most likely due to the difficulties in identification of species, slow 
growth rate, problematic axenic culture, as well as collection of large enough 
quantities for biological evaluation and isolation of compounds (Boustie and 
Grube, 2005).  Eloff (1998b) showed that extraction of plant material with 
acetone yields the highest number of compounds, subsequently resulting in the 
best antimicrobial activity when compared to other extraction solvents such as 
ethanol, methanol and water.  Due to the small quantities of lichen material 
collected, as well as previous literature reports on extract preparation from 
lichens (Madamombe and Afolayan, 2003), acetone was therefore used as the 
primary extractant.  In an attempt to produce research of a high quality, every 
effort was taken to work according to internationally acceptable 
recommendations, as proposed by Cos et al. (2006).   
 
The acetone extract of Teloschistes chrysophthalmum  displayed the greatest 
activity against any of the micro-organisms tested exhibiting an MIC of 15.6 to 
31.3µg/ml (IC50 of 1.1µg/ml) against S. aureus.  Antimicrobial activity has 
previously been reported from a Teloschistes species in New Zealand (Perry et 
al., 1999).  In general, none of the lichen extracts displayed good activity against 
C. albicans and K. pneumoniae.  Paudel et al. (2008) similarly reported activity of 
extracts of Antarctic lichens against Gram-positive organisms, but no activity 
against Gram-negative bacteria or fungi was observed.  The fact that none of the 
crude lichen extracts exhibited activity against K. pneumoniae is not surprising, 
as Gram-negative bacteria are known to be intrinsically more resistant to 
antimicrobial agents as a result of their relatively impermeable cell wall, as well 
as efficient efflux systems which actively pump the drug out of the cell (Berlanga 
et al., 2004; Verhoef and Fluit, 2006).  In a similar study involving plant extracts, 
Rabe and Van Staden (1997) found that almost all of the observed activity from 
their 21 plant extracts was against Gram-positive organisms, while none of the 














Other than T. chrysophthalmum, only two other extracts showed promising 
activity, namely that of X. semiviridis of the Eastern Cape against S. aureus and 
U. rubrotincta against S.aureus and M. aurum.  The differences in the activities of 
the two X. semiviridis species collected from two different provinces of South 
Africa shows the impact of habitat on the compounds produced by the lichens 
and subsequently affecting activity, as has been described in the literature by 
various authors (Fiscus, 1972; Hesbacher et al., 1996; Culberson, 1967; 
Culberson et al., 1973; Culberson, 1969).   
 
Bio-autography is a useful tool in pin-pointing active compounds within a mixture 
(Cos et al., 2006; Nostro et al., 2000).  However, this method was unsuccessful 
in the evaluation of lichen extracts due to the requirement of high levels of either 
formic acid or trifluoroacetic acid in the mobile phase to facilitate adequate 
separation.  Despite various attempts to remove residual acid from the plates, 
remaining traces were enough to inhibit organism growth, as mentioned in the 
literature (Cos et al., 2006).  Therefore, for the purposes of identifying those 
compounds responsible for the observed activity in the crude fractions, HPLC 
was used as the primary means of isolation.   
 
The common lichen metabolite, usnic acid, has previously been shown to display 
potent activity against mycobacteria (Ingólfsdóttir et al., 1998) and moderate to 
good activity against bacteria (Lauterwein et al., 1995, Francolini et al., 2004), 
including activity of the salt thereof against drug-resistant bacterial pathogens 
(Elo et al., 2007), but its activity against the malaria-causing organism, 
Plasmodium falciparum, albeit moderate, has not been reported previously.  By 
means of HPLC analysis, the presence of usnic acid was found in the lichen U. 
rubrotincta, and its moderate activity against M. aurum and S. aureus was 
attributed to the presence of this compound.  Extracts of a related species, U. 
barbata, from the Eastern Cape Province of South Africa, has also displayed a 













Although the active principle was not isolated, it seems plausible that usnic acid 
was responsible for the observed activity (Madamombe and Afolayan, 2003).  
Similarly, usnic acid was also found in the petroleum ether and dichloromethane 
precipitate of X. semiviridis from the Eastern Cape, explaining their activities 
against the same two organisms.  Lauterwien et al. (1995) showed that usnic 
acid exhibited an MIC of 2µg/ml against clinical isolates of S. aureus.  In this 
study utilizing a reference strain of S. aureus, the compound exhibited an MIC of 
500µg/ml.  The results of broth micro-dilution testing showed that usnic acid had 
an MIC of 15.6µg/ml against M. aurum, similar to the findings of Ingólfsdóttir et al. 
(1998) who found that it inhibited the growth of M. aurum at a concentration of 
32µg/ml.  Further work on these two lichens was therefore not continued.   
 
The acetone extract of the most active lichen, namely T. chrysophthalmum, was 
fractionated using ACN and PE to further prepare the sample for reversed-phase 
HPLC, as acetone has the ability to extract very non-polar, fatty substances 
which could damage a C18 column.  Three compounds were subsequently 
isolated from the ACN fraction.  L17-1 and L17-3 displayed moderate MIC 
values, but potent IC50 values of 1.1 and 0.7µg/ml respectively against drug-
sensitive S. aureus, while L17-2 was inactive at the highest concentration tested, 
namely 250µg/ml.  As suggested by Cos et al., (2006), a hit against the drug 
sensitive strain of S. aureus was followed up with testing against a reference 
strain of MRSA. These compounds showed less activity against MRSA, with IC 50 
values of 11.1 and 11.4µg/ml for compounds L17-1 and L17-3 respectively.  L17-
1 and L17-3 displayed cytotoxicity at 81 and greater than 100µg/ml respectively, 
resulting in very promising selectivity indices of 73.6 and >100 respectively 
against drug-sensitive S. aureus.  An SI value of greater than ten indicates a 
promising compound with good in vitro activity and low cytotoxicity which should 
be further evaluated in the drug-development process (Orme, 2001).   
 
Furthermore, to ensure that the anti-Staphylococcal compounds isolated were in 













HPLC analysis was performed on extracts of the lichen and the substrate .  From 
these chromatograms, it is apparent that the isolated compounds are lichen 
metabolites.  These results also showed that the PE fraction of the acetone 
extract of T. chrysophthalmum also contains a high concentration of L17-3 
isolated from the ACN fraction. 
 
Despite obtaining NMR spectral data from 600 MHz and 900 MHz NMR 
instruments, as well as high-resolution mass spectrometry data, it has not been 
possible to completely decipher the structures of L17-1 and L17-3 isolated from 
T. chrysophthalmum.  Furthermore, attempts to grow crystals for X-ray 
crystallographic purposes have been unsuccessful over a period of eight months.  
Time constraints have forced the continuation of this project in the absence of 
structural information.  It is recognized that identification of lichen metabolites can 
be challenging, and that crystallization is often required to confirm structural 
characteristics (Boustie and Grube, 2005).  However, the aromatic ring of L17-1 
shares the same characteristics as those reported by Mahandru and Gilbert 
(1979) for the aromatic ring of the depsidone, fulgidin, containing two methyl 
groups, an aromatic methoxy group, two chlorine atoms and an aromatic proton.  
L17-1 further displays resonances associated with two carbonyl groups.  L17-3 
has similar characteristics for the aromatic ring, differing from L17-1 only with 
regards to the absence of an aromatic proton, suggesting a fully substituted 
aromatic ring.  Other depsidones with similar structures include fulgoicin, 
caloploicin and vicanicin, the latter of which have fully substituted aromatic rings, 
but whose masses do not correspond to that of L17-3.  Furthermore, these 
compounds possess an aromatic hydroxyl group which does not appear to be 
present in L17-3.   
 
Over 800 compounds have been identified from lichens, but most of these 
compounds have not been well studied for pharmacological activity (Kokubun et 
al. 2007).  Kokubun et al. (2007) evaluated the activities of several lichen-derived 













authors found that depsidones containing long alkyl chains on both aromatic 
rings were active against the panel of bacterial strains tested in ranges 
comparable to those of clinical antibacterial drugs, results suggesting a novel 
mechanism of action.  These depsidones exhibited activity against the various 
strains of S. aureus with MIC’s ranging from 16 to 128µg/ml, values similar to 
those displayed by L17-1 and L17-3.  Despite the structures of L17-1 and L17-3 
being unclear at this stage, the possibility exists that they may in fact be 
depsidones, based on the similarities of the A-ring spectral data.  However, the 
compounds isolated in this project definitely contain chlorine atoms, a feature not 
present in the compounds tested by Kokubun et al. (2007).  Depsidones, 
aromatic rings linked with ester bonds, have previously been shown to display 
antiviral, anti-inflammatory and photoprotective properties (Müller, 2001).  Abdou 
et al. (2010) evaluated four depsidones (no chlorine atoms), botryorhodines A to 
D, isolated from an endophytic fungus, for biological activity.  The authors found 
that two of the four compounds displayed moderate to weak cytotoxicity (96.97 
and 36.41µg/ml) while the other two compounds displayed no cytotoxicity.  
Furthermore, two of the compounds displayed mild antibacterial activity (data not 
shown), while the other two compounds also displayed moderate activity against 
pathogenic fungi.     
 
The genuses of the family Teloschistaceae have much morphological and 
ecological heterogeneity, often distinguished by the yellow/orange colour due to 
the presence of anthraquinones (Gaya et al., 2008).  Several compounds have 
been isolated from the genus, Teloschistes, including fatty acids (Reis et al., 
2005) and polysaccharides (Reis et al., 2002).  The former authors found that the 
degree of saturation of these compounds changed with each season and that the 
fatty acid composition of the lichen and its individual symbionts did not 
correspond.  The anthraquinones parietin, teloschistin, emodin and 7-
chloroemodin have been isolated from T. exilis and Caloplaca erhythrantha 
(Rosso et al., 2003).  Furthermore, the authors successfully isolated parietin and 













attempts were made to culture the fungal component of the lichen species, as 
described by Crittendon et al. (1995) and Kranner et al. (2002a) (data not 
shown).  Repeated wide-spread contamination of the culture plates and the 
distinct possibility of the produced metabolites being lichen-specific, both of 
which have been previously reported, led to the halting of culture efforts (Boustie 
and Grube, 2005; Crittendon et al., 1995 and Kranner et al., 2002a). 
  
In comparison to literature reports of promising antibiotic lead compounds, the 
two lichen-derived compounds with anti-Staphylococcal activity isolated in this 
study have moderate activity.  Three novel promising1ß-methylcarbanpenems 
exhibited activity against drug-sensitive S. aureus with MIC’s of 0.016 to 
0.031µg/ml and against MRSA with MIC’s of 2-4µg/ml (Ueda and Sunagawa, 
2003). A promising drug candidate, the 3-(heteroarylthio)cepham RWJ333441, 
displayed in vitro activity against methicillin susceptible and resistant strains of S. 
aureus at 0.25µg/ml and 2µg/ml respectively (Glinka et al., 2003).  Similarly a 
synthetic compound arising from high-throughput screening of a compound 
library showed in vitro activity against drug-sensitive and -resistant strains of S. 
aureus with MIC’s of 1µg/ml.  Another 1ß-methyl carbapenem with broad-
spectrum Gram-positive activity, SM-17466, had an in vitro MIC90 of 0.006µg/ml 
against S. aureus and 3.13µg/ml against MRSA.  In comparison, vancomycin has 
MIC90’s of 1.56µg/ml against methicillin sensitive and resistant S. aureus.  
Furthermore, this activity against MRSA was shown to be bactericidal (Sumita et 
al., 1995).  Despite L17-1 and L17-3 having moderate MIC values in comparison 
to literature reports of promising anti-Staphylococcal drug candidates, both 
compounds appear to have growth inhibitory effects at much lower 
concentrations, with subsequently low IC 50 values of 0.7 and 1.1µg/ml.  This 
activity, together with the apparent lack of cytotoxicity, counts in the favour of 
these two compounds, particularly L17-3, which showed no toxicity at the highest 



















Higher plants with the ability to survive drought conditions represent a potentially 
interesting source of uniquely bioactive compounds.  Desiccation-tolerant plants 
have the ability to enter a quiescent state during prolonged dry periods and then 
spring back to life in the presence of water by channeling essential compounds 
into storage organelles.  Other than the compounds involved in the desiccation 
mechanisms, it is possible that these plants produce defensive metabolites to 
protect them from herbivores or environmental microbial pathogens.  
Furthermore, many of these plants have a history of use in traditional medicines.  
This project aimed to evaluate several desiccation-tolerant plants occurring in 
southern Africa for antimicrobial activity. 
 
3.2 Results: Desiccation-tolerant plants  
3.2.1 Antimicrobial activities of crude extracts 
As described in Section 7.8.2, sequential extracts were prepared from the plant 
material of four desiccation-tolerant plants, namely Myrothamnus flabellifolius 
(whole plant), Xerophyta retinervis (stem, husks and leaves), Cheilanthes 
contract (whole plant) and Selaginella dreggier (whole plant).  The extract yields 
are illustrated in Table 35 of the Appendix.  Figure 31 illustrates the four studied 
desiccation-tolerant plants.  The extracts were tested for activity against 
Staphylococcus aureus, Klebsiella pneumoniae, Candida albicans and 
Mycobacterium aurum  using the broth microdilution method as described in 
Section 7.2.  The results are exhibited in Table 9 as MIC’s.  IC50 values were 













Figure 31: Pictures of Xerophyta retinervis in flower (A) (R. Botha) and (B) desiccated state at 
collection (P.C. Zietsman); Myrothamnus flabellifolius in wet (C) and desiccated (D) states (P.C. 
Zietsman); Selaginella dregei (E) (P.C. Zietsman) and Cheilanthes contracta (F) (T. Kellermann) 
in their desiccated states. 
      
   
 
The antimicrobial controls were within an acceptable range for these assays and 
the highest concentration of DMSO, namely 2.5%, had no negative effect on 
organism growth when compared to the drug-free growth control.  For all of the 
assays, the organism-free wells remained free of growth indicating growth 
medium sterility.  Samples with an MIC of less than or equal to 125µg/ml were 
considered to be active.  None of the extracts exhibited activity against S. aureus 
or K. pneumoniae at the highest concentration tested, namely 2mg/ml.  Of the 30 
extracts tested, only the methanol extract of the stems of X. retinervis and the 
methanol extract of M. flabellifolius exhibited any activity.  The former was active 
against C. albicans with an MIC of 62.5µg/ml and against M. aurum with an MIC 
of 125µg/ml.  The methanol extract of the leaves and husks of X. retinervis did 
not exhibit the same activity, indicating the presence of compounds with 
antimicrobial activity unique to the stem, or alternatively present at large enough 
quantities in the stem to display appreciable activity.   
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Table 9: The antimicrobial activity of four South African desiccation-tolerant plants.  Results are 
expressed as MIC’s followed by IC50 values, where applicable, in µg/ml.   
Plant Extract S. aureus K. pneumoniae C. albicans M. aurum 
PE >2000 >2000 >2000 >2000 
DCM >2000 >2000 2000 2000 
EA >2000 >2000 2000 2000 
MeOH >2000 1000 <7.8 to >2000* >2000 
Myrothamnus 
flabellifolius 
water >2000 >2000 >2000 >2000 
PE >2000 >2000 >2000 1000 
DCM >2000 >2000 >2000 1000-2000 
EA 2000 >2000 >2000 2000 




water contamination >2000 >2000 >2000 
PE >2000 >2000 >2000 2000 
DCM 1000-2000 >2000 2000 2000 
EA 2000 >2000 2000 >2000 




water 2000 2000 >2000 >2000 
PE >2000 >2000 >2000 >2000 
DCM >2000 >2000 >2000 >2000 
EA 2000 >2000 2000 >2000 




water contamination >2000 >2000 >2000 
PE >2000 >2000 >2000 1000-2000 
DCM >2000 >2000 2000 >2000 
EA >2000 >2000 2000 >2000 
MeOH >2000 >2000 >2000 >2000 
Selaginella 
dregei 
water >2000 >2000 >2000 >2000 
PE >2000 >2000 >2000 >2000 
DCM >2000 >2000 >2000 >2000 
Ac >2000 >2000 2000 >2000 
MeOH >2000 >2000 250 >2000 
Cheilanthes 
contracta 





0.625, 0.247 ± 
0.103 
0.078, 0.042 ± 
0.002 




*variable activity which could not be replicated despite testing on eight separate occasions 
Abbreviations: MIC - minimum inhibitory concentration, PE - petroleum ether, DCM -  
dichloromethane, EA - ethyl acetate, Ac - acetone, MeOH - methanol, contam - contamination, 
Cip - ciprofloxacin, Nys - nystatin, INH - isoniazid 
 
The methanol extract of the whole plant of M. flabellifolius showed variable 
activity against C. albicans, initially as extremely potent activity (less than the 
lowest concentration tested, namely 7.8µg/ml) which became weaker with 
subsequent testing, eventually showing no activity at all.  The sample was freshly 
prepared on each day of testing from the solvent-free, but oily, crude extract to 













3.2.2 Myrothamnus flabellifolius fractions 
Due to the large quantity of M. flabellifolius available and the interesting, but 
variable, activity observed in the methanol extract, an exhaustive investigation of 
its possible pharmacological properties was undertaken, as illustrated by the 
flow-diagram in Figure 32.  As indicated in Chapter 7, IC50 values were only 
calculated for fractions with MIC’s of 62.5µg/ml or less.   
 
The DCM extract of M. flabellifolius did not show activity in the broth micro-
dilution methods employed (Table 9).  Despite these findings, this extract was 
further fractionated by means of liquid-liquid fractionation with ACN and PE to 
evaluate the possible existence of low levels of active compounds in a less 
complex mixture.   Bio-autography was used for the detection of possible actives 
in the fractions.  The ACN fraction of the DCM extract exhibited inhibition against 
S. aureus over a zone from the origin to an Rf value of 0.75 and against M. 
aurum A+ over a zone from Rf 0.4 to 0.69, as shown in Figure 33a. The PE 
fraction exhibited no activity against S. aureus, but two clear zones of inhibition at 
Rf 0.36 and 0.4, as well as a more faint zone at Rf 0.28, were observed against 
M. aurum as shown in Figure 33b.  TLC bands 1-3 from the PE fraction with 
activity against M. aurum were isolated as described in Section 7.8.4 and tested 
against M. aurum, S. aureus and K. pneumoniae in the broth microdilution assay.  
The PE extract was also further investigated using bio-autography against M. 
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Figure 33: An example of bio-autographic plates containing M. aurum A+ exhibiting a large zone 
of inhibition in the ACN fraction on the left (A) and three zones of inhibition in the PE fraction on 
the right (B) from the DCM extract of M. flabellifolius. 
 
 
The three active bands from the PE fraction of the DCM extract were 
subsequently isolated from a reference TLC plate and tested in the broth micro-
dilution method.  Despite showing activity against M. aurum in the bioautography 
assay, none of the three TLC bands had MIC’s of less than 1000µg/ml against 
this organism (Table 10).  
 
The ACN fraction of the DCM extract which showed a broad zone of activity 
against S. aureus and M. aurum using bio-autography was subsequently further 
purified into its constituents by means of HPLC to generate nine fractions (4-12).  
The small quantity of these fractions available was used to test for activity 
against S. aureus, C. albicans, M. aurum and K. pneumoniae and the results are 
exhibited in Table 10.  None of the fractions displayed potent activity against any 
of the organisms.  Fractions 4 to 11 exhibited MIC’s of 250µg/ml and fraction 12 
had an MIC of 250-500µg/ml against M. aurum, while fractions 9 to 12 displayed 
MIC’s of 250 to 500µg/ml against S. aureus. 
 
3: Rf = 0.40 
Large zone from 
Rf 0.4 to 0.69 
1: Rf = 0.28 














Table 10: The bioactivity of fractions originating from the dichloromethane and ethyl acetate 
extracts of Myrothamnus flabellifolius.  The results are described as MIC’s followed by IC50 
values, if applicable, in µg/ml.   
Extract Fraction Source S. aureus K. pneumoniae C. albicans M. aurum 
PE L-L >2000 >2000 >2000 >2000 
1 TLC 125-250 125-250 n/t >1000 
2 TLC 125-250 125-250 n/t >1000 
3 TLC 250-500 125 n/t >1000 
ACN L-L 1000-2000 >2000 2000 1000 
4 HPLC >1000 >1000 >1000 250 
5 HPLC >1000 >1000 >1000 250 
6 HPLC =1000 >1000 >1000 250 
7 HPLC 1000 >1000 >1000 250 
8 HPLC 500-1000 >1000 1000 250 
9 HPLC 250-500 >1000 >1000 250 
10 HPLC 250-500 >1000 >1000 250 
11 HPLC 250-500 >1000 >1000 250 
DCM 
12 HPLC 250-500 >1000 >1000 250-500 
Water L-L =2000 2000 =2000 2000 
DCM L-L >2000 >2000 2000 125-250 
PE L-L >2000 >2000 =2000 2000 
ACN L-L 500-1000 =2000 250 250 
13 HPLC >1000 >1000 >1000 >125 
14 HPLC >1000 >1000 >1000 >125 
15 HPLC >1000 >1000 1000 >500 
16 HPLC >1000 >1000 500 >500 
17 HPLC 1000 >1000 =1000 >500 
EA 
18 HPLC 500-1000 >1000 >125 >500 




0.08, 0.042 ± 
0.002 n/a n/a 




Nys   n/a n/a 3.1, 1.7 ± 
0.04 
n/a 
Abbreviations: MIC- minimum inhibitory concentration, TLC- thin layer chromatography, HPLC- 
high performance liquid chromatography, DCM - dichloromethane, ACN - acetonitrile, EA - ethyl 
acetate, L-L - liquid-liquid extraction, Cip - ciprofloxacin, INH - isoniazid, Nys - nystatin; n/t - not 
tested  
 
The ethyl acetate extract of M. flabellifolius was subjected to liquid-liquid 
extraction with DCM and water.  When evaluated against S. aureus, the DCM 
fraction exhibited a zone of inhibition over an Rf range of 0.13 to 0.44.  Further 
liquid-liquid extraction of the DCM fraction with ACN and PE was performed to 
prepare the sample for HPLC fractionation.  The ACN fraction was further 
purified by means of HPLC into six fractions (13-18), as described in Section 













against S. aureus, K. pneumoniae, M. aurum and C. albicans and the results are 
shown in Table 10.  None of these fractions displayed activity against any of the 
organisms tested.  
 
The initial potent activity exhibited by the methanol extract of M. flabellifolius 
against C. albicans in the broth micro-dilution method (Table 9) prompted a 
thorough fractionation and investigation into the bioactive constituents.  A liquid-
liquid extraction of the extract yielded an ethyl acetate and a water fraction.  The 
ethyl acetate fraction was further fractionated by means of HPLC, as described in 
Section 7.8.4, into seven fractions (19-25).  These seven HPLC fractions were 
tested against a range of organisms at three concentrations (0.5, 1 and 2 mg/ml) 
and the results are displayed in Table 11 below.  Similarly, the water fraction was 
also further fractionated into six fractions (26-31) and these samples were tested 
only against C. albicans due to small sample quantities and potent activity 
displayed against this organism of the precursor water fraction.  However, none 
of these samples displayed activity at less than 500µg/ml (data not shown).  
 
Table 11: The MIC’s (µg/ml) of the seven fractions resulting from the semi-preparative HPLC 
separation of the ethyl acetate fraction of the methanol extract of Myrothamnus flabellifolius.  The 
precursor fractions arising from the liquid-liquid extraction of the methanol extract with ethyl 
acetate and water are also recorded here.   
Fraction M. aurum  S. aureus  K. pneumoniae  C. albicans  
Water >2000 >2000 >2000 <7.8 - >2000* 
EA 1000 2000 2000 <7.8 - >2000* 
19 > 2000 > 2000 2000 = 2000 
20 > 2000 1000 1000 2000 
21 > 2000 <500 1000 >2000 
22 > 2000 1000 1000 >2000 
23 > 2000 2000 2000 = 2000 
24 > 2000 > 2000 2000 = 2000 
25 > 2000 2000 >2000 >2000 
*activity dissipates with repeated testing  
Abbreviations: EA - ethyl acetate 
 
None of the HPLC fractions originating from the EA fraction of the methanol 
extract of M. flabellifolius exhibited activity against M. aurum A+ at the highest 
concentration tested, namely 2mg/ml.  Fraction 21 was the only sample to exhibit 














excellent activity of the crude methanol extract, as well as the EA and water 
fractions thereof, against C. albicans (original MIC of less than 7.8µg/ml), none of 
the HPLC fractions exhibited inhibition at less than 2mg/ml against this organism.  
Interestingly, fractions 20 to 22 exhibited some activity, albeit poor, against K. 
pneumoniae with MIC’s of 1mg/ml. 
 
Figure 34: The dose response curves of (A) compound 21c (pure) and (B) fraction 21d from the 
third HPLC fraction of the methanol extract of M. flabellifolius against S. aureus ATCC 12600.  
Figure (C) illustrates the effect of ciprofloxacin on S. aureus. 
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Based on the results described in Table 11, further HPLC purification of fraction 
21 arising from the ethyl acetate fraction of the methanol extract of M. 
flabellifolius was performed.  This fractionation step, as described in Chapter 
7.8.4, yielded six partially or completely pure compounds (21a-f).  These 
fractions/compounds were tested against S. aureus ATCC 12600 at serially 
diluted concentrations ranging from 0.5 to 250µg/ml.  Fractions/compounds a, b, 
e and f did not exhibit activity at the highest concentration tested, while 














illustrated by the dose response curve in Figure 34A.  Fraction d showed slight 
inhibition of bacterial growth (IC 50 175µg/ml) (Figure 34B).  
 
It appears from this set of data that despite the initial potent antifungal activity 
exhibited by the methanol extract of M. flabellifolius and its subsequent liquid-
liquid fractions, activity deteriorates with subsequent testing, as well as with 
further chromatographic purification.  Due to the variable nature of this activity, as 
well as time constraints, further work on M. flabellifolius was discontinued. 
 
3.3 Discussion 
Of the 30 crude extracts prepared from four species of desiccation-tolerant 
plants, only two samples exhibited activity at less than or equal to 125µg/ml, 
namely the methanol extract of the stems of X. retinervis and the methanol 
extract of M. flabellifolius.  Two other parts of X. retinervis, namely the husks and 
leaves, were also sequentially extracted and did not exhibit the same activity as 
seen in the methanol extract of the stems.  It can therefore be concluded that the 
compounds responsible for activity are either unique to the stems or are present 
in the husks and leaves in much smaller quantities.  The acetone and methanol 
extracts of X. retinervis have previously been shown to exhibit moderate activity 
(greater than or equal to 250µg/ml) against a range of Gram-positive and –
negative bacteria, as well as C. albicans (Seaman, 2005). Compounds with anti-
malarial activity have been isolated from X. retinervis and the related X. villosa 
(Wiesner, 2007).  Further work on X. retinervis in this project was discontinued 
due to the availability of more potent antibacterial compounds isolated from the 
lichen T. chrysophthalmum, as described in Chapter 2. 
 
The activity of the methanol extract of M. flabellifolius against C. albicans was 
variable.  Initial experiments showed the activity to be very low (less than 
7.8µg/ml), but these results could not be confirmed with the activity becoming 














each experiment.  Further fractionation of the extracts also led to a loss of 
antifungal activity.  Despite the intensive fractionation of all but the petroleum 
ether extracts, none of the fractions exhibited activity at less than 125µg/ml.  It is 
possible that the initial potent activity exhibited by the methanol extract of M. 
flabellifolius could have resulted from the co-extraction of the active essential oil, 
which has been shown to exhibit antifungal activity (Viljoen et al., 2002).  This 
particular extract had a very oily texture, despite the solvent being removed 
under nitrogen.  Essential oils contain many volatile components which could be 
prone to evaporation over time if not stored under conditions suitable for such a 
substance.  The possibility also exists that the instability of the active ingredient 
led to its degradation (Taylor et al., 2001) and subsequent loss of activity.  Even 
in the unlikely event that the active constituent of this plant was isolated, its 
potential instability would make it an unsuitable drug-like compound.  For this 
reason, further work on this plant was discontinued.   
 
Kelmanson et al. (2000) found that the methanol extracts of Cheilanthes viridis 
leaves and stems from South Africa exhibited antimicrobial activity against Gram-
positive and –negative bacteria using the disc diffusion method.  The methanol 
extract of the leaves was shown to have MIC’s of 4mg/ml against S. aureus, P. 
aeruginosa and Micrococcus luteus, and an MIC of 8mg/ml against Bacillus 
subtilis in the broth micro-dilution method.  However, the results of this project 
found that a related species, namely C. contracta, with similar desiccation 
tolerance, did not exhibit any activity against the bacteria tested.  It should be 
noted, however, that the extracts in this project were tested at a maximum 
concentration of 2mg/ml as higher concentrations of crude extracts affect 
visualisation of results due to colour interference.  Furthermore, extracts were 
only considered to be active and worth pursuing if activity of 125µg/ml or less 
was observed, as recommended by various authors (Cos et al., 2006; Newton et 
al.,2002; Rios and Recio, 2005), while some even recommend a lower cut-off 















The results of the antimicrobial testing of these South African desiccation-tolerant 
plants are somewhat surprising, as most of these species, or related species, are 
used in the medicinal treatment of microbial-associated diseases (Hutchings et 
al., 1996; Van Wyk et al., 2002).  It is possible that these plants are in fact not 
used to kill or inhibit the growth of disease-causing organisms, but rather to 
alleviate the symptoms of the disease (Newton et al.,2002), or alternatively to 
boost the host immune system (Cos et al., 2006).  Furthermore, it has been 
suggested that higher plants in fact only produce antimicrobial substances when 
counteracting a pathogenic infection, as the manufacture of such substances 



















Trees belonging to the Warburgia genus are widely used across the African 
continent as potent traditional medicines (Muthaura et al., 2007; Olila et al., 
2001).  In Southern Africa, the bark of W. salutaris is used to treat a wide variety 
of ailments, including coughs, colds and miscellaneous chest complaints 
(Hutchings et al., 1996; Van Wyk et al., 2002).  Plant parts of commercially 
cultivated W. salutaris were made available for this project with the intention of 
investigating the pharmacological efficacy of this plant.  As described in Section 
7.9.2, sequential extracts were prepared from the bark, leaves, stems and twigs 
which were subsequently tested for in vitro antimicrobial activity.  The most active 
extracts and resulting fractions or compounds were then also tested for 
cytotoxicity with the intention of evaluating a fraction with in vitro activity, 
consisting of identified compounds, in an animal model to determine which 
compounds have the most promising pharmacological profile. 
 
4.2 Results: Warburgia salutaris 
4.2.1 Bioactivity of crude extracts 
DCM, ethyl acetate and methanol extracts of various plant parts of W. salutaris 
were prepared, as described in Section 7.9.2 and the extract yields are tabulated 
in the Appendix, Table 36.  The crude extracts of the leaves, bark, stem and 
twigs of Warburgia salutaris were tested against S. aureus, K. pneumoniae, C. 
albicans and M. aurum as described in Chapter 7.2.  The results are displayed in 
Table 12.  Four extracts had activity at 125µg/ml or less, namely the DCM 














the DCM extract of the leaves.  These extracts were all active against C. 
albicans, with the DCM extract of the bark having the lowest MIC of 7.8 to 
15.6µg/ml, and an IC50 value of 4.24µg/ml, as illustrated in Figure 35.  The DCM 
extract of the bark also exhibited activity against S. aureus and M. aurum (MIC’s 
of 62.5 and125µg/ml respectively).   
 
Table 12: The activity of Warburgia salutaris extracts against Staphylococcus aureus, Klebsiella 
pneumoniae, Candida albicans  and Mycobacterium aurum.  The results are described as MIC’s 











PE >2000 >2000  >2000 >2000 
DCM 1000-2000 2000 250 1000 
EA 2000 >2000 >2000 2000 
MeOH >2000 >2000 >2000 >2000 
Leaves 
ACN 250 2000 31, 20.64±2.85 250 
DCM 62.5, 19.4±2.2   >2000 7.8– 15.6, 
4.2±0.4 
125, 60.9±6.4 
EA >2000 >2000 250-500 2000 
Bark 
MeOH 2000 >2000 >2000 2000 
DCM 250-500 2000 31, 17.4±0.3 250 
EA >2000 >2000 >2000 2000 
Stems 
MeOH =2000 =2000 >2000 >2000 
DCM 250 >2000 31, 17.6±0.5 500 
EA >2000 >2000 >2000 2000 
Twigs 






Nys n/a n/a 1.6, 0.96±0.25 n/a 
Controls 
INH n/a n/a n/a 0.078, 
0.062±0.014 
Abbreviations: PE - petroleum ether; DCM - dichloromethane; EA - ethyl acetate; MeOH - 
methanol; ACN - acetonitrile; Cip - ciprofloxacin; Nys- nystatin; INH - isoniazid 
 
 
Figure 35: The dose response curve of the dichloromethane extract of Warburgia salutaris bark 
against Candida albicans ATCC 90028.  This data represents nine replicates performed over 
three separate experiments. 




























A comparison of the chromatographic profiles of the DCM extracts of the leaves 
(ACN fraction), bark, stems and twigs indicate that the same predominant 
compounds appear in all of these plant parts eluting at approximately 17.5, 18.3, 
21.2 and 22.6 minutes.  These HPLC profiles are shown in Figures 36 to 39 
respectively, generated as described in Section 7.9.3.   
 
Figure 36: A chromatogram of the acetonitrile fraction of the dichloromethane extract of the 


































































































































































The most active extracts, namely the DCM extracts of the leaves (ACN fraction), 
bark, stems and twigs were further evaluated for cytotoxicity against CHO cells, 















Table 13: The cytotoxicity of the four most active crude extracts from Warburgia salutaris.  The 
results are displayed as IC50 values in µg/ml and the selectivity indices (cytotoxicity/activity 
against C. albicans) are shown. 
Plant part Extract IC50 value SI value  
Leaves 
ACN fraction from 
DCM 
3.791±0.296 0.18 
Bark DCM 3.829±2.929 0.90 
Stems DCM 5.218±3.511 0.30 
Twigs DCM 6.209±1.031 0.36 
Control Emitine 0.085±0.004 n/a 
Abbreviations: SI - selectivity index; ACN - acetonitrile; DCM - dichloromethane 
 
From Table 13, it is evident that the extracts which exhibited the most potent 
antimicrobial activity are also extremely toxic to CHO cells as indicated by the 
IC50 values of less than 10µg/ml.  Furthermore, the selectivity indices were 
calculated for the activity against C. albicans (the most potent antimicrobial 
activity observed) and the values are very low for all of the tested extracts.  For a 
pure compound to be considered a promising hit it should have a value of 10 or 
greater, indicating low cytotoxicity coupled with good antimicrobial activity (Orme, 
2001).  In the instance of crude extracts which may consist of many different 
compounds, it is possible that only one or a few of the compounds are 
responsible for the potent cytotoxicity.  For this reason, it was decided to 
continue with the fractionation of the extract which exhibited the most potent 
broad-spectrum antimicrobial activity together with the best SI value, namely the 
DCM extract of the bark of W. salutaris.  This is also the plant part most 
frequently utilized in traditional medicine applications (Van Wyk et al., 2002; 
Hutchings et al., 1996). 
  
4.2.2 Antimicrobial activity of the bark dichloromethane fractions 
The DCM extract of the bark of W. salutaris, which displayed the most potent 
activity against C. albicans, was further fractionated by means of liquid-liquid 
fractionation into a petroleum ether fraction (WSBD1), an insoluble layer 














(WSBD3).  These four fractions were tested for activity against C. albicans and 
M. aurum and the results are exhibited in Table 14. 
 
Table 14: The effect of the fractions of the dichloromethane extract of the bark of Warburgia 
salutaris on Candida albicans and Mycobacterium aurum.  The results are expressed as MIC’s 
followed by IC50 values where applicable, in µg/ml.   
Fraction Candida albicans ATCC 90028 Mycobacterium aurum A+ 
WSBD1 31.3, 16.4±0.4 >250 
WSBD2 31.3 – 62.5, 17.9±1.1 >250 
WSBD3 7.8, 4.3±0.2 125, 53.6±8.0 
WSBD4 7.8, 4.0±0.5 62.5, 47.8±12.7 
Nystatin 0.8, 0.6±0.4 n/a 
Isoniazid n/a 0.08 – 0.16, 0.066±0.004 
 
HPLC chromatograms of these four fractions, generated as described in Section 
7.9.4 and displayed in Figures 59 and 60 of the Appendix, indicated similarities 
between WSBD1 and WSBD2, reflected by similar bioactivities.  Fractions 
WSBD3 and WSBD4 had MIC’s of 7.8µg/ml against C. albicans and also 
displayed similar bioactivity (MIC of 125 and 62.5µg/ml respectively) against M. 
aurum.  Furthermore, these two fractions also showed similar chromatographic 
profiles, as shown in Figures 40 and 41.  They were subsequently collected 
together and referred to as the acetonitrile fraction of the DCM extract of W. 















Figure 40: The HPLC chromatogram of fraction WSBD3 from the acetonitrile fraction of the 



























Figure 41: The HPLC chromatogram of fraction WSBD4 from the acetonitrile fraction of the 


































Eight HPLC fractions were subsequently collected from WSBDA, as described in 
Chapter 7.9.4 and exhibited in Figure 57.  These fractions were tested against C. 
albicans and M. aurum, as well as for cytotoxicity against CHO cells , as shown in 
Table 15.  Fractions three and five were accidentally combined and therefore 















Table 15: The effect of eight HPLC fractions isolated from WSBDA, the acetonitrile fraction of the 
dichloromethane extract of the bark of Warburgia salutaris, on Candida albicans and 
Mycobacterium aurum.  The results are expressed in terms of MIC’s and IC50’s, where applicable, 
in µg/ml.  The cytotoxicity results against CHO cells are recorded as IC50 values in µg/ml. 
 C. albicans ATCC90028 M. aurum A+ CHO 
Fraction MIC IC50 MIC IC50 IC50 
1 >250 n/a >250 n/a >100 
2 =250 n/a >250 n/a 15.3±11.49 
3+5 125 33.0±6.1 250 n/a 8.5±3.24 
4 31.3 - 62.5 19.2±0.2 62.5 28.0±7.1 1.4±0.77 
6 7.8 – 15.6 5.8±0.9 125 27.5±6.3 2.6±0.15 
7 7.8 4.7±0.3 125 - 250 n/a 21.7±4.78 
8 62.5 - 125 32.9±15.6 62.5 - 125 41.4±11.3 1.4±0.60 
Nystatin 1.6 1.2±0.3 n/a n/a n/a 
Isoniazid n/a n/a 0.078 0.0698±0.0008 n/a 
Emitine n/a n/a n/a n/a 0.08±0.006 
 
Table 15 shows that fractions six and seven exhibit the greatest antifungal 
activity with IC50 values of 5.8 and 4.7µg/ml, respectively, while fractions four and 
six show the strongest antimycobacterial activity with IC50 values of 28.0 and 
27.5µg/ml respectively.  However, fractions 4 and 8 display the greatest 
cytotoxicity with IC50 values of 1.44 and 1.43µg/ml respectively.  Due to the fact 
that fraction six was available in the largest quantities and appeared to have the 
most complex chromatographic profile, it was further purified into its seven 
primary constituents, as described in Section 7.9.4.  These seven 
fractions/compounds were subsequently tested for activity against C. albicans 
and M. aurum, as well as for cytotoxicity against CHO cells  (Table 16). 
 
From Table 16, it is evident that as with the DCM extract of the bark of W. 
salutaris, the subsequent pure/semi-pure compounds arising from the ACN 
fraction of this extract responsible for bioactivity are also extremely cytotoxic.  
Compounds 4, 5 and 6, subsequently identified as the well-known drimane 
sesquiterpenoids muzigadial, warburganal and ugandensidial, exhibited the most 
potent activity against both C. albicans and M. aurum , but other than 














Table 16: The bioactivity of seven HPLC fractions and pure compounds isolated from fraction six 
of the acetonitrile fraction of Warburgia salutaris bark dichloromethane extract.  The antimicrobial 
results are described as MIC’s, followed by IC50 values, if applicable, in µg/ml.  The cytotoxicity 
results are described as IC50 values in µg/ml. 
Fraction/ 
compound 
C. albicans M. aurum Cytotoxicity 
SI for 
C. albicans 
H6-1 125 125 0.5±0.06 n/a 
H6-2a =250 >250 50.3±3.8 n/a 
H6-2b 250 >250 55.6±7.95 n/a 
H6-3 125 >250 32.5±6.1 n/a 
H6-4 (muzigadial) 3.9-7.8, 2.1±0.04 125 4.3±2.3 2.1 
H6-5 (warburganal) 7.8-16.6, 4.5±0.08 125 1.7±1.3 0.4 
H6-6 (ugandensidial) 31.3-62.5, 25.2±11.41 125 1.2±1.6 0.05 





Emetine n/a n/a 0.045±0.03 n/a 
 
The other two fractions arising from the HPLC separation of the ACN fraction of 
the DCM extract of W. salutaris bark exhibiting potent antimycobacterial and 
antifungal activity, namely fractions 4 and 7 (Table 15), were also subjected to 
HPLC fractionation and those pure/semi-pure compounds were further tested 
against C. albicans and M. aurum (Table 17).  
 
Of the 12 pure/semi-pure compounds arising from HPLC fractions 4 and 7 of the 
ACN fraction of the DCM extract of the bark of W. salutaris, the most promising 
activity was from H7-4, which exhibited an IC 50 of 15.3µg/ml against C. albicans.  
The only fraction for which sufficient quantities remained for cytotoxicity testing 
was H7-1 with an IC50 of 2.05µg/ml.  The observed moderate to poor activity of 
these 12 pure/semi-pure compounds prevented further collection and 














Table 17: The activity of the fractions/compounds isolated from the HPLC fractions 4 and 7 of the 
acetonitrile fraction of the dichloromethane extract of Warburgia salutaris bark against Candida 
albicans and Mycobacterium aurum.  Each result is displayed as an MIC value, followed by the 
IC50 value where applicable, in µg/ml. 
Fraction/compound C. albicans M. aurum 
H4-1 >250 125 
H4-2 125-250 125-250 
H4-3 >250 >250 
H4-4 >250 >250 
H4-5 62.5, 38.9±0.56 =250 
H4-6 62.5-125, 45.0±17.15 125-250 
H7-1 31.3-62.5, 13.2±6.66 125-250 
H7-2 125 250 
H7-3 15.6-31.3, 19.1±1.86 >250 
H7-4 31.3, 15.3±4.17 >250 
H7-5 >250 >250 
H7-6 =250 >250 
Nystatin 1.6, 0.78±0.11 n/a 
Isoniazid n/a 0.15, 0.068±0.002 
 
Due to the cytotoxic nature of the most active compounds and fractions isolated 
in this study, the use of an active fraction of Warburgia salutaris for the 
development of an in vivo method to fast-track pharmacokinetic profiling of lead-
like compounds was not continued.  
 
4.2.3 Identification of compounds isolated from W. salutaris 
The structures of the three most active compounds isolated from fraction six 
arising from the HPLC separation of the ACN fraction of the DCM extract of the 
bark of W. salutaris, namely compounds 4, 5 and 6 shown in Figure 42 were 















Figure 42: A chromatogram at 229nm of fraction six originating from the HPLC separation of the 






























The spectroscopic methods used for structure elucidation are described in 
Section 7.9.5.  The compounds were identified as the drimane sesquiterpenoids 
muzigadial (4), warburganal (5) and ugandensidial (6).  The 13C and 1H NMR 
spectra are displayed in the Appendix, Figures 80 to 85, while the assigned 
resonances are displayed in Tables 18 and 19.  The chemical structures are 
depicted in Figure 43.  
 
 
Figure 43: The chemical structures of muzigadial (4), warburganal (5) and ugandensidial (6) 





























































Table 18: The resonances of the 13C NMR spectra of muzigadial, warburganal and ugandensidial 
isolated from the bark of Warburgia salutaris. 
 Muzigadial (d) Warburganal (d) Ugandensidial (d) 
C1 31.95 31.36 32.02 or 32.79 
C2 31.09 17.95 17.88 
C3 38.43 41.50 44.21 
C4 151.85 33.25 34.21 
C5 40.47 41.93 45.16 
C6 27.84 26.16 66.26 
C7 136.07 157.72 148.86 
C8  140.53 141.14 
C9 77.86 77.90  
C10 43.23 41.67 41.85 
C11 201.43 202.4 201.32 
C12 192.89 192.86 193.24 
C13 15.32 33.25 32.02 or 32.79 
C14 18.64 22.31 24.96 
C15 106.31 17.29 20.15 
   CH3CO 21.67 
   CH3CO 170.27 
 
All three of these drimane sesquiterpenoids have the characteristic aldehydes 
resonances at positions 11 and 12 (d = 201 to 202 and 192 to 193 respectively).  
The carbon spectrum of ugandensidial corresponds well with that described by 
Clarkson et al. (2007), the most prominent feature being the resonances of the 
carbons corresponding with the acetoxy group (21.67 and 120.27).  The three 
compounds all have methyl groups at position 13, and warburganal and 
ugandensidial each have a further two methyl groups at position 4.  In this same 
position on muzigadial, a double bonded methine group occurs, and a further 




















Table 19: The resonances of the 1H NMR spectra of muzigadial, warburganal and ugandensidial 
isolated from the bark of Warburgia salutaris. 
 Muzigadial (d) Warburganal (d) Ugandensidial (d) 
H-1   a: 1.77 (d, J=12, 5.5Hz) 
ß: 0.98 (m) 
H-2 2.00 (2H, m)  a: 1.52 (dm, J=12, 6Hz) 
ß: 1.59 (qt, J=12, 4.5Hz) 
H-3 4.39 (1H, m, J=6Hz)  a: 1.27 (tm, J=18, 9Hz) 
ß: 1.39 (dm, J= 12Hz) 
H-5 2.63 (1H, m) 1.89 (1H, dd, J=6, 6Hz) 2.04 (1H, d, J=6Hz) 
H-6  a: 2.58 (1H, dt; J=18, 6Hz) 
ß: 2.34 (1H, ddd, J=12, 
6Hz) 
 
5.89 (1H, t, J=6Hz) 
H-7 7.23 (m) 7.25 (m) 7.00 (1H, d, J=4.8Hz) 
H-11 9.65 (1H, s) 9.72 (1H, s) 9.76 (1H,s) 
H-12 9.44 (1H, s) 9.41 (s) 9.48(1H, s) 
H-13 0.87 (3H, s) 0.94 (3H, s) 1.02 (s) 
H-14 1.08 (1H, d, J=6Hz) 0.99 (3H, s) 1.16 (s) 
H-15 4.93 and 4.76 (2x1H, 2xbr) 1.09 (3H, s) 1.33 (s) 
9-OH  4.08 (1H, s) 4.10 (1H,brs) 
CH3CO   2.14 (s) 
 
For muzigadial and warburganal, the multiplicity of the proton resonating at 
approximately 7.23 to 7.26 was obscured due the solvent peak, chloroform.  The 
proton spectrum for all three compounds showed the presence of two aldehyde 
groups (d = 9.7, H-11; 9.4, H-12) and an olefinic hydrogen doublet or multiplet at 
d = 7.0 (H-7).  Ugandensidial shows a resonance for a methine group (d = 5.89, 
H-6) associated with an acetoxy group (d = 2.14).  Warburganal and 
ugandensidial each have three methyl singlets (H-13, H-14, and H-15.  
Muzigadial is characterized by the methine group at H-15 (d4.93 and 4.76).  This 
compound has a molecular formula of C15H20O3 and a reported molecular mass 
of 248.1412. The molecular formula for ugandensidial is C17H24O5 and the 
compound has a reported mass of 308.1624, while warburganal has a m/z of 
















Testing of the extracts of various plant parts of W. salutaris revealed that the 
dichloromethane extracts of the woody material, namely the bark, stems and 
twigs, displayed potent activity against yeast and moderate activity against 
Gram-positive bacteria and mycobacteria.  Poor activity of crude plant extracts 
against Gram-negative bacteria as observed in this project has previously been 
reported (Rabe and Van Staden, 1997).  
 
This study adds to the wealth of knowledge available on the potent antimicrobial 
activity of the bark of this genus.  The methanol and water extracts of the bark of 
W. salutaris have been reported to exhibit activity against Gram-positive bacteria 
in the disc-diffusion assay, while the methanol extract also showed some activity 
against E. coli (Rabe and Van Staden, 1997).  When evaluating the methanol 
extract in a broth micro-dilution assay, the authors observed an MIC of 0.5mg/ml 
against S. aureus and B. subtilis, and an MIC of 2mg/ml against Staphylococcus 
epidermis. In the current project, the methanol extract of the bark of W. salutaris 
exhibited an MIC of 2mg/ml against S. aureus.  This observed difference in 
activity to that reported by Rabe and Van Staden could be due to many factors, 
including environmental influences.  However, it is most likely that in the current 
project the active components were extracted earlier in the sequential extraction 
process, while these authors only prepared methanol and aqueous extracts of 
the plant material.  Extracts of the stem bark of a related species, W. ugandensis, 
have previously been shown to have antibacterial and antifungal activity, with the 
component responsible for the antifungal activity being muzigadial (Olila et al., 
2001).   
 
Extracts of the bark of this genus have also displayed antimalarial activity against 
chloroquine sensitive and resistant strains of Plasmodium falciparum , while 














2007), as well as antileishmanial activity (Ngure et al., 2009).  Despite not 
showing good antimicrobial activity in this study, extracts of the leaves of W. 
salutaris have previously been shown to exhibit in vitro anti-inflammatory and 
antioxidant activity, suggesting a basis for their use in treating topical skin 
diseases in Southern Africa (Frum and Viljoen, 2006; Muchuweti et al., 2006).  
An aqueous extract of the leaves has also been shown to have good molluscidal 
activity (Clark and Appleton, 1997).  
 
The extracts with good in vitro antimicrobial activity were evaluated for in vitro 
cytotoxicity against CHO cells.  The results indicated that all of the extracts were 
more cytotoxic than they were active.  In vitro cytotoxicity from crude extracts of 
the genus Warburgia has previously been reported (Olila et al., 2002).  However, 
there have also been reports of weak cytotoxicity from extracts of the stem bark 
of this genus.  Ngure et al. (2009) found that the hexane extract W. ugandensis 
displayed less toxicity to VERO cells than the control drug, pentostam, but the 
dichloromethane and ethyl acetate extracts were more toxic.  However, the 
authors report that none of the extracts were toxic at less than 31.25µg/ml and 
the hexane and DCM extracts had cytotoxicity comparable to that of 
amphotericin B (Ngure et al., 2009).  Similarly, Muthaura et al. (2007) reported 
the cytotoxicity of the methanol extract of the bark against VERO cells as being 
233µg/ml (IC50).   In this project, the dichloromethane extracts of the bark, stem 
and twigs all exhibited potent cytotoxicity of less than 10µg/ml.  It is possible that 
the difference in cytotoxicity compared to the two latter literature reports is due to 
the use of the CHO cell line for in vitro cytotoxicity testing as opposed to VERO 
cells. 
 
Despite the observed cytotoxicity, further fractionation of the very active 
dichloromethane extract was continued due to the possibility that only a small 
portion of the compounds are responsible for the toxic effects.  A liquid-liquid 
extraction of the crude plant material was prepared using acetonitrile and 














activity against C. albicans (IC50’s of 4.3 and 4.0µg/ml) and moderate activity 
against M. aurum.  The similar chromatographic profile allowed for these 
fractions to be combined and separated by means of HPLC into eight further 
fractions.  Fractions 6 and 7 displayed the most potent activity against C. 
albicans with IC50’s of 5.75 and 4.7µg/ml respectively, while fractions 4 and 6 
displayed moderate activity against M. aurum (IC50’s of 28.0 and 27.5µg/ml 
respectively).  In vitro cytotoxicity testing against CHO cells revealed that 
fractions 4, 6 and 7 had IC 50’s of 1.44, 2.6 and 21.7µg/ml respectively.  These 
three fractions were still further purified to obtain 6, 7 and 6 pure or partially pure 
compounds respectively.  These 19 pure/semi-pure compounds were tested 
against M. aurum and C. albicans.   
 
The compound with the most promising antifungal activity was H6-4 with an IC50 
of 2.07 against C. albicans.  This compound also displayed cytotoxicity with an 
IC50 4.3µg/ml, resulting in an SI value of 2.1.  H6-4 was identified as the drimane 
sesquiterpenoid muzigadial, which has previously been identified as the primary 
compound responsible for antifungal activity in W. ugandensis (Olila et al., 2001).  
The proton spectrum for muzigadial is in agreement with that published by Kioy 
et al. (1990) and Ying et al. (1995).  Muzigadial has also been shown to display 
potent antibacterial activity (Rabe and Van Staden, 2000).  H6-5 also had good 
antifungal activity with an IC 50 value of 4.45µg/ml against C. albicans, and 
cytotoxicity at 1.7µg/ml, leading to an SI value of 0.4.  Spectroscopic methods led 
to it being identified as warburganal, another well-known drimane 
sesquiterpenoid with antimicrobial activity frequently isolated from the family 
Canellaceae (Taniguchi et al., 1984).  The NMR spectra of warburganal are in 
agreement with those published by Kioy et al. (1990), Mashimbye et al. (1999) 
and Hollinshead et al. (1983). The most abundant compound in fraction 6 was 
identified as the structurally related ugandensidial, with moderate antifungal (IC 50 
of 25.2µg/ml) activity and potent cytotoxicity (IC 50 of 1.16µg/ml).  The structure 
for ugandensidial is in agreement with that proposed by Clarkson et al. (2007) 














antimycobacterial fraction arising from an extract of W. salutaris bark (Clarkson 
et al., 2007).  However, this research has shown that ugandensidial only exhibits 
moderate activity against mycobacteria (MIC of 125µg/ml).  Three further 
pure/semi-pure compounds showed moderate antifungal activity, namely H7-1 
(IC50 of 13.2µg/ml), H7-3 (IC50 of 19.1µg/ml) and H7-4 (IC50 of 15.3µg/ml).  
However, the isolated pure/semi-pure compounds of fractions 4 and 7 exhibited 
decreased activity against C. albicans and M. aurum in comparison to the original 
fractions, suggesting that the compounds may work together synergistically to 
obtain the observed bioactivity.  None of the 19 compounds displayed activity 
against M. aurum at less than 125µg/ml. 
 
Two comprehensive reviews by Jansen and De Groot (1991 and 2004) 
summarise the occurrence and biological activity of drimane sesquiterpenoids 
based on literature reports up to 2003.  These bioactivities include antibacterial, 
antifungal, antifeedant, plant-growth regulatory, cytotoxic, phytotoxic, piscicidal 
and molluscicidal effects.  Drimane sesquiterpenoids are relatively rare in nature 
(Jansen and De Groot, 2004), but occur frequently within the family Canellaceae 
(Bastos et al., 1999) and have been isolated from fungi, molluscs and marine 
sponges (Jansen and De Groot 1991 and 2004).  Several methods have been 
proposed for the synthesis of these bioactive compounds, including enzymatic, 
cationic polyolefin cyclization, from decalones, radical cyclizations and by 
cycloaddition reactions (Jansen and De Groot, 2004).  Hollinshead et al. (1983) 
have shown that it is possible to synthesise drimane sesquiterpenoids by means 
of diels-alder reactions.  Furthermore, research has shown that sesquiterpenoid 
dialdehydes may function as vanilloid receptors, and therefore may represent 
leads for the development of vanilloid drugs (Szallasi et al., 1998; Sterner and 
Szallasi, 1999).   
 
Taniguchi et al. (1984) have shown that muzigadial and warburganal have similar 
antimicrobial activity, while polygodial has greater activity, suggesting that the 














that the 9ß-aldehyde group confers antimicrobial activity and that the activity of 
the Warburgia sesquiterpene dialdehydes can potentially be attributed to their 
very specific reactivity with sulfhydral groups at the enal moiety.  Wube et al. 
(2005) noted that the polarity of these compounds appears to influence 
antimycobacterial activity, where greater lipophilicity elicits better in vitro activity.  
Kubo and Taniguchi (1988) isolated three drimane sesquiterpenoids, namely 
polygodial, muzigadial and warburganal, from W. ugandensis and W. stuhlmanii.  
They demonstrated that the structurally most simple of these compounds, 
polygodial, was more active than the commercial antifungal, amphotericin B, 
which is also highly toxic to humans.  Furthermore, the authors demonstrated 
that polygodial used in conjunction with actinomycin D against Saccharomyces 
cerevisiae, remarkably improved the activity of this drug.  This same drug is 
relatively inactive against Candida utilis.  However, when used in combination 
with polygodial, the activity was significantly improved.  The primary target of 
polygodial action was shown to be the plasma membrane and the authors 
hypothesize that this compound could be used to facilitate the movement of 
drugs into cells by punching holes in the membrane, which could furthermore 
allow for the use of safer, lower doses of conventional drugs.   
 
An aim of this project was to develop a method in which the pharmacokinetic 
profile of an active fraction of a well-known medicinal plant, namely W. salutaris, 
could be evaluated.  Current pre-clinical drug development focuses on testing the 
bioavailability of a single active compound at a time.  However, in medicinal 
plants the activity does not necessarily arise as a result of a single active, but 
instead due to multiple active components.  The ability to test an active fraction 
containing many compounds could speed up the drug development process 
significantly.  However, the medicinal plant chosen for this evaluation showed 
severe toxicity in all of the active extracts and fractions tested, making it 
















In vivo bioavailability of lichen-derived compounds 
 
5.1 Introduction 
Two compounds with promising in vitro activity against S. aureus and low 
cytotoxicity were isolated from the lichen Teloschistes chrysophthalmum, as 
described in the Chapter 2.  The next step in the drug development process is to 
determine whether or not these hit compounds have good lead-like properties.  
Some of the properties that need to be investigated are in vivo toxicity and 
bioavailability to determine whether or not the compounds would theoretically be 
capable of clearing an S. aureus infection in vivo (Koehn and Carter, 2005; 
Butler, 2004; Lipinski et al., 2001; Wunberg et al., 2006).   
 
Traditionally, researchers would immediately test promising compounds for 
efficacy in an in vivo model of disease.  However, the majority of compounds with 
promising in vitro activity are either toxic or poorly absorbed.  It therefore makes 
sense to first determine bioavailability of the test compound in a small animal 
model.   The advantage of performing these experiments earlier on in the drug 
development process is that within a relatively short period of time, one can 
determine whether or not the compound is bioavailable or is toxic to the test 
animals.  Furthermore, from an ethical perspective, in most cases it will negate 
the need to inflict unnecessary trauma on test animals as would be the case in a 
disease model.  Previous work done at the Division of Pharmacology has shown 
that it is possible to do bioavailability studies on small numbers of mice by using 
10µl of blood per sampling point with the use of LC-MS/MS technology.  It is 
therefore not necessary to sacrifice an animal at every sampling point and 















5.2.1 Assay development 
Firstly, a sensitive LC-MS/MS method for the detection of both compounds in 
small volumes of mouse blood was developed, as described in Section 8.3.  
Briefly, it was found that both compounds ionised well in the negative ion mode 
and the API 2000 mass spectrometer was optimized for maximum detection 
ability, the parameters of which are tabulated in Section 8.3.1, Tables 31 and 32.  
A chromatographic method was then developed for the optimal separation of the 
two compounds in a single run, as shown in Figure 46 below.  Briefly, a gradient 
was run at a flow rate of 300µl/min from 32 to 77% ACN with 2.5mM ammonium 
bicarbonate in 2.9 minutes, followed by an equilibration step in 32% ACN up to 8 
minutes. 
 
Figure 44: Chromatogram of the LC-MS method for the detection of L17-1 and L17-3 
XIC of -MRM (4 pairs): 386.9/328.0 amu from Sample 1 (pH 9-3) of 1028.wiff (Turbo Spray) Max. 1200.0 cps.























7.317.180.22 1.21 5.824.944.26 4.390.69 5.962.52 6.411.81 2.670.52 3.982.34 5.273.11 5.721.42 3.902.23 7.496.60 7.86
 
Red and blue: L17-1 (386 ?  328; 386 ?  350) 















L17-1 eluted at approximately 1.0 minute, while L17-3 eluted at 1.5 minutes.  
These methods were then also applied to an API 4000 LC/MS-MS for greater 
sensitivity in the negative ion mode. 
 
After development of a suitable method for the detection of L17-1 and L17-3 on 
the LC-MS/MS, a liquid-liquid extraction method for the optimal extraction of both 
compounds from 10µl of mouse whole blood was investigated.  Ethyl acetate was 
chosen as an extraction solvent and a wide pH range of buffers examined as 
described in Section 8.3.3, to determine the pH at which the highest 
concentration of compounds would be extracted.  The results are depicted in 
Figure 45 below, each bar of the graph representing an average of three 
replicates per pH.   
 
Figure 45: The relative quantities of L17-1 and L17-3 extracted from mouse whole blood using 




























The compounds were well extracted across the entire pH range with pH7 buffer 
resulting in the extraction of the highest quantities of L17-1 and L17-3 from 
mouse whole blood.  However, pH9 was chosen for the extraction method as it 
would theoretically result in the extraction of fewer neutral components of the 
blood matrix which could in turn result in ion suppression.  Furthermore, for both 
compounds, pH9 resulted in less variation amongst the three replicates than 
pH7, as indicated by the standard deviations. 
 
Further optimization of the extraction method was not performed due to limited 
sample quantities and the fact that the current method as described in Figure 58 
of Section 8.3.3 utilizing ethyl acetate and pH9 buffer resulted in adequate 
retrieval of both compounds (approximately 100%) from mouse whole blood.   
 
The assay method was also evaluated for sensitivity.  The lowest level of 
quantification (LLOQ) for L17-3 was determined to be 781ng/ml on an API 2000 
LC-MS/MS, as shown in Table 20.  The same method applied to an API 4000 
mass spectrometer reached an LLOQ of 24.4ng/ml (Table 21), a 32-fold increase 
in sensitivity.  Figure 46 shows the peak obtained for L17-3 at 24.4ng/ml on an 
API 4000 with a good signal to background ratio.   Similarly, the LLOQ for L17-1 
on an API 4000 mass spectrometer was also 24.4ng/ml. 
 
Table 20: A representative table to illustrate the lowest level of quantification for L17-3 as being 
781ng/ml on an API 2000 mass spectrometer. 
Analyte Concentration (ug/mL) 




25 25.53 102.13 
12.5 11.73 93.87 
6.25 6.65 106.45 
3.125 3.18 101.65 
1.563 1.55 99.17 
0.781 0.76 97.14 






















Table 21: A representative table to illustrate the lowest level of quantification for L17-3 as being 
24ng/ml on an API 4000 mass spectrometer. 
Analyte concentration 
(µg/ml) 




25 25.87 103.49 
12.5 N/A N/A 
6.25 5.66 90.54 
3.13 2.73 87.17 
1.56 1.47 93.99 
0.781 0.94 120.49 
0.391 0.45 114.74 
0.195 0.19 97.61 
0.0977 0.089 91.25 
0.0488 0.048 99.25 
0.0244 0.025 101.56 
0.0122 No peak n/a 
 
Figure 46: A chromatogram depicting the lowest level of quantification of L17-3, 24.4ng/ml, on an 
API4000 LC-MS/MS 
Sample Name: "L17-3 0.02"    Sample ID: ""    File: "1008.wiff"
Peak Name: "400.9 / 349.8"    Mass(es): "400.9/349.8 amu"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Unknown  
Concentration:      N/A            
Calculated Conc:    0.00    ng/mL  
Acq. Date:       6/2/2009  
Acq. Time:       3:10:11 AM  
 
Modified:           No    
Proc. Algorithm: IntelliQuan - IQA  
Min. Peak Height:   0.00   cps
Min. Peak Width:    0.00   sec
Smoothing Width:  5       points
RT Window:         30.0    sec
Expected RT:        1.47   min
Use Relative RT:    No    
 
Int. Type:        Valley  
Retention Time:     1.49   min
Area:         1.10e+004   counts
Height:         1.57e+003  cps
Start Time:         1.36   min
End Time:           1.66   min
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7.304.87 5.014.64 5.41 5.78
 
 
To obtain greater sensitivity for the detection of L17-1 and L17-3 from 10µl 
mouse whole blood samples, an API 4000 LC-MS/MS was therefore utilized for 
the analysis of samples from in vivo experiments.  Calibration standards were 














These standards were included in every batch of samples analysed to establish 
the integrity of the data.  A representative curve for the calibration standards of 
L17-3 is illustrated in Figure 47 below.  Three of the data points for this particular 
batch of samples were considered to be outliers and were excluded from the 
data set, resulting in the curve being generated from 9/12 (75%) of the calibration 
standards, a percentage considered to be acceptable . 
 
Figure 47: A representative calibration curve for L17-3 obtained on an API 4000 LC-MS/MS. 
 
 
5.2.2 Initial bioavailability study of L17-1 and L17-3 
An initial in vivo experiment was performed to obtain information on the length of 
time for which compounds L17-1 and L17-3 remained at detectable levels in the 
blood.  The two compounds in combination were administered orally and 
subcutaneously to three mice per group at a concentration of 10mg/kg each in 
DMSO:water 1:9 (v/v).  A volume of 10µl of whole blood was collected from each 
mouse at one, three, five and seven hours after dosing.  The samples were 
extracted as described in Section 8.3.3 and analysed as described in 8.3.1 and 
Untitled 7 (L17-3): "Quadratic" Regression ("1 / x" weighting): y = 1.26e+003 x^2 + 1.25e+005 x + 1.5e+003 (r = 0.9995)










































8.3.2.  The subsequent pharmacokinetic parameters for each compound and 
administration route are shown in Tables 22 to 25 and the average levels of L17-
1 and L17-3 over the seven hour test period are shown in Figures 48 and 49.  
The graphs pertaining to the levels of L17-1 and L17-3 in each of the three mice 
are found in the Appendix (Figures 86 to 89). 
  
Table 22: The pharmacokinetic parameters of L17-1 after oral administration at 10mg/kg to three 
mice in combination with L17-3.   
Parameters Mouse 1 Mouse 2 Mouse 3 Average 
Tmax (hours) 1.000 1.000 1.000 1.000 ± 0.000 
Cmax (µg/ml) 4.546 3.344 3.988 3.959 ± 0.602 
t1/2z (hours) 1.3444 3.0577 1.16 1.854 ± 1.046 
AUC 0-tlast (µg.h/ml) 13.292 11.815 10.241 11.783 ± 1.526 
AUC 0-8 obs (µg.h/ml) 13.806 15.9396 10.4803 13.409 ± 2.751 
 
The acceptable RSQ values for the data set resulting from the oral dosing of 
three mice with L17-1 at 10mg/kg (average of 0.952 ± 0.044), allow for the 
determination of the average elimination half life of this compound, which is 1.85 
hours.  Similarly, the elimination half-life after subcutaneous administration is 
1.94 hours, as shown in Table 23 below (RSQ values of 0.985 ± 0.006).  A 
comparison of the AUC values for the two administration routes shows that 
subcutaneous dosing results in a greater area under the curve, with resultant 
greater bioavailability. 
 
Table 23: The pharmacokinetic parameters of L17-1 after subcutaneous administration at 
10mg/kg to three mice in combination with L17-3.   
Parameters Mouse 1 Mouse 2 Mouse 3 Average 
Tmax (hours) 1.000 3.000 1.000 1.667 ± 1.155 
Cmax (µg/ml) 4.553 3.624 3.961 4.046 ± 0.470 
t1/2z (hours) 1.3934 2.9217 1.492 1.936 ± 0.855 
AUC 0-tlast (µg.h/ml) 15.9895 17.7945 11.3385 15.041 ± 3.331 
AUC 0-8 obs (µg.h/ml) 16.9183 23.7083 11.9261 17.518 ± 5.914 
 
From Figure 48 it is evident that levels of L17-1 steadily decrease from one to 














highest level measured (3.96 and 4.05µg/ml for the oral and subcutaneous 
groups respectively) was at one hour after dosing for all three mice in the oral 
group and two of the three mice in the subcutaneous group.  After seven hours, 
mice dosed orally had average levels of 0.45µg/ml and those dosed 
subcutaneously had levels of 0.71µg/ml.  Over the entire test period with the 
exception of the one  hour time point, those mice that received subcutaneous 
doses appeared to have higher levels of L17-1 in the bloodstream, as can be 
verified by the greater AUC values for this administration route. 
 
Figure 48: Levels of L17-1 in mouse whole blood after the administration of 10mg/kg by oral and 





























Figure 49 indicates that high levels of L17-3 remained in the bloodstream after 
seven hours after both oral and subcutaneous dosing.  This prevented the 
calculation of an elimination rate constant, as there was no evidence of an 
elimination phase in the profile and therefore also affected the ability to 
determine most of the pharmacokinetic parameters, as witnessed by the RSQ 















Table 24: The pharmacokinetic parameters of L17-3 after oral administration at 10mg/kg to three 
mice in combination with L17-1.   
Parameters Mouse 1 Mouse 2 Mouse 3 Average 
Tmax (hours) 3.000 3.000 3.000 3.000 ± 0.000 
Cmax (µg/ml) 17.153 13.486 12.897 14.512 ± 2.3061 
t1/2z (hours) 3.066 n/a 2.9359 n/a 
 
In Table 24 above, the only subject for which an accurate half-life after oral 
dosing of L17-3 could be calculated (2.94 hours) as witnessed by the RSQ value 
of 0.9773, is subject 3.  Similarly, only subject 1 could be used to determine the 
half-life after subcutaneous dosing (Table 25 below) and this was shown to be 
6.4 hours (RSQ value of 0.9996). 
 
Table 25: The pharmacokinetic parameters of L17-3 after subcutaneous administration at 
10mg/kg to three mice in combination with L17-1.   
Parameters Mouse 1 Mouse 2 Mouse 3 Average 
Tmax (hours) 3.000 7.000 3.000 4.333 ± 2.3094 
Cmax (µg/ml) 15.653 12.825 9.275 12.5843 ± 3.1958 
t1/2z (hours) 6.4165 n/a n/a  n/a 
 
Figure 49: Levels of L17-3 in mouse whole blood after the administration of 10mg/kg by oral and 











































The levels of L17-3 at one hour after oral administration are more than double 
(average of 10.9µg/ml versus 4.2µg/ml) those receiving the subcutaneous dose.  
The Cmax concentrations of L17-3 were 14.5µg/ml after oral dosing, and 
12.6µg/ml after subcutaneous administration were reached at three and 4.3 
hours respectively. 
 
From this initial in vivo experiment in which both compounds were co-
administered to mice via oral and subcutaneous routes, it is evident that the 
sampling time needed to be extended beyond seven hours.  Furthermore, L17-3 
reaches much higher levels in the bloodstream than L17-1, suggesting that it is 
more bioavailable. 
 
5.2.3 Bioavailability study of L17-3 in mice 
Based on the initial in vivo experiment described in section 5.2.2 using oral and 
subcutaneous dosing of L17-1 and L17-3 in combination, further in vivo work 
focused on the bioavailability of L17-3 only.  Furthermore, the experiment was 
lengthened up to 96 hours to allow for more sampling time points.  The dosage of 
L17-3 per mouse was also halved due to the high levels observed in mouse 
whole blood in the initial experiment. An extra group of six mice to be dosed 
intravenously were also included in the subsequent study to allow for the actual 
oral and subcutaneous bioavailability determination.  The experimental details 
are described in Section 8.5. 
5.2.3.1 Oral 
Oral dosing of L17-3 at 5mg/kg and sampling over a period of 96 hours resulted 
in a Cmax value 2.8 ± 0.7 µg/ml at a Tmax time of 3.4 hours as shown in Table 26.  
At 24 hours, all but one of the mice showed levels of L17-3 below the LLOQ of 
24.4ng/ml (Appendix, Table 37).  The half life (tl/2z) of the compound in the 
animals is on average 2.98 hours.  None of the mice displayed any signs of 
toxicity after dosing.  The data for each mouse was also found to be within 





























































































































































Table 26: The pharmacokinetic parameters as obtained by WinNonlin analysis for the oral dosing 
of five mice with L17-3 at 5mg/kg. 
PK parameters Mouse 1 Mouse 2 Mouse 3 Mouse 4 Mouse 5 Average 
t 1/2z (hours) 3.9092 3.4011 2.6540 2.7303 2.2132 2.9816 ± 0.6703  
Tmax (hours) 3.0000 3.0000 3.0000 5.0000 3.0000 3.4000 ± 0.8944 
Cmax (µg/ml) 2.8500 3.0200 3.2200 1.5700 3.2600 2.7840 ± 0.6983 
AUC0-tlast (µg.h/ml) 19.8100 19.4810 29.6778 19.2116 31.2666 23.8894 ± 6.0392 
AUCall (µg.h/ml) 23.5600 22.2290 30.0234 19.5008 31.4478 25.3522 ± 5.1522 
AUC0-8 obs (µg.h/ml) 23.3349 21.7283 29.7881 19.3065 31.3148 25.0945 ± 5.2118 
RSQ 0.9760 0.9925 0.9837 0.9771 0.9863 0.9831 ± 0.0068 
Abbrevi ations: AUC - area under the concentration curve 
 
Figure 50 shows the graphs of each individual mouse after oral dosing with L17-
3, while the actual levels in each mouse over the experimental period are 
tabulated in the Appendix, Table 37.  The sample taken at three hours from 
mouse 4 was excluded from the analysis of the data due to experimental error.  




The half-life of L17-3 after subcutaneous administration is 2.04 hours with a Tmax 
value at 3 hours and a Cmax concentration of 4.35µg/ml (Table 27).  The 
parameters for each mouse are within acceptable limits as shown by the RSQ 
values (average of 0.9765 ± 0.03).  At 24 hours, all the mice showed levels of 
L17-3 below the level of quantification (Appendix, Table 38).  The dose of 
compound administered did not appear to have any negative effects on the mice. 
 
Table 27: The pharmacokinetic parameters as obtained by WinNonlin analysis for the 
subcutaneous dosing of five mice with L17-3 at 5mg/kg. 
PK parameters Mouse 1 Mouse 2 Mouse 3 Mouse 4 Mouse 5 Average 
t 1/2z (hours) 2.1646 2.1807 1.5943 2.2682 1.9695 2.0355 ± 0.2697 
Tmax (hours) 3.0000 3.0000 3.0000 3.0000 3.0000 3.0000 ± 0.0000 
Cmax (µg/ml) 3.6520 4.6950 5.0170 4.0740 4.3030 4.3482 ± 0.5314 
AUC0-tlast (µg.h/ml) 22.1580 25.8260 29.2210 21.0960 24.6340 24.5870 ± 3.2054 
AUCall (µg.h/ml) 23.2680 27.4760 30.1930 22.8000 25.9720 25.9418 ± 3.0597 

















































































































































As observed in Figure 51, the levels of L17-3 in the individual mice appear to 
follow the same trends, with all obtaining maximum concentrations in the 
bloodstream of between 3.65 to 5.02µg/ml at 3 hours after dosing. 
 
5.2.3.3 Intravenous 
Six mice were dosed intravenously with 5mg/kg of L17-3.  However, one mouse 
(subject 3) died immediately.  A heart puncture was performed and it was found 
that the mouse had 34.05µg/ml of compound in its blood, more than 4.5 times the 
amount seen in the other mice one hour after dosing.  This was most likely as a 
result of initial leakage and re-administration of the compound during the dosing 
procedure.  These data was therefore omitted from the analysis.  However, at 
this dosage, the mice remained inert for one hour after dosing.  Within three 
hours the mice appeared to have recovered and remained healthy for the 
duration of the experiment.  In Table 28 it is evident that the elimination half-life 
of L17-3 after intravenous administration is 3.28 hours.  It is not possible to 
calculate the Cmax concentration, as the compound should be at its highest levels 
immediately after being injected directly into the bloodstream.  At 24 hours, three 
of the remaining five mice had levels of L17-3 below the LLOQ of 24.4ng/ml and 
by 48 hours the compound had been eliminated completely from the bloodstream 
(Appendix, Table 39).   
 
Table 28: The pharmacokinetic parameters as obtained by WinNonlin analysis for the intravenous 
dosing of five mice with L17-3 at 5mg/kg. 
PK parameters Mouse 1 Mouse 2 Mouse 4 Mouse 5 Mouse 6 Average 
t 1/2z (hours) 2.8737 6.1400 2.0737 1.9997 3.3293 3.2833 ± 1.6913 
AUC0-tlast (µg.h/ml) 66.3680 51.4700 56.9660 67.0995 56.2420 59.6291 ± 6.8256 
AUCall (µg.h/ml) 67.4840 61.4480 57.2300 67.3755 57.6220 62.2319 ± 5.0231 
AUC0-8 obs (µg.h/ml) 66.7536 66.2010 57.0318 67.1659 56.7944 62.7893 ± 5.3758 
 
Figure 52 shows the levels of L17-3 in each of five mice after intravenous 
administration at 5mg/kg.  Various differences are noted in the five animals.  For 






























































































































































for mice 1 and 2 the levels stay relatively unchanged between 5 and 8 hours.  
After 8 hours the concentration of compound in the bloodstream of all the mice 
decreases steadily until it is eliminated from the system between 24 and 48 hours 
(Appendix, Table 39).  The RSQ value for mouse 2 is very low at 0.804 and it is 
possible that omitting this data could confer greater uniformity to the data set as 
a whole. 
 
The pharmacokinetic parameters of L17-3 after intravenous, oral and 
subcutaneous administration are summarised in Table 29 while the levels of L17-
3 after the various administration routes over 96 hours are shown in Figure 53.  
The highest Cmax concentration is obtained by subcutaneous administration 
(4.35µg/ml) followed by oral (2.78µg/ml).  The time at which the highest levels of 
compound in the blood are observed is at 3.4 hours for oral and at 3 hours after 
subcutaneous dosing.  The half-life of L17-3 in the bloodstream is greatest for IV 
dosing, followed by oral and then subcutaneous administration.  After 
subcutaneous dosing, the compound levels decrease most rapidly with an 
average of 0.23µg/ml being detected at 12 hours in comparison to 0.78 and 
1.80µg/ml for the oral and IV groups respectively (Appendix).  At 24 hours, only 
the IV group of mice had on average levels of L17-3 above the LLOQ 
(0.05µg/ml).  
 
Table 29: The average pharmacokinetic parameters of L17-3 after intravenous, oral and 
subcutaneous dosing at 5mg/kg. 
PK parameters Intravenous Oral Subcutaneous 
Tmax (hours) n/a 3.4000 ± 0.8944 3.0000 ± 0.0000 
Cmax (µg/ml) n/a 2.7840 ± 0.6983 4.3482 ± 0.5314 
t 1/2z (hours) 3.2833 ± 1.6913 2.9816 ± 0.6703 2.0355 ± 0.2697 
AUC 0-tlast 59.6291 ± 6.8256 23.8894 ± 6.0392 24.5870 ± 3.2054 
AUC all 62.2319 ± 5.0231 25.3522 ± 5.1522 25.9418 ± 3.0597 
AUC 0-8obs 62.7893 ± 5.3758 25.0945 ± 5.2118 25.2627 ± 3.0685 














Figure 53: The levels of L17-3 after oral, subcutaneous and intravenous dosing at 5mg/kg over 96 




























By comparing the respective oral and subcutaneous AUC values to the AUC 
value after intravenous dosing, it is possible to determine the overall oral and 
subcutaneous bioavailability of the compound. 
 
F (bioavailability) = (AUC all oral / AUC all IV ) x 100 = (25.3522/62.2319) x 100 
= 40.74% 
F (bioavailability) = (AUC all sub / AUC all IV ) x 100 = (25.9418/62.2319) x 100 
= 41.69% 
 
From the equation above it is evident that the bioavailability of L17-3 after oral 
and subcutaneous dosing is 40.7 and 41.7% respectively.  Furthermore, Figure 
53 above indicates that higher compound concentrations are achieved in mouse 
blood after subcutaneous administration, although the levels drop more quickly 
















The purpose of this work was to determine whether compounds exhibiting good 
in vitro activity exhibited good lead-like properties (no toxicity and good 
bioavailability) in vivo.  One of the major problems in drug-development is that 
many compounds showing efficacy in vitro, have poor bioavailability and/or 
exhibit toxicity in pre-clinical small animal studies, partly due to enzymes involved 
in drug metabolism (Guengerich, 2006).   Several researchers have suggested 
microdosing in humans as a means of predicting drug pharmacokinetics to aid in 
the early selection of drug candidates.  This method involves dosing humans with 
trace subpharmacological amounts of drug, thereby reducing the need for the 
intensive safety approval associated with a study utilizing the full drug dosage 
(Lappin et al., 2006). A drawback of natural product research is the length of time 
required to generate the large quantities of pure compound required for in vivo 
efficacy and bioavailability experiments.  Previous work performed in the Division 
of Pharmacology at the University of Cape Town has shown that it is possible to 
study the pharmacokinetics of test compounds in very small quantities (10µl) of 
blood (Wiesner, 2008).  This permits the use of smaller numbers of experimental 
animals as it is not necessary to sacrifice an animal at each sampling point and 
multiple data sets can subsequently be obtained from a single subject.  
Furthermore, it reduces the amount of pure test compound required for the 
detection of low levels in the blood for bioavailability research. 
 
The method developed for the detection of two compounds derived from the 
lichen T. chrysophthalmum, namely L17-1 and L17-3, proved to be capable of 
detecting small quantities of compound from 10µl of mouse whole blood.  The 
method was developed on an Applied Biosystems API 2000 mass spectrometer 
which allowed for an LLOQ of 781ng/ml for both compounds in the negative ion 
mode.  When this method was directly applied to the more sensitive Applied 
Biosystems API 4000 LC-MS/MS, it allowed for a greatly improved level of 
quantification, namely 24.4ng/ml.  It is possible that the method could still be 














extraction method based on ethyl acetate and pH9 universal buffer was effective 
at retrieving the compounds from the blood matrix.  Despite the fact that pH7 
buffer resulted in slightly better retrieval of the compounds, a more alkaline buffer 
(pH9) was used as it resulted in less variability amongst the replicates and would 
theoretically reduce the extraction of neutral blood components.  These matrix 
components could result in ion suppression or enhancement of the analyte which 
could in turn affect the quantitation of the drug in a biological fluid (Van Eeckhaut 
et al., 2009).  To further refine this method, the matrix effects would need to be 
investigated more thoroughly.  In the case of greater sample quantities, this 
method could be even further optimized by investigating other extraction solvents 
in a cost-effective liquid-liquid system, such as hexane or dichloromethane.     
 
A cursory in vivo experiment was set up to determine the ideal sampling time for 
the bioavailability study of the two compounds of interest.  Furthermore, this 
experiment served to determine whether or not one can investigate the 
bioavailability of a mixture of known compounds in a single mouse.  The 
advantage of such an approach would be the use of fewer animals to obtain data 
on more than one compound.  This has been made possible by using small 
(10µl) blood samples at each collection point, avoiding the sacrificing of a single 
mouse per time point.  This experiment could also prove to be relevant in the 
study of natural products, which rarely occur as single compounds.  The isolation 
and accumulation of large enough quantities of a single compound from a 
complex mixture to perform in vivo work is time-consuming and often impossible 
due to limited material, such as in the case of lichens.  Performing bioavailability 
studies on a mixture of known compounds could greatly decrease the amount of 
material and time required to accumulate pure compounds while focusing 
research efforts on those few compounds that are bioavailable and therefore 
have drug-like potential.   
 
The results of the initial in vivo study involving two groups of three mice each, 














other group dosed subcutaneously with the same amount of compound, showed 
that at this dosage, the compounds had no toxic effects on the mice.  
Furthermore, it became evident that the compounds were still detectable in the 
bloodstream at 7 hours after dosing.  Each 20g mouse received 200µg of each 
compound, and after one hour, L17-1 was measured at approximately 4µg/ml for 
both administration routes.  Thereafter, the levels decreased until the last 
sampling point, namely 7 hours.  The subcutaneously administered L17-1 was 
available at higher levels at 3, 5 and 7 hours than that arising from oral dosing.  
In comparison, L17-3 administered orally was available at an average of 
10.9µg/ml at one hour, increasing to 14.5µg/ml at 3 hours.  Thereafter the levels 
decreased steadily, reaching a concentration of 7.5µg/ml at 7 hours.  Although 
the subcutaneously administered L17-3 did not reach the same levels as that 
administered orally, it also reached Tmax at 3 hours, as for the oral dose.  
However, the levels of L17-3 then remained fairly constant until 7 hours 
(approximately 10µg/ml). 
 
This initial experiment clearly showed that L17-3 is more bioavailable than L17-1, 
reaching the highest concentration of 14.5µg/ml after oral dosing in comparison 
to 4.0µg/ml for L17-1 – more than a three-fold difference.  Furthermore, while the 
levels of L17-1 steadily decrease from 1 to 7 hours, L17-3 concentrations 
increase until three hours, after which they decrease to seven hours for the oral 
dose and remain constant for the subcutaneous dose.  It is possible that the co-
administration of two closely-related compounds could have an effect on the 
bioavailability of each compound in the bloodstream.   
 
Based on the initial in vivo experiment, a subsequent investigation was 
undertaken to determine the bioavailability of the most promising compound, 
namely L17-3.  In this experiment, two groups of five mice and one group of six 
mice were dosed at 5mg/kg by means of oral, subcutaneous and intravenous 
administration respectively.  Samples were taken from one to 96 hours after 














to small sample quantities and good bioavailability.  As for the initial experiment, 
none of the animals were negatively affected by the oral and subcutaneous 
doses.  However, the mice receiving the IV dose remained inert for one hour 
after dosing, but recovered and remained healthy for the remainder of the 
experiment.  One animal in this group died, probably as a result of overdosing, 
with levels of 34µg/ml being detected from a heart puncture performed one hour 
after dosing.  Although unfortunate, this information could be useful as it provides 
an end-point of toxicity, information which is necessary in the development and 
approval of a potential drug candidate (Guengerich, 2006).  In this case, it is 
apparent that toxicity occurred as a result of over-dosing as opposed to the 
compound’s mechanism of action, bioactivation or immunological reactions 
(Guengerich, 2006).  Typically, IV doses are administered at a concentration of 
ten-fold less than the oral dose, and realistically, one would expect to see some 
adverse effects at such a high dose.   
 
For the oral administration route, Tmax was reached at 3.4 hours, whereas the 
subcutaneous dose resulted in Tmax at three hours.  It is interesting to note that 
for the IV dose which is injected directly into the bloodstream, the levels of L17-3 
peak at 3.4 hours, suggesting potential tissue absorption.  Future work should 
include sampling points between zero and one hour to investigate the 
bioavailability of the compound immediately after dosing.  It is possible that the 
one mouse that died immediately after IV dosing, despite the near certainty that 
the animal was overdosed, could in fact give a more accurate reflection of 
compound levels in the blood shortly after dosing, suggesting that the compound 
is in fact available at higher levels before one hour as opposed to after one hour.  
Many compounds are subjected to enterohepatic recycling in vivo, which could 
also explain the perceived delayed peak concentration after IV administration.  
Briefly, this phenomenon occurs as a result of biliary excretion and reabsorption 
of the solute into the intestine, leading to the appearance of multiple peaks and 














certain degree of enterohepatic cycling include morphine, cardiac glycosides, 
rifampicin and ampicillin (Roberts et al., 2002). 
 
The highest Cmax concentration was achieved by subcutaneous and then oral 
administration.  The fact that subcutaneous dosing results in greater levels of 
compound in the mice than oral administration is in contrast to the results of the 
initial in vivo experiment performed which showed higher levels of L17-3 after 
oral dosing.  This can be explained by the fact that in the initial in vivo 
experiment, it was noticed that there was a small amount of ‘leakage’ from the 
puncture wound after subcutaneous administration.  Therefore, less compound 
would have been administered by subcutaneous dosing in comparison to oral 
dosing.  In the subsequent experiment, care was taken to administer the same 
dosages by all administration routes.  For both the oral and subcutaneous doses, 
levels of L17-3 were below the LLOQ by 24 hours, whereas the levels were 
completely eliminated after 48 hours for the IV dose.  All three curves 
representing the compound levels over the experiment duration followed roughly 
the same trend.  A comparison of the areas under the curves showed that the 
oral and subcutaneous bioavailabilities were very similar at 40.7 and 41.7% 
respectively. 
 
When considering the in vitro and in vivo data together, it is evident that L17-1, 
with in vitro activity against S. aureus of 31.3µg/ml (MIC) and an IC50 of 1.1µg/ml, 
is also more cytotoxic in vitro and was more poorly bioavailable with a Cmax of 
approximately 4µg/ml after oral and subcutaneous administration at 10mg/kg.    
For L17-3, after dosing mice orally at 10mg/kg, a C max of 14.5µg/ml is achieved, a 
level just below the in vitro MIC of 15.6µg/ml (IC50 of 0.7µg/ml) and MBC of 15.6 
to 31.3µg/ml against S. aureus.  At this dosage, the mice displayed no signs of 
toxicity, and it is conceivable that a higher dosage, for instance 20mg/kg, would 
also be well tolerated as the two test compounds were administered together at a 
total concentration of 20mg/kg in the initial experiment with no signs of toxicity.   














compound, but at a dose of 5mg/kg, which only results in an average Cmax of 
6.6µg/ml, the mice appeared to be adversely affected shortly after dosing, 
although they did make a full recovery.  Furthermore, subcutaneous 
administration of L17-3 in the second experiment resulted in a higher Cmax than 
for oral administration, with similar lack of toxicity.  It is possible that 
subcutaneous administration of 10mg/kg or 20mg/kg may in fact yield a blood 
concentration of L17-3 capable of neutralising a systemic S. aureus infection.  
The concentration of L17-3 required to kill 50% of S. aureus in vitro is 0.7µg/ml 
and this compound exerts bactericidal activity at 15.6 to 31.3µg/ml.  In practice, 
one may find that prolonged or repeated exposure to a sublethal dose of L17-3 
may in fact be sufficient to eliminate a systemic S. aureus infection.  There is 
evidence to suggest that the instant killing of bacterial cells in an infection is not 
always desirable, for instance in central nervous system infections.  Sudden lysis 
of the bacterial cell wall (for example by vancomycin) results in the release of 
cellular components which trigger cytokine production and potentially lethal 
inflammation (Finberg et al., 2004).   
  
How do these results measure up to published reports of established or 
promising antibiotics?  During efficacy studies in animal models of disease, which 
could not be performed in this project, a 50% effective dose (ED50) is determined.  
For instance, the ED50 of the widely-used antibiotic, ciprofloxacin, has been 
shown to be 10mg/kg in an in vivo model of S. aureus sepsis (Freiberg et al., 
2006). A promising drug candidate, the 3-(heteroarylthio)cepham RWJ333441, 
displayed an ED50 of 0.39mg/kg in a mouse model of sepsis. (Glinka et al., 
2003). This same compound showed in vitro activity against methicillin 
susceptible and resistant strains of S. aureus at 0.25µg/ml and 2µg/ml 
respectively. There are also reports of compounds which have potent in vitro 
efficacy, but require a relatively high in vivo dose to clear disease from an animal 
model.  For instance, Freiberg et al. (2006) evaluated pseudopeptide antibiotic 














of S. aureus sepsis and found that the most active derivative had a 100% 
effective dose of 25mg/kg. 
 
A study involving a natural product-derived compound, AC98-6446, found that 
the compound had an ED50 of 0.08mg/kg of body weight after IV administration in 
a murine acute lethal S. aureus infection model.  The ED50 for MRSA was 
0.27mg/kg.  After a 20mg/kg IV dose, the Cmax in mice was 316µg/ml with an 
AUC of 164µg/h/ml and a half-life of 3.3 hours (Weiss et al., 2004).  In 
comparison, the most promising compound in this project, namely the lichen-
derived L17-3, had a similar half-life after IV and oral administration, but the mice 
showed adverse effects after IV administration at a quarter of the dose.  
 
Similarly a synthetic compound arising from high-throughput screening of a 
compound library showed in vitro activity against drug sensitive and resistant 
strains of S. aureus with MIC’s of 1µg/ml, significantly better in vitro activity than 
L17-3.  Furthermore, this compound showed oral efficacy (ED50) at 19.5mg/kg 
against MRSA in a mouse model of systemic infection.  When administered 
subcutaneously, this compound displayed an ED50 of 12.5mg/ml and was non-
toxic up to 200mg/kg (Miller et al., 2008).  When administered at an oral dose of 
20.3mg/kg, this compound had a half-life of 0.9 hours and a Cmax of 15.7µg/ml 
(AUC of 27.6µg h/ml).  In the current project, L17-3 had a longer half-life than this 
compound and at half the oral dose, the observed Cmax was not much lower at 
12.6µg/ml.   
 
Recently, several groups have undertaken work on promising oxazolidinone 
derivatives.  Takhi et al. (2008) investigated oxazolidinone derivatives in vitro and 
after oral administration in a mouse model of systemic S. aureus infection.  The 
most active derivative had an ED50 of 18.9 mg/kg/day in comparison to the 
approved oxazolidinone drug linezolid which had an ED50 of 5.3mg/kg/day.  
Furthermore, this compound displayed a Cmax of 0.68µg/ml and a half-life of 2.17 














1.37 hours (AUC 10.98 µg h/ml).  Two further oxazolidinones under investigation 
showed in vitro MIC’s of 0.25 and 1µg/ml against S. aureus and MIC’s of 0.5 and 
2µg/ml against MRSA.  These two compounds exhibited in vivo ED50’s of 6.25 
and 9.92mg/kg for a once –daily dose and 4.96 and 5.56mg/kg for a twice daily 
dose in a model of systemic MRSA infection.  The two compounds furthermore 
had oral bioavailabilities of 48% and 73% with half-lives of 13.5 and 3.2 hours 
(Barman et al., 2009).  Hilliard et al. (2009) also investigated the in vivo efficacy 
of another promising oxazolidinone, RWJ-416457, in murine models of systemic 
and skin S. aureus infections.  This compound had an ED50 ranging from 1.5 to 
5mg/kg of body weight per day for systemic staphylococcal infection.  After an 
oral dose of 10mg/kg, a Cmax of 3.5µg/ml was achieved at two hours, with an 
AUC24 of 13 and a half-life of 3.4 hours.   
 
An example of a promising drug candidate with favourable pharmacokinetic 
properties is MK-826, a 1ß-methyl carbapenem with broad-spectrum antibiotic 
activity (Gill et al., 1998).  After a single 10mg/kg dose in mice, this compound 
displayed a long half-life (3.2 hours) compared to ceftriazone (2.3 hours) and 
also had a higher peak concentration in serum (62.8µg/ml) as well as a larger 
area under the curve (150.8 µg.hr/ml).  Furthermore, MK-826 levels decrease 
slowly with levels of 3.6µg/ml being detected at 6 hours after treatment.  For 
murine systemic S. aureus infection, the ED50 of MK-826 was 1.58mg/kg of body 
weight (MIC of 0.125µg/ml).  In comparison, L17-3 has a similar half-life, but 
much lower Cmax and AUC.  Interestingly, after the same dose of L17-3, higher 
levels (10.3 and 7.5µg/ml) are detected at seven hours.   
 
Similarly, another 1ß-methyl carbapenem with broad-spectrum Gram-positive 
activity, SM-17466, had an in vitro MIC90 of 0.006µg/ml against S. aureus (ED50 
of 0.021mg/kg) and 3.13µg/ml against MRSA (ED50 of 8.0mg/kg).  In comparison, 
vancomycin has MIC90’s of 1.56µg/ml against methicillin sensitive (ED50 of 
1.8mg/kg) and resistant (ED50 of 9.5mg/kg) S. aureus.  Furthermore, this activity 














25mg/kg, this compound achieved a Cmax of 53.9µg/ml at 15 minutes in 
comparison to 32.9µg/ml at the same sampling point for vancomycin.  SM-17466 
displayed a half-life of 17.9 minutes (vancomycin has a half-life of 21.8minutes) 
and an AUC of 19112µg.min/ml (Sumita et al., 1995).  As can be seen from the 
Cmax parameters of these drugs, a shortfall of the current study is the lack of 
sampling points prior to one hour after dosing.  It is possible that the highest drug 
levels are in fact observed prior to the first sampling point. 
 
Topical antibiotics are very useful in the treatment of skin infections as they 
provide high local concentrations of drug which in turn reduces the chance of 
resistance development and avoids systemic toxicity (Critchley and Ochsner, 
2008).  One such drug-candidate is REP8839, a fluorovinylthipphene-containing 
diaryldiamine, which inhibits bacterial methionyl rRNA synthetase.  It has MIC’s 
of 0.5µg/ml against methicillin-sensitive and -resistant S. aureus and less than or 
equal to 0.008 to 0.5µg/ml against mupirocin-resistant S. aureus.  In comparison, 
mupirocin has MIC’s of 0.12 and 16µg/ml against methicillin-sensitive and -
resistant S. aureus.  Although there are no standardised models for the 
evaluation of topical antibiotics, this drug (2% w/v) has been shown to effectively 
clear S. aureus infection in porcine skin wounds (Critchley and Ochsner, 2008). 
 
So, in the absence of efficacy studies, certain pharmacokinetic-
pharmacodynamic (PK-PD) parameters can aid in the prediction of antimicrobial 
efficacy.   Three such indicators are firstly, the amount of time for which the drug 
levels remain above the in vitro MIC (T>MIC), secondly the ratio of the maximum 
drug concentration to the MIC (Cmax:MIC) and thirdly, the ratio of the area under 
the curve at 24 hours to the MIC (AUC0-24:MIC).  Some antibiotics display 
concentration-dependent activity, such as streptomycin, while others display 
time-dependent activity, such as penicillin.  An investigation into a promising drug 
candidate for the treatment of S. aureus bacteraemia, oritavancin, showed that in 
subjects achieving an fT>MIC value of =22% of the dosing interval, 93% 














exposure was achieved.   These predictive parameters can also facilitate the 
understanding of drug exposure levels necessary to avoid the development of 
drug resistant bacterial populations (Ambrose et al., 2007).   
 
The two lichen-derived compounds identified in this study have been tested for in 
vivo bioavailability, but not for in vivo efficacy in a disease model, which was not 
possible due to lack of such a model and limited sample quantities.  When taking 
these PK-PD parameters into consideration, it is evident that neither L17-1 nor 
L17-3 reach in vivo concentrations above the in vitro MIC’s, irrespective of 
administration route at the highest dosage investigated.  L17-3, however, 
reaches levels marginally short of the MIC after oral administration at 10mg/kg.  
The possibility exists that between the time of administration and one hour, the 
compound levels do reach higher levels in the bloodstream than those detected 
at one hour.  Furthermore, it is possible that the oral and subcutaneous dose of 
L17-3 could be increased substantially above 10mg/kg without showing signs of 
toxicity.  The IV administration resulted in the highest blood levels of L17-3, but at 
this exceptionally high dosage of 5mg/kg, the mice appeared to be briefly 
adversely affected.  The most promising compound, L17-3, exhibited a Cmax:MIC 
ratio of 1:1.08 after oral administration of 10mg/kg.  After IV dosing at 5mg/kg, 
the most favourable AUC:MIC ratio was obtained, namely 1:0.54.  Therefore, in 
the instance of L17-1, the PK-PD predictive parameters suggest that this 
compound does not have favourable lead-like properties.  However, in 
comparison to literature reports of promising anti-staphylococcal antibiotics in 
development, L17-3 does have good pharmacokinetic properties, displaying an 
elimination half life of 3 to 3.4 hours and achieving a Cmax concentration after a 
non-toxic dose just short of the in vitro MIC, with the distinct possibility of 
increasing the dosage without toxicity being observed.  Furthermore, it is 
relatively slowly removed from the bloodstream and is still detectable at high 















Limited sample quantities and the slow growth rate of T. chrysophthalmum have 
unfortunately made efficacy studies in mice impossible at this time, but it is 
envisaged that such work will be performed when more material becomes 
available.  A method similar to that utilized by Ueda and Sunagawa (2003) 
should be evaluated, looking at septicaemia and subcutaneous abscesses in 
murine models of S. aureus infection. A complimentary method that would not 
require an animal model of disease, is one suggested by Gruppo et al. (2006), 
who developed an in vivo assay to measure compound bioavailability after oral 
administration to mice.  Briefly, they tested the serially diluted serum in a broth 
micro-dilution fashion against the bacterium of choice.  This assay therefore 
measures the antimicrobial activity of the free, unbound drug or active 
metabolites thereof.  Furthermore, synthetic analogues and metabolites of L17-3 
would be investigated for in vitro bioactivity and in vivo pharmacokinetics for the 
purpose of understanding the mechanism of action and improving on the current 
in vitro antibiotic activity.  Biotransformation reactions, such as those performed 
in microsomes in vitro, could be performed to generate active metabolites, which 
could in turn become lead candidates for new drugs in their own right (Fura, 

















The objective of this project was to contribute to the field of drug discovery from 
South African natural products, as well as to introduce potentially useful 
approaches to distinguishing a promising lead-like compound from a simple ‘hit’ 
arising from in vitro testing.  Due to the lack of research performed on South 
African lichens, as well as the unique and often extreme local environments in 
which lichens are found, an investigation was conducted into the antimicrobial 
activities of ten lichen species growing in various parts of the country.  South 
Africa is deemed a semi-arid country, often being exposed to periods of drought.  
Subsequently, several true desiccation-tolerant plant species are found with the 
unique ability to enter a dormant state during dry periods, only to flourish with the 
arrival of rain.  The hypothesis was made that other than those compounds that 
aid in the process of desiccation-tolerance, these plants could make unique 
defensive compounds as a means of protection against microbial infections and 
grazing by herbivores, particularly when in a perceived vulnerable state of 
quiescence.  Furthermore, there have been reports of the use of both lichens and 
several desiccation-tolerant species in traditional medicines.  Another well-used 
traditional remedy throughout Africa, is the pepper-bark tree, Warburgia salutaris.  
Commercially cultivated plant material of this species was made available for this 
project with the intention of performing an intensive investigation into the 
antimicrobial activity, with the aim of researching the in vivo bioavailability of 
individual compounds within a relatively complex fraction. 
 
None of the lichen extracts showed marked activity against Gram-negative 
bacteria or yeast.  Only one extract, that of Usnea rubrotincta, displayed activity 
against Mycobacterium aurum, later attributed to the presences of large 
quantities of usnic acid, previously shown to exhibit antimycobacterial activity.   














Xanthoparmelia semiviridis, was also attributed to the presence usnic acid.  
Despite being well-researched, this common lichen metabolite has never been 
tested for antimalarial activity, and was subsequently found to have moderate 
activity against the causative organism, Plasmodium falciparum (IC50 of 
15.1µg/ml).  Several extracts exhibited good activity against the Gram-positive  
Staphylococcus aureus, the most potent being the acetone extract of 
Teloschistes chrysophthalmum , with an MIC of 15.6 to 31.3µg/ml.  Further 
fractionation of this extract led to the isolation of three compounds, two of which 
exhibited potent anti-Staphylococcal activity with IC 50’s of 1.1 (L17-1) and 
0.7µg/ml (L17-3) against a drug-sensitive reference strain.  When tested against 
methicillin-resistant S. aureus, these compounds displayed less activity, with 
IC50’s of 11.1 (L17-1) and 11.4µg/ml (L17-3).  Due to the good in vitro 
antimicrobial activity, these compounds were also evaluated for in vitro 
cytotoxicity.  Both exhibited favourable toxicity, with L17-1 having an IC50 of 
81µg/ml and L17-3 not showing toxicity at the highest concentration tested, 
namely 100µg/ml.  The resultant selectivity indices for L17-1 and L17-3 against 
drug sensitive S. aureus are therefore 73.6 and greater than 142.9 respectively, 
with a value of greater than ten indicating a promising ‘hit’ compound.  Various 
attempts to elucidate the complete structures of these two compounds were 
unsuccessful.   
 
Four desiccation-tolerant plants were investigated for antimicrobial activity, 
namely Xerophyta retinervis, Myrothamnus flabellifolius, Cheilanthes contracta 
and Selaginella dregei.  Of the 30 sequential extracts generated, only two 
displayed any activity, surprising considering the reported use of these plants or 
related species in traditional medicines.  The methanol extract of X. retinervis 
exhibited activity against C. albicans and M. aurum with MIC’s of 62.5 and 
125µg/ml.  The most potent activity observed was from the methanol extract of 
M. flabellifolius against C. albicans, exhibiting an initial MIC of less than 7.8µg/ml.  
However, this activity slowly dissipated with repeated tested, eventually showing 














fractionation of this extract yielded similar results, initially as active, eventually 
becoming inactive with repeated testing as a means to confirm activity.  In an 
attempt to isolate the compound/s responsible for this potent, but variable 
activity, exhaustive fractionation of the sequential extracts was performed, using 
liquid-liquid fractionation, TLC and HPLC.  The most active stable compound 
eventually isolated was that originating from the methanol extract, exhibiting an 
IC50 of 67.8µg/ml.  It is evident that this was not the original compound 
responsible for the potent activity of the extract.  The variable nature of this 
activity could be attributed to the presence of volatile components that either 
degrade or evaporate over time, as is possible with an essential oil, such as has 
reportedly been isolated from the plant in question, displaying potent antifungal 
activity.  Due to the moderate and/or variable nature of activity from extracts of 
the desiccation-tolerant plants, as well as the potent lichen-derived compounds 
isolated, further work in this field was not continued. 
 
Sequential extracts prepared from the bark, stems, leaves and twigs of the 
medicinal tree, W. salutaris, revealed that the DCM extracts of the bark, stems 
and twigs exhibited potent antifungal and moderate antimycobacterial activity, 
with the DCM extract of the bark displaying the most potent IC 50 of 4.24µg/ml.  
HPLC chromatograms revealed that the DCM extracts of these three plant parts 
all appeared to contain the same predominant compounds.  The bark extract was 
further fractionated, leading to the isolation of 19 pure/semi-pure compounds.  
Three of the compounds exhibiting potent antifungal activity were identified as 
muzigadial, warburganal and ugandensidial, with IC 50’s against C. albicans of 
2.07, 4.45 and 25.2µg/ml respectively.  However, these compounds also 
displayed potent toxicity against CHO cells with IC 50 values of 4.3, 1.7 and 
1.2µg/ml respectively.  The fraction from which these compounds was isolated 
exhibited an IC50 of 5.8µg/ml against C. albicans, but displayed toxicity against 
CHO cells at 2.6µg/ml, therefore rendering it more toxic than active.  Despite the 
promising antifungal activity, the cytotoxicity of the individual compounds, as well 














means of determining which hit-compound displayed the best oral bioavailability, 
thereby making it the most promising lead-candidate.  Fraction 7 arising from the 
ACN fraction of the bark of the DCM extract of W. salutaris, was the only fraction 
to display good activity against C. albicans (IC50 of 4.7µg/ml) and relatively weak 
cytotoxicity, with an IC50 value of 21.7µg/ml.  However, upon isolation of the 
individual compounds, a subsequent loss of activity was noted, with the most 
active compound (H7-1) displaying an IC 50 of 13.16µg/ml against C. albicans.  
This resultant moderate activity suggests compounds acting together 
synergistically to confer activity against C. albicans, or perhaps the loss of the 
most active component, possibly due to degradation.  Once again, in comparison 
to the active and non-toxic hit compounds and fractions isolated from the lichen, 
T. chrysophthalmum , further work on the well-known medicinal plant, W. 
salutaris, as a vehicle to study oral bioavailability of a complex mixture, was 
abandoned.   
 
To date, no clinically-relevant antibiotics have been discovered in higher plants, a 
trend confirmed in this study.  Furthermore, none of the plant material tested 
exhibited any activity against Gram-negative bacteria, most likely due to the 
organisms’ cell wall which is known to act as a virtually impenetrable permeability 
barrier.  It has been suggested that higher plants only produce antimicrobial 
substances when threatened with a microbial invasion (Lewis and Ausubel, 
2006), a possible explanation for the lack of in vitro activity.  However, the more 
evolutionary primitive lichens yielded a greater number of hits, particularly 
against Gram-positive bacteria and mycobacteria, most likely produced by the 
fungal component of the symbiosis.  This research confirms previous reports of 
the enormous potential that lichens have in the drug discovery process.  Many 
antibiotics currently on the market originate from fungi, such as penicillin and 
streptomycin.  It is widely recognized that as a result of the symbiosis of fungi 
and algae and/or cyanobacteria, a range of compounds often distinct from those 
produced by the individual substituents are produced, despite lichens having 














1973; Culberson, 1969). Furthermore, the promising bioavailability of the lichen-
derived L17-3 suggests that, in comparison to compounds from higher plants 
with substituents easily recognized by mammalian enzymes in vivo making them 
prone to being metabolized, lichens may in fact produce antibiotic substances 
with more favourable drug-like properties.  This work therefore indicates that the 
unique compounds produced by lichens represent a largely untapped source of 
pharmacologically interesting antimicrobial substances. 
 
The most promising hit compounds discovered in this study, were L17-1 and 
L17-3 derived from the lichen, T. chrysophthalmum, with potent in vitro anti-
Staphylococcal activity and low cytotoxicity.  As a means of determining which 
compound exhibited the most promising in vivo bioavailability, an initial 
experiment was designed in which the two compounds were administered in 
combination at 10mg/kg each to mice and the pharmacokinetic parameters 
evaluated from four sampling time points to a maximum of seven hours.  This 
was made possible by collecting only 10µl samples from each experimental 
animal at each time point, negating the need to sacrifice an animal for each 
sampling point.  With the use of sensitive LC-MS/MS technology, these initial 
results showed that L17-3 was available at greater quantities after oral and 
subcutaneous administration to mice than L17-1, reaching a Cmax concentration 
of 14.5µg/ml at 3 hours after oral dosing.  Furthermore, the mice displayed no 
signs of toxicity on administration of the two compounds in combination at 
10mg/kg each.   
 
Based on these initial results, L17-3 was selected for further pharmacokinetic 
evaluation.  Three groups of mice were further dosed orally, subcutaneously and 
intravenously with 5mg/kg of compound and evaluated up to 96 hours, collecting 
10µl of blood from each animal per sampling time point.  The mice appeared to 
be briefly adversely affected after IV dosing at this concentration, but were not 
affected by oral and subcutaneous administration.  As to be expected, the IV 














oral, which exhibited similar values of 25.9 and 25.4.  The subcutaneous group 
achieved a Cmax of 4.4µg/ml at 3 hours and the oral group a Cmax of 2.8µg/ml at 
3.4 hours.  L17-3 exhibited a relatively good half life of 3 and 3.3 hours after oral 
and IV dosing respectively.  The absolute bioavailability after subcutaneous and 
oral administration was 41.7 and 40.7% respectively. 
 
The lack of sampling time points directly after dosing up to one hour is a 
weakness of this experiment.  However, with the data in hand, it is evident that 
L17-3 reaches a Cmax level after oral dosing at 10mg/kg only slightly lower than 
the in vitro MIC of 15.6µg/ml.  It is conceivable that increasing the oral or 
subcutaneous dosing to above 10mg/kg will achieve bloodstream levels of above 
the in vitro MIC, making it theoretically possible to clear a Staphylococcus aureus 
infection in vivo.  When one considers that the in vitro IC50 of this compound is 
0.7µg/ml, it is possible that prolonged or repeated exposure of sub-lethal doses 
of antibiotic to gradually clear the infection could in fact be beneficial in the 
treatment of a systemic bacterial infection. 
 
An obstacle to natural product-based drug discovery is the length of time 
required to isolate large enough quantities of compound to enable in vivo efficacy 
and bioavailability work. From a methodology perspective, this project has shown 
the utility of bioavailability testing of relatively small quantities of compounds or 
fractions considered to be hits from in vitro high throughput screening before 
performing efficacy work in animal models of disease.  Furthermore, it provides a 
more ethical alternative to immediately testing efficacy in an animal model of 
disease, as many compounds with in vitro activity will not be bioavailable and by 
association, good lead-like compounds.  Based on the pharmacokinetic 
information gained, L17-3 was shown to be a better lead-candidate than L17-1 
early on in the drug discovery process, displaying bioavailability at higher 
concentrations in the blood as well as a longer half-life.  This information has 
enabled the research to focus on the more bioavailable compound.  Based on 














systemic S. aureus infection in an animal model of disease.  However, future 
work will involve determining the bioavailability of L17-3 immediately after dosing 
as well as obtaining the chemical structures of these two compounds.  In the 
event of promising data as a result of this work, efficacy studies will be 
considered to assess the ability of this lead-candidate to clear either a systemic 




















Materials and methods 
  
7.1 Chemicals and reagents 
Analytical grade petroleum ether, dichloromethane, ethyl acetate, methanol and 
acetone used for extract preparation were obtained from KIMIX (Cape Town, 
South Africa) or Merck (Darmstadt, Germany) and distilled using a Buchi rotary 
evaporator.  HPLC grade LiChrosolv® methanol, water and acetonitrile were 
obtained from Merck (Darmstadt, Germany) .  Test samples were typically 
dissolved in dimethyl sulphoxide (DMSO) (uniLAB) and organism stocks were 
stored in glycerol uniVAR, both from Saarchem (Wadeville, South Africa).  
Formic acid (99%) was sourced from Merck (Darmstadt, Germany) while 
trifluoroacetic acid was obtained from Riedel-de Haën (Sigma-Aldrich, St Louis, 
USA). 
7.2 Broth micro-dilution assay 
Each plant extract was evaluated against a panel of drug-sensitive test 
organisms comprising of a Gram-positive bacterium, a Gram-negative bacterium, 
a mycobacterium and a fungus, as recommended by Cos et al. (2006).  The 
basic broth micro-dilution assay (Eloff, 1998a) was adapted for each organism, 
as described in sections 7.2.1 (mycobacteria), 7.2.2 (bacteria) and 7.2.3 (yeast) 
below.  The results are expressed in terms of a minimum inhibitory concentration 
(MIC) defined as the lowest concentration at which no visible organism growth is 
present.  An MIC was determined for a minimum of four replicates, performed in 
two separate experiments.  An IC50 value was further determined for active 
samples, defined as the value at which 50% of organism growth is inhibited.  An 
average IC50 value was determined from a minimum of four replicates performed 
in two separate experiments.  These IC50 values were determined for extracts 














62.5µg/ml or less, and for pure compounds with an MIC of 31.25µg/ml or less.  
For samples with strong colour interference, an IC 50 value could not be calculated 
and this information is stated in the results.  For active pure compounds, the 
minimum bactericidal or fungicidal activity (MBC or MFC), termed as the lowest 
concentration at which bacterial or fungal death occurs (Finberg et al, 2004), was 
determined.   
 
7.2.1 Antimycobacterial assay 
The method described by Chung et al. (1995) and  Eldeen and van Staden 
(2007) was used to determine the susceptibility of Mycobacterium aurum A+ to 
the test samples, with a few minor modifications.  The organism was stored at -
70°C in 20% glycerol and 500µl of this suspension was used to inoculate a 
Lowenstein-Jensen (LJ) slant, which was incubated at 37°C for one week, or until 
sufficient growth was obtained.  For the broth micro-dilution assay, a sterile loop 
was used to inoculate from the LJ into 5ml of Middlebrook 7H9 (DifcoTM, Becton 
Dickinson, Sparks, MD, USA) containing 10% OADC (oleic acid, albumin, 
dextrose, catalase; Becton Dickinson) and this inoculum was incubated overnight 
at 37°C.  For the assay, 7H9 Middlebrook medium was prepared at double the 
strength (1.88g in 160ml Millipore water) and autoclaved with 0.8ml glycerol at 
121°C for 15 minutes.  Once cooled, 40ml of OADC was added to the solution to 
yield a concentration of 20%.  This solution will be referred as 2x7H9.  A volume 
of 100µl of sterile distilled water was added to all the wells of a 96-well flat 
bottomed plate.  The test sample, prepared in a maximum of 10% DMSO at the 
desired concentration, isoniazid (Sigma-Aldrich, St Louis, USA) and solvent 
control were added at a volume of 100µl to the wells of column three.  A serial 
doubling dilution was then performed by removing 100µl from column three and 
resuspending it in the wells of column four, before transferring the same volume 
to column five.  This dilution series was affected from columns three to twelve.  
The remaining 100µl was discarded.  The M. aurum A+ inoculum was prepared 
by adding 1ml of an overnight culture into 20ml of double strength 7H9 with 20% 














(approximately 1 x 105 CFU/ml).  Each well was inoculated with 100µl of this 
suspension, excepting for the wells of column one, which received the same 
volume of organism-free medium.  In instances where sample quantities were 
low, the assay volumes specified above were halved to 50µl, with reproducible 
and accurate results.  The plates were sealed in plastic packets and incubated at 
37°C for 72 hours.   
 
After incubation, 40µl of 0.4mg/ml of p-iodonitrotetrazolium salt (INT, Fluka, 
Sigma-Aldrich, Steinheim, Austria) was added to each well of the microtitre plate  
and the plate was incubated for six hours.  The plate was visualized for the red 
colour produced in the presence of metabolizing organisms.  The MIC is termed 
as the lowest concentration of extract with no visible growth (red).  The value at 
which 50% of organism growth is inhibited, or IC 50, was determined for samples 
with no colour interference.  The wells of the 96-well plate were resuspended and 
read at 600nm on a Midas Microplate Reader (Turner BioSystems, California, 
USA). The cell viability was calculated for wells in a 96-well plate using the 
formula: 
 
% Cell Viability =           absorbance at 600nm test well (cells + drug)                 x 100 
          absorbance at 600nm cell control well (cells + no drug) 
 
GraphPad Prism Version 4.00 software was used to construct dose response 
curves using non-linear dose response curve fitting analyses from the 
percentage viability data (Microsoft Excel) of cells.  The concentration of the 
compound at which 50% of the cell growth was inhibited (IC 50 values) was 
determined from the dose response curves generated by GraphPad Prism.  Each 
















7.2.2 Antibacterial assay 
The method as described by Eloff (1998a) was utilized for testing of the Gram-
positive Staphylococcus aureus ATCC 12600 and the Gram-negative Klebsiella 
pneumoniae ATCC 13883.  A sterile loop was used to inoculate a tryptone soya 
agar (TSA, Oxoid, Basingstoke, England) plate from a 20% glycerol stock 
originally stored at -70°C.  The plate was incubated overnight at 37°C.  A single 
colony was picked from the plate and used to inoculate 5ml of sterile tryptone 
soya broth (TSB, Oxoid).  This inoculum was incubated overnight at 37°C.  The 
Middlebrook medium specified for the antimycobacterial broth micro-dilution 
assay was substituted with TSB, prepared as per manufacturer’s instructions.  
The assay inoculum was prepared by resuspending 100µl of the overnight 
culture in 20ml of TSB to yield an inoculum of approximately 105 CFU/ml.  The 
96-well plates were incubated at 37°C overnight, after which INT was added, as 
above.  The plates were incubated for three hours at 37°C and an MIC and/or 
IC50 value determined.  This method was also shown to be robust when 
decreasing the assay volumes by half, as with the antimycobacterial assay. 
 
To determine if an active compound exhibited bactericidal or bacteristatic effects, 
50µl of each well of the 96-well plate in which growth was not observed was 
plated out onto TSA quarter plates, as recommended by Cos et al. (2006), which 
were subsequently incubated overnight at 37°C.  The minimum bactericidal 
concentration (MBC), defined as the minimum concentration at which less than 
1% of growth is observed in comparison to the untreated control, was 
determined. 
7.2.3 Antifungal assay 
The NCCLS M27-A2 reference method for broth dilution antifungal susceptibility 
testing of yeasts (Clinical and Laboratory Standards Institute) was utilized, with 
the following changes.  A sterile loop was used to inoculate Soubaroud-dextrose 
agar (SDA, Oxoid) from a 20% glycerol stock containing Candida albicans ATCC 














in sterile RPMI medium   (Highveld Biologicals, Lyndhurst, South Africa) at pH 
7.0, prepared as per manufacturer’s instructions.  For the assay, 1ml of the 
overnight culture was used to inoculate 20ml of sterile double strength RPMI at 
pH7.0 to yield an inoculum strength of between 103 and 104 CFU/ml (Cos et al., 
2006).  The 96-well plate was prepared as described in section 6.2.1 and 100µl 
of inoculum added to each well.  The plate was incubated at 35°C for 48 hours, 
after which INT was added, followed by a further six hour incubation at 35°C.  
MIC and IC50 values were determined as described previously.  As with the 
antimycobacterial broth micro-dilution assay, the method also proved to be 
accurate when reducing volumes by half, as has similarly been shown by Rex et 
al. (1995a). 
7.3 Bio-autography 
Bio-autography is primarily used a means of pin-pointing active constituents of a 
complex sample, such as a crude extract (Nostro et al., 2000; Cos et al., 2006).  
In this project, bio-autography was performed with M. aurum A+, S. aureus ATCC 
12600, K. pneumoniae ATCC 13883, and C. albicans ATCC 90028.  In this 
investigation the use of direct bio-autography in the search for activity against C. 
albicans has been accomplished successfully, despite a previous report that 
suggested this method not possible, alternatively making use of agar-overlay 
bioautography (Hostettmann and Marston, 1994).  The inocula for each 
respective organism was prepared as described in sections 7.2.1, 7.2.2 and 7.2.3 
and applied by means of sterile cotton wool to a TLC plate dried of all mobile 
phase.  The TLC plate was placed on wet, sterile paper towel in a large Petri dish 
and sealed in a plastic packet to avoid dehydration.  The plate was incubated for 
24 (37°C), 48 (35°C) or 72 (37°C) hours for the bacteria, fungi and 
mycobacterium, respectively, after which it was sprayed with a solution of 
0.4mg/ml INT and allowed to develop for four to six hours at the appropriate 
temperature.  Active compounds were indicated by zones of inhibition against a 














from an organism-free reference plate, dissolved in the original extractant, and 
evaluated by means of HPLC. 
 
7.4 Antimalarial assay 
Testing against the malaria parasite, Plasmodium falciparum , was performed by 
Mrs Sumaya Salie under the supervision of Dr Carmen Lategan in the Division of 
Clinical Pharmacology, University of Cape Town.  The parasites were routinely 
cultured as described by Trager and Jensen (1976).  The in vitro parasite lactate 
dehydrogenase assay (pLDH) was performed according to the procedures 
described by Makler et al. (1993).  The control drug, chloroquine (Sigma-Aldrich), 
and the test samples were prepared at 2mg/ml in DMSO:water 1:9 (v/v).  For the 
96-well assay, a parasite stock solution of 2% hematocrit and 2% parasitaemia is 
prepared.  The wells of row one contain the assay ‘blanks’ consisting of 100µl of 
2% hematocrit and 100µl of complete medium (CM) (10% heat inactivated foetal 
calf serum, Highveld Biologicals,  Lyndhurst, South Africa + 45% Dulbecos 
modified Eagles Medium, Gibco, Auckland, New Zealand + 45% F-12 HAM, 
Sigma-Aldrich).  For the positive control in row two, 100µl of 2% parasitaemia 
and 100µl of CM is added to each well.  The test samples are added to the wells 
of row three in duplicate and 100µl of CM is added to rows four to twelve.  Serial 
doubling dilutions are then prepared from rows three to twelve, after which 100µl 
of 2% parasitaemia is added to all the wells of rows three to twelve.  The final 
volume in each well is therefore 200µl.  The plate is then placed in a gassing 
chamber, gassed for two minutes and incubated at 37°C for 48 hours. 
 
After incubation, the contents of each well are resuspended.   A volume of 100µl 
of Malstat (Sigma-Aldrich) is added to each well of a separate microtitre plate, 
followed by 15µl of the cell suspension.  Thereafter, 25µl of nitro blue tetrazolium 
salt (NBT) (Sigma-Aldrich)  is added.  Air bubbles are removed and the plate is 
kept in a dark cupboard while developing, after which the absorbance is 















7.5 Cytotoxicity assay 
Toxicity testing against Chinese hamster ovarian (CHO) cells was performed by 
Mrs Sumaya Salie under the supervision of Dr Carmen Lategan in the Division of 
Clinical Pharmacology, University of Cape Town. The cells were routinely 
maintained as adherent monolayers in 75cm3 culture flasks in CM.  The cells 
were incubated in a 5% carbon dioxide (CO2)-air humidified atmosphere at 37°C.  
The culture medium was changed every two to three days and the cells sub-
cultured once confluent, which involved digestion of the cellular matrix with a 1% 
trypsin solution. 
 
A volume of 100µl of a 105/ml cell concentration was added to each well, except 
those in row H (blank) in a 96 well plate.  The plates were incubated at 37°C for 
24 hours in a humidified atmosphere containing 5% CO2 after which the medium 
was carefully aspirated from the adherent cells and replaced with 100µl of the 
control and test compound dilutions. An initial stock of 2mg/ml emitine (Sigma-
Aldrich) , the positive control was prepared in Millipore water.  Six ten-fold 
dilutions of the positive control and test samples were prepared in CM on the day 
of experimentation.  Test samples were originally prepared at 2mg/ml in DMSO/ 
sterile distilled water 1:9 (v/v) and have a final test concentration range of 1ng/ml 
to 100µg/ml.  Each concentration was at least tested in duplicate.  100µl of CM 
was then added to all wells containing cells and test samples, and 200µl of CM 
was added to row H (blank) and column 2 (culture control).  The plate was 
incubated at 37°C for 48 hours. 
 
The MTT (3-[4,5-Dimethylthiazol-2-y]-2,5-diphenyltetrazolium bromide) (Sigma-
Aldrich) assay described by Mosmann (1983) was used to determine the effect of 
the test samples on mammalian cell survival and proliferation.  This colorimetric 
assay is based on the ability of cells to metabolize the yellow water soluble 
tetrazolium salt into a water-insoluble purple formazan product, thereby 














the metabolic activity and number of cells in the wells and was measured using a 
Midas microplate reader. 
 
After incubation, 25µl of sterile MTT (Sigma-Aldrich) (5mg/ml in PBS, Oxoid) was 
added to each well and the plate re-incubated for 4 hours at 37°C.  The plates 
were centrifuged for 10 minutes at 2050rpm and the supernatant aspirated from 
the wells without disturbing the formazan crystals.  100µl of DMSO was added to 
each well and the plate was gently shaken for 5 minutes on a microplate shaker 
to dissolve the crystals.  The microplate reader was set at a wavelength of 
540nm and the plate blanked on the wells in row H after which the absorbance of 
the formazan was measured.  The cell viability was calculated in each well using 
the formula: 
 
% Cell Viability =           absorbance at 540nm test well (cells + drug)                 x 100 
          absorbance at 540nm cell control well (cells + no drug) 
 
GraphPad Prism V.4.00 software was used to construct dose response curves 
using non-linear dose response curve fitting analyses from the percentage 
viability data (Microsoft Excel) of cells.  The concentration of the compound at 
which 50% of the cell growth was inhibited (IC 50 values) was determined from the 
dose response curves generated by GraphPad Prism.  Each data point 
represents the average of at least four wells of a microtitre plate from two 
experiments. 
7.6 High performance liquid chromatography 
All the methods used for the analysis and collection of extracts, fractions and 
compounds in this project were generated using a Waters 1525 Binary HPLC 
pump connected to a Waters 996 photodiode array detector controlled by 
Millenium32 version 4.00 software.  The sample was introduced by means of a 
Midas (Spark Holland) auto-sampler.  The column temperature was kept 
constant at 30°C.  Solvents were first fed through a Supelco degasser before 














by means of a Waters Fractions Collector III programmed according to elution 
time.   
 
7.7 Lichen materials and methods 
7.7.1 Collection of lichen material 
Lichen material was collected in Paarl, Swellendam and Tulbagh regions of the 
Western Cape of South Africa, predominantly within the Fynbos biome.  Further 
collections were also performed in the Eastern Cape Province of South Africa in 
the city of East London.  The collection details are specified in Table 2 and the 
lichen pictures are illustrated in Figure 10 in Chapter 2 ‘Lichens’.   Voucher 
specimens were prepared and are housed in the Lichen Collection of the Bolus 
Herbarium at the University o f Cape Town, Cape Town, South Africa. 
  
7.7.2 Lichen identification 
Lichens were genetically identified by Dr Tassilo Feuerer of the University of 
Hamburg (Germany), with the assistance of electron micrographs which were 
provided by Miranda Waldon at the Electron Microscopy Department of the 
University of Cape Town.  The electron micrograph images were obtained using 
a LEO S440 electron microscope with an electron high tension (EHT) probe of 
10kV and a working distance of 10 to 15 mm, as illustrated in Figure 9. 
 
Despite having the genetic sequences of the lichens available, a lichen from the 
Eastern Cape and another from the Western Cape are unknown, although the 
former was tentatively identified as a Parmotrema species on visual inspection by 
Dr E. Timdal (Natural History Museum, University of Oslo, Norway).  Seven of 
the ten collected lichen species are foliose lichens, while three, namely T. 
chrysophthalmum , U. rubrotincta and T. subuliforme, are classified as fruiticose 















7.7.3 Extract preparation 
The lichen material was rinsed with water to remove sand and debris.  The 
samples were then left to air dry before being finely ground with an electric 
grinder.  The ground material was then exhaustively extracted with acetone, as 
recommended in the literature (Eloff, 1998), on a Labcon laboratory shaker at 
room temperature.  Furthermore, for samples of which sufficient quantities were 
available, sequential extractions were prepared with solvents of increasing 
polarity (petroleum ether, dichloromethane, ethyl acetate, methanol and water).  
The extracts were dried under reduced pressure with a Buchi rotary evaporator 
and under nitrogen gas.  Water was removed from the extracts by means of a 
freeze-dryer.  The extracts were quantified, and  stored at -20°C until required. 
Together with the lichen samples, a finely ground sample of the roof tiles on 
which the lichens from the Eastern Cape were found growing was also extracted 
with acetone and concentrated to dryness as described above. 
 
7.7.4 HPLC profiles of lichen extracts and precipitates 
Each extract or precipitate thereof was prepared at a concentration of 20mg/ml in 
100% DMSO.  The common lichen metabolite, usnic acid (Sigma-Aldrich) was 
prepared at 1mg/ml in ACN/DMSO 1:1 (v/v) .   For the comparison of the acetone 
extract of the roof tiles and the ACN and PE fractions of the T. chrysophthalmum 
acetone extract, the samples were prepared at 2.5mg/ml in ACN/DMSO 1:1 (v/v).  
The samples were thoroughly vortexed to dissolve and then centrifuged to pellet 
insoluble extract.  Between 10 to 30µl of the supernatant was injected onto a 
Supelco Discovery reversed-phase C18 analytical column (4.6 x 150mm, 5µ 
particle size) coupled to a Waters HPLC run by Millenium Version 4.00 software.  
The mobile phase was run over 40 minutes from 10% ACN/ 90% 0.1% TFA in 















7.7.5 Bioactivity testing 
Lichen extracts were tested for activity against S. aureus ATCC 12600, K. 
pneumoniae ATCC 13883, C. albicans ATCC 90028 and M. aurum  A+ as 
described in Sections 7.2.1 to 7.2.3.  The active compounds were furthermore 
tested for cytotoxicity against CHO cells as described in the section 7.5.  
Fractions and compounds isolated from T. chrysophthalmum were also tested 
against the reference strain of methicillin-resistant S. aureus ATCC 43300 as 
described in Section 7.2.2 for the broth micro-dilution assay for drug-sensitive S. 
aureus. 
 
Crude extracts were prepared at 80mg/ml in 100% DMSO.  A ten-fold dilution 
was then prepared in sterile distilled water to 8mg/ml.  The samples were tested 
in duplicate against each organism from 3.9 to 2000µg/ml and activity was 
confirmed in a further experiment containing two replicates of each sample.  The 
highest concentration of DMSO in the assay was therefore 2.5%.  The ACN and 
PE fractions of T. chrysophthalmum had to be further diluted in sterile distilled 
water and were tested from 0.2 to 2500µg/ml. The pure compounds from the 
same species were prepared at 10mg/ml in 100% DMSO and diluted ten-fold in 
sterile distilled water to 1mg/ml.  These compounds were tested against two 
strains of S. aureus from 0.5 to 250µg/ml. Viable counts performed indicated that 
for testing against S. aureus ATCC 12600 an inoculum of 2.30 x 105 cuff’s was 
added to each well, while 2.25 x 105 cuff’s was added to each well for MRSA 
ATCC 43300.   
 
7.7.6 Isolation of compounds from Teloschistes chrysophthalmum 
7.7.6.1 Fractionation of the acetone extract 
The acetone extract of T. chrysophthalmum was subjected to liquid-liquid 
extraction with ACN and PE.  Briefly, 114mg of extract was alternatively 
dissolved in 50ml of ACN and 50ml of PE, which was combined and added to a 














distinct layers.  The two layers were collected and dried under reduced pressure 
and under nitrogen gas.   
 
7.7.6.2 HPLC collections 
The ACN fraction of T. chrysophthalmum acetone extract was prepared at 
30mg/ml in DMSO/ACN 2:1 (v/v).  The sample was then centrifuged at 5000rpm 
for five minutes and the supernatant removed from the pellet.  A volume of 30µl 
of this sample was injected onto a Supelco Discovery reversed-phase C18 
analytical column in an isocratic solvent system consisting of 58% ACN / 42% 
0.1% TFA in water over 20 minutes at a flow rate of 1ml/min.  By means of auto-
sampling, repeated injections allowed the collection of three HPLC peaks eluting 
at 10.9, 14.6 and 16.7 minutes with the use of a fraction collector.  The solvent 
was removed from the three samples under reduced pressure and the water with 
the help of a freeze-dryer.  The dried samples were frozen at -20°C until 
required.   
 
7.7.6.3 Nuclear Magnetic Resonance 
NMR spectral analysis was performed at the University of Stellenbosch, South 
Africa, on a Varian UnityInova 600 NMR spectrometer with a 1H frequency of 600 
MHz and 13C frequency of 150 MHz.  Two dimensional spectral data (GHSQC, 
GHMBC, GCOSY and DEPT) were also obtained.  The samples were analysed 
in deuterated chloroform with TMS as internal standard.  Due to the inability to 
resolve the structures of L17-1 and L17-3 from these one and two dimensional 
data, approximately 100µg of L17-3 was analysed by Dr Mary Grace of North 
Carolina State University (USA) on a Bruker 950mHz instrument to obtain 1H,  















7.7.6.4 Mass spectrometry 
Compounds L17-1 and L17-3 were prepared at a concentration of 10µg/ml in 
ACN/ 10mM ammonium acetate 1:1 (v/v) and infused from a 4.6 diameter 
Hamilton syringe in an external syringe pump at a flow rate of 10µl/min onto an 
API 2000 LC/MS/MS system (Applied Biosystems, MDS Sciex).  The compound 
masses were thereafter confirmed by high resolution LCMS performed at the 
University of Stellenbosch on a Waters API Q-TOF Ultima instrument at a flow 
rate of 300µl/min and an injection volume of 5µl of a 1µg/ml concentration of 
each compound. (ESI source; capillary voltage 3.5kV; cone voltage 35; RFI 40; 
source 100°C; desolvation temperature 350°C; desolvation gas 350L/h; cone gas 
50L/h).  The most likely elemental composition was also determined by means of 
single mass analysis. 
 
 
7.7.6.5 Compound  identification 
Despite having both 600 MHz and 900 MHz NMR spectral data, together with 
LC-MS/MS and HR-MS data, the structures of L17-1 and L17-3 could not be 
resolved.  Various futile attempts were also made to grow crystals for each 
compound at the Department of Chemistry, University of Cape Town (Cape 
Town, South Africa) with the aim of obtaining X-ray crystallography information.   
 
7.7.7 Fractionation of Xanthoparmelia semiviridis (Eastern Cape)        
7.7.7.1 Preparation of extracts 
Due to large sample quantities, sequential extractions were performed on X. 
semiviridis.  During the drying process, precipitates were noticed in the DCM, 
ethyl acetate and methanol extracts.  The drying process was halted and the 
sample centrifuged to pellet the precipitate.  The supernatant was then dried and 
stored separately.  The extracts and precipitates were all tested individually for a 















7.7.7.2  HPLC evaluation of the active extracts 
The petroleum ether extract and precipitate of the dichloromethane extract were 
evaluated by means of HPLC for the presence of usnic acid as described in 
Section 7.7.4.    
 
7.8 Materials and methods for desiccation-tolerant plants 
7.8.1 Plant collection 
Myrothamnus flabellifolius and Selaginella dregei (Family Selaginellaceae) were 
collected in the Mpumulanga province of South Africa by P.C. Zietsman (collector 
number 4354) in winter (July) in the vicinity of Belvedere near the Blyde River 
Canyon and voucher specimens NMB22617 and 22618 respectively were 
deposited in the herbarium of the National Museum in Bloemfontein, South 
Africa.  Xerophyta retinervis was also collected by P.C. Zietsman in winter (July) 
on a farm near Hoedspruit, Mpumulanga, South Africa (GPS coordinates 24° 20’ 
6.9 “E; 30°51’ 4.9 “S) and a voucher specimen NMB 22616 lodged with the same 
herbarium.  Cheilanthes contracta was collected in Autumn (April) near 
Swellendam in the Western Cape growing on a rocky outcrop (GPS coordinates 
30°5’ 3 “S; 20° 2’ 8 “E).  This species was identified by Dr J.P. Roux of the 
Compton Herbarium at Kirstenbosch National Botanical Gardens (Cape Town, 
South Africa) and is represented by voucher bar code 40283 lodged at the Bolus 
herbarium of the University of Cape Town (Cape Town, South Africa).  Pictures 
of these plants are shown in Figure 31. 
 
7.8.2 Extract preparation 
The plant material was allowed to air dry before being finely ground with an 
electric laboratory grinder.  For all the plants except X. retinervis, the whole plant 














were extracted separately.  The plants were exhaustively extracted with distilled 
petroleum ether, dichloromethane, ethyl acetate or acetone, methanol and finally 
water, on a Labcon laboratory shaker at room temperature.  An extra extraction 
was performed with distilled acetone for all the individual plant parts of X. 
retinervis as the yields of the first extraction process remained very low, possibly 
due to the fibrous nature of the plant material, even after grinding.  The samples 
were dried under reduced pressure using a Bucchi Rotary Evaporator and 
nitrogen.  Water was removed by freezing at -20°C and freeze-drying on a 
DuraDry MP freeze dryer.  Samples were quantified and stored at -20°C until 
required. 
 
7.8.3 Bioactivity testing 
7.8.3.1 Microtitre-plate assays 
Extracts and fractions were prepared at 80mg/ml in 100% DMSO and dissolved 
by vortexing and sonicating.  A ten-fold dilution was prepared in sterile distilled 
water to 8mg/ml and the samples were tested against S. aureus ATCC 12600, K. 
pneumoniae ATCC 13883, C. albicans ATCC90028 and M. aurum  A+ as 
described in Sections 7.2.1 to 7.2.3.  The samples were tested in duplicate from 
3.9 to 2000µg/ml and activity confirmed by duplicate testing in a separate 
experiment.  Fractions/compounds 21a to 21f arising from the ethyl acetate 
fraction of the methanol extract of M. flabellifolius were tested against S. aureus 
ATCC 1600 using the broth micro-dilution method.  These samples were 
prepared at a concentration of 1mg/ml in ACN/water 1:9 (v/v), resulting in a test 
concentration range of 0.5 to 250µg/ml.  Each sample was tested in duplicate in 
two separate experiments. The ethyl acetate and water fractions of the methanol 
extract of X. retinervis stems were prepared at 4mg/ml in DMSO/sterile distilled 

















Bio-autography, as described in Section 7.3, was used to test the bioactivity of 
several extracts and fractions.  Each extract was prepared in the original 
extractant.  The mobile phases used to effectively separate each extract/fraction 
on a TLC plate are described in Table 30 below. 
 
Table 30: The TLC conditions applied and the bioactivity tested for using the bioautography 
method. 
Plant Extract Fraction Mobile Phase  
M. flabellifolius PE, 2.5mg n/a toluene: ethyl acetate (8:2) 
M. flabellifolius DCM PE, 1.2mg toluene: ethyl acetate (4:1) 
M. flabellifolius DCM ACN, 1.2mg toluene: ethyl acetate (3:2) 
M. flabellifolius EA DCM, 0.4mg 
toluene: ethyl acetate:methanol 
(1:1:0.1) 
Abbreviations: PE - petroleum ether; EA - Ethyl acetate; DCM - dichloromethane 
 
7.8.4 Fractionation and isolation of compounds from M. flabellifolius 
7.8.4.1 Dichloromethane extract  
Fractions responsible for activity were identified from the DCM extract by means 
of bio-autography and these active bands were scraped from the reference TLC 
plates and dissolved in 1ml DCM with sonication for 5 minutes.  The samples 
were centrifuged for 2 minutes as 10800rpm and the supernatant removed.  The 
DCM was removed from each sample under nitrogen and the sample was 
dissolved in 50µl DMSO. 
 
A mass of 2g of DCM extract was further fractionated by means of liquid-liquid 
separation using PE and ACN.  Each fraction was concentrated to dryness under 
reduced pressure.  The ACN fraction amounted to roughly 32% of the original dry 
extract.  The ACN fraction was then prepared at a concentration of 150mg/ml in 
ACN/DMSO 1:1 (v/v) and centrifuged at 10000rpm for 5 minutes.  A volume of 
50µl of the supernatant was injected onto a semi-preparative Supelco Discovery 














was run at 2ml/min over a gradient from 50% ACN in water to 100% ACN over 
30 minutes, after which the column was washed with 100% ACN for 3 minutes 
and allowed to equilibrate in 50% ACN for 5 minutes.  Nine fractions were 
collected and dried of ACN under reduced pressure and of the aqueous phase by 
freeze-drying. 
 
7.8.4.2 Ethyl acetate extract  
Liquid-liquid extraction was performed on the ethyl acetate extract of M. 
flabellifolius using ethyl acetate and water, where after the ethyl acetate fraction 
was further fractionated using DCM and water.  The active zone (Rf of 0.13 to 
0.44) of the DCM fraction, as determined by bioautography, was scraped off of 
the reference plate and dissolved in 200µl ethyl acetate with sonication.  This 
mixture was centrifuged at 10800rpm for 2 minutes and the supernatant was 
removed from the silica and dried under nitrogen.  The sample was dissolved in 
DMSO and 50µl was injected onto an analytical reversed-phase C18 column (4.6 
x 150mm, 5µ particle size; Supelco, Discovery).  A gradient of 20% to 100% ACN 
in water was run over 40 minutes to obtain an initial profile. 
 
The above-mentioned TLC method was repeated on a larger scale.  The active 
TLC zone was scraped off and dissolved in ethyl acetate with sonication for 30 
minutes and centrifuged at 700rpm for 3 minutes to pellet the silica.  The 
supernatant was concentrated under reduced pressure and the remainder of the 
ethyl acetate removed under nitrogen.  Of a total mass of 144mg of DCM fraction 
applied to TLC plates, the final mass of the active band was 27.57mg (19.2% 
yield).  This sample was prepared at a concentration of 20mg/ml in 50% 
DMSO/ACN.  The sample was further fractionated by means of HPLC using a 
reversed-phase semi-preparative C18 column (250 x 10mm, 5µ particle size; 
Supelco Discovery).  An injection volume of 50µl was run at a flow rate of 
2ml/min at a gradient of 30 to 70% ACN in water over 30 minutes.  Eight fractions 














Figure 54: The HPLC profile at 210nm of the active TLC band originating from the DCM fraction 

















































7.8.4.3 Methanol extract 
The methanol extract was further fractionated by means of liquid-liquid extraction 
with ethyl acetate and water.  The ethyl acetate fraction was again concentrated 
to dryness under reduced pressure, while the water fraction was frozen at -20°C 
and dried on a freeze-dryer.  The ethyl acetate fraction was prepared to a 
concentration of 200mg/ml in 100% DMSO.  The sample dissolved completely.  
A volume of 40µl of this sample was injected onto a Supelco Discovery® semi-
preparative reversed phase C18 column (25 cm x 10mm) with a 5µm particle size.  
A gradient ranging from 18% acetonitrile in water to 30% acetonitrile over 30 
minutes yielded the best separation of peaks at a flow rate of 2ml/min.  This was 
followed by an increase to 100% ACN in three minutes, a three minute wash with 
100% ACN, a decrease to 18% ACN in three minutes and equilibration at this 
concentration for five minutes.  A Waters fraction collector was programmed to 
collect fractions as shown in Figure 55.  The ACN was removed from the 
fractions by evaporation under reduced pressure, followed by freeze-drying of the 























Figure 55: The HPLC chromatogram at 254nm of the ethyl acetate fraction of the methanol 
extract of Myrothamnus flabellifolius run at 2ml/min over a gradient of 18 to 30% ACN in 30 



































The purity of the fractions was determined using a Supelco Discovery analytical 
C18 column (150 x 4.6mm) with a 5µm particle size.  The mobile phase consisted 
of ACN and 0.1% TFA in water at a flow rate of 1ml/min.  A volume of 25µl of a 
5mg/ml (DMSO/ACN 1:1, v/v) concentration of each fraction was injected onto 
the system and run from 10% ACN to 50% ACN over 30 minutes.   
 
Fraction 21 resulting from the  HPLC separation of the ethyl acetate fraction of the 
MeOH extract was prepared at a concentration of 50mg/ml in 100% DMSO.  An 
injection volume of 20µl was added to an analytical C16 amide column (4.6 x 
150mm; particle size) and run over a gradient of 15% to 22% acetonitrile in water 
containing 0.1% TFA over 25 minutes.  This was followed by a three minute 
wash with 50% ACN after which the column was equilibrated for five minutes.  





















Figure 56: The HPLC profile of the subsequent collections from fraction 21 (semi-preparative 
HPLC) of the ethyl acetate fraction of the methanol extract of M. flabellifolius.  The dotted lines 































7.9 Materials and methods: Warburgia salutaris 
7.9.1 Plant material 
Plant material was provided by Mr Rodger Stewart of New Guelderland Sugar 
Estates (NGSE; KwaZulu-Natal, South Africa) where W. salutaris is farmed 
commercially to supply the traditional medicines trade.   
7.9.2 Extract preparation 
The dried plant material was finely ground with a laboratory grinder and 
subjected to sequential exhaustive extraction with dichloromethane, ethyl acetate 
and methanol on a Labcon laboratory shaker at room temperature.  The 
dichloromethane extract of the leaves was further fractionated with petroleum 
ether and acetonitrile.  Extracts were dried on a Buchi rotary evaporator and 
under nitrogen. 
 
7.9.3 HPLC profiling of crude extracts of W. salutaris 
Crude extract profiles were obtained by preparing the extracts at 30mg/ml in 
100% DMSO, centrifuging at 10 000rpm for 5 minutes, and injecting 30µl of the 


















150 mm; 5µ particle size).  A gradient of 10 to 100% ACN with water was run 
over 30 minutes, followed by a three minute wash at 100% ACN and an 
equilibration at 10% ACN for a total run time of 40 minutes at a flow rate of 
1ml/min.   
 
7.9.4 Fractionation of dichloromethane bark extract 
W. salutaris DCM bark extract was further fractionated using liquid-liquid 
separation with petroleum ether and acetonitrile.  The petroleum ether fraction 
(WSBD1); insoluble layer (WSBD2); ACN fraction separated into green ‘oily’ 
(WSBD4) and white component (WSBD3).  The chromatographic analysis of the 
fractions arising from the liquid-liquid separation of the DCM bark extract with 
ACN and PE (WSBD1-4) was performed under the same conditions described 
for the extracts, but the samples were prepared at 25mg/ml in 100% DMSO.  
Similar chromatographic profiles subsequently led to the combination of fractions 
WSBD3 and 4 to form WSBDA.  This fraction was separated on a Supelco 
Discovery reversed-phase C18 semi-preparative column using a gradient of 25 to 
100% ACN with water over 40 minutes at a flow rate of 2ml/min.  The column 
was washed at 100% ACN for three minutes and equilibrated for 14 minutes for a 
total run time of 60 minutes.  Eight fractions were collected, as shown in Figure 
57.  The sample was prepared at 30mg/ml in ACN/ DMSO 2:3 (v/v) and 














Figure 57: A chromatogram at 210nm depicting the eight collected fractions originating from the 
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Fraction six was subsequently further fractionated using an Agilent Eclipse XDB 
C18 reversed-phase column (4.6 x 150mm; 5µ particle size).  The sample was 
prepared at 20mg/ml in 100% DMSO, centrifuged at 10 000rpm for 5 minutes, 
and 30µl of the supernatant injected at a time.  An isocratic method at ACN / 
0.1% formic acid 45:55 (v/v) in water for 17 minutes at a flow rate of 1ml/min 
yielded seven well separated peaks which were subsequently collected. 
 
7.9.5 Compound identification 
NMR spectral analysis was performed at the University of Stellenbosch, South 
Africa, on a Varian UnityInova 600 NMR spectrometer with a 1H frequency of 600 
MHz and 13C frequency of 150 MHz.  Only three of the seven compound 
structures could be resolved based on comparison with spectral data in 
published reports. 
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In vivo materials and methods  
8.1 Ethics approval 
Ethics approval was obtained from the Animal Research Ethics Committee in the 
Faculty of Health Sciences at the University of Cape Town (HSFAEC 009/024) 
prior to commencement of in vivo experiments.  All work was based on 
guidelines for the ethical use of animals in research (Austin et al., 2004). 
8.2 Test animals 
Six to seven week old male C57/BL6 mice obtained from the University of Cape 
Town Medical School Animal Unit were used in this study.  Males were utilized 
as the intravenous administration was performed via the dorsal penis veins.  
Animals were caged in groups of five in filter top cages (30cm x 15cm x 15cm) 
with a constant supply of food and water.  Animals were monitored twice daily 
and at every time point on the days of experimentation.  At the completion of the 
study, animals were killed with 4% halothane and the carcasses were bagged, 
frozen and incinerated. 
8.3 Assay development for detection of compounds in 
whole blood 
8.3.1 Mass spectrometer optimisation 
Compounds L17-1 and L17-3 were each prepared at 10mg/ml in 1:1 (v/v) ACN 
and 0.1% formic acid in water as well as at 10mg/ml in 1:1 (v/v) ACN and 10mM 
ammonium acetate (Sigma-Aldrich) in water for scans in the positive and 
negative ESI modes respectively on an API 2000 mass spectrometer (Applied 
Biosystems, MDS Sciex) to search for the molecular ion of interest.  The 
compounds were infused into the mass spectrometer at a flow rate of 10µl/min 














spectrometer (Applied Biosystems, MDS Sciex) was also tuned to detect the 
molecular ions of L17-1 and L17-3 by preparing the compounds at 100ng/ml in 
1:1 (v/v) ACN and 2.5mM ammonium bicarbonate (Sigma-Aldrich) , infusing these 
solutions into the mass spectrometer at 10µl/min from an external syringe pump 
(Harvard Apparatus II Plus).   
 
The molecular ions of interest were best observed in the negative ion mode for 
both compounds and these were selected and further fragmented to form product 
ions, the most abundant of which were used to set the MS in the MRM (multi 
reaction monitoring mode).  The mass spectrometer was set to detect L17-1 
(386.9 ?  328.0) and L17-3 (400.9 ?  349.7) in the MRM mode on an API 2000 
mass spectrometer in a single method.  The instrument settings are summarised 
in Tables 31 and 32 below.  This method was developed on an API 2000 mass 
spectrometer and also applied to an API 4000 mass spectrometer for the 
purpose of greater sensitivity in the negative ion mode. 
 
Table 31: ESI settings for compounds L17-1 and L17-3 on an API 2000 LC-MS/MS 
Curtain gas (CUR) (arbitrary value) 20 
Collision gas (CAD) (arbitrary value) 5 
Ionspray voltage (IS) (volts) -4200 
Temperature (TEM) (°C) 450 
Ion source gas 1 (GS1) (arbitrary value) 50 
















Table 32: MS/MS settings for compounds L17-1 and L17-3 on an API 2000 LC-MS/MS 
Setting L17-1 L17-3 
Q1 Mass 386.9 386.9 400.9 400.9 
Q3 Mass 328.0 350.6 349.7 364.6 
Dwell time (msec) 150 150 150 150 
Declustering potential (volts) -41 -41 -26 -26 
Focusing potential (volts) -350 -350 -240 -240 
Entrance potential (volts) -3.5 -3.5 -5 -5 
Collision cell entrance potential (volts) -18 -18 -20 -20 
Collision energy (volts) -24 -22 -26 -22 
Collision cell exit potential (volts) -54 -58 -56 -58 
 
Two product ions (Q3 mass) were selected for each compound, one as a 
qualifier to ensure the detected peaks on LC-MS are not matrix-derived, and the 
other as a quantifier, used to determine the drug concentration. 
8.3.2 Chromatography development 
Liquid chromatography for the optimal separation of L17-1 and L17-3 in the same 
sample was achieved using a Phenomenex NX column (5µm particle size, 2mm 
x 5cm) and a flow rate of 300µl/min.  The mobile phase consisted of ACN and 
2.5mM ammonium bicarbonate run over a gradient of 32 to 77% ACN in 2.9 
minutes followed by an equilibration step of 32% ACN until 8 minutes.  L17-1 and 
L17-3 eluted at approximately 1.02 and 1.5 minutes respectively.  The 
temperature of the column compartment was maintained at 20°C and the 
autosampler temperature at 5°C.   
 
8.3.3 Extraction 
A liquid-liquid extraction procedure was developed for the retrieval of the lichen-
derived compounds from blood.  Firstly, a range of pH buffers was evaluated for 
the optimal extraction of compounds L17-1 and L17-3 from mouse whole blood. 
Mouse whole  blood was spiked with 25µg/ml of L17-1 and L17-3 from a 5mg/ml 
stock of each compound prepared in 100% DMSO.  Briefly, 50µl of Britton-














Figure 58: A flow diagram of the extraction method for L17-1 and L17-3 from mouse whole blood 
 
 
together with 250µl of ethyl acetate.  Each pH was tested in triplicate and 
samples were kept on ice at all times.  The samples were vortexed for 1 minute 
and centrifuged at 13000 rpm for five minutes.  A volume of 200µl of the top 
solvent layer was then transferred into an insert and dried under vacuum in a 
rotary evaporator for approximately 45 minutes, after which the samples were 
resuspended in 100µl of mobile phase (32% ACN/68% 2.3mM ammonium 
Vortex for 1 minute 
Centrifuge at 13000rpm for 5 minutes 
Transfer 200µl of the top layer to an insert in an eppendorf 
Dry in a rotary evaporator for 45 minutes 
Add 100µl of mobile phase 
(32% ACN / 68% 2.5mM ammonium bicarbonate) 
Vortex for 30 seconds 
10µl mouse whole blood 
+ 
50µl pH9 universal buffer 
+ 














bicarbonate).  The samples were vortexed for 30 seconds and 5µl of each 
sample injected onto an API 2000 LCMS (Applied Biosystems).  Based on the 
results of this experiment (section 5.2.1), pH 9 buffer was used for the extraction 
method.  The complete method is illustrated in Figure 58. 
  
8.3.4 Preparation of calibration standards 
Stock solutions of 250µg/ml of L17-1 and L17-3 were prepared in DMSO/ water 
5:95, v/v.  Calibration standards were prepared from these stocks by performing 
half dilutions in mouse whole blood.  Each concentration was prepared in 
triplicate ranging from 12ng/ml to 25µg/ml for L17-1 and 1.53ng/ml to 25µg/ml for 
L17-3.  These samples were extracted using pH9 Universal buffer as described 
in section 8.3.3 together with unspiked whole mouse blood, which was finally 
resuspended in mobile phase spiked with 6.25µg/ml of L17-3.  A volume of 20µl 
of each sample was analysed on an API 2000 LCMS under the conditions 
described in sections 8.3.1 and 8.3.2 to allow for quantification of results for the 
initial in vivo experiment described in section 8.4 below.  Furthermore, a volume 
of 5µl of each sample was analysed on an API 4000 LCMS under the same 
conditions described in sections 8.3.1 and 8.3.2 to generate a calibration curve 
on this instrument for the quantification L17-1 and L17-3 in the initial in vivo 
experiment as well as for L17-3 in the bioavailability study described in section 
8.5. Calibration standards were included in each batch of test samples analysed. 
 
8.4 Initial bioavailability study of lichen compounds 
administered together in mice 
An initial in vivo experiment was performed by administering compounds L17-1 
and L17-3 combined in a single dose by means of two administration routes, 
namely orally and subcutaneously.  This experiment was performed on three 
animals in each group to provide an indication as to the level of absorption of 














8.4.1 Oral dose 
Each of the two compounds was prepared at 20mg/ml in 100% DMSO and then 
further diluted to 2mg/ml in sterile distilled water.  Equal volumes were combined 
to prepare a mixture containing 1mg/ml of each compound.  A volume of 200µl of 
this solution was administered by gastric gavage to three healthy mice to yield a 
dose of approximately 10mg/kg (average mice mass of 20g).  The mice were 
closely observed for potential toxicity.  Samples were collected at one, three, five 
and seven hours by making a nick in the end of the tail and collecting 10µl of 
blood which was immediately added to 50µl of pH7 buffer in an eppendorf on ice.  
The samples were vortexed and frozen at -20°C until extraction.  The extraction 
procedure as described in section 8.3.3 was performed with one exception in that 
pH7 buffer was utilized instead of pH9.  A volume of 20µl of each sample was 
analysed on an API 2000 LC-MS/MS. 
8.4.2 Subcutaneous dose 
The two compounds were prepared as described above  for the oral dosage and 
a volume of 200µl of the mixture was administered to each of three healthy mice 
subcutaneously.  Once again, the mice were closely observed for any signs of 
toxicity.  Samples were collected at three, five and seven hours as described 
above for the oral dose and extracted and analysed as described in section 
8.4.1. 
8.5 Bioavailability study of L17-3 in mice 
From the results of the initial in vivo study in which L17-1 and L17-3 were co-
administered, it appeared that L17-3 was more bioavailable than L17-1 and 
therefore the former was used for continued in vivo investigation.  Furthermore, 
the high levels of L17-3 observed in the bloodstream over a relatively long period 
of time, lead to a lower concentration being administered in further experiments. 
8.5.1 Oral dose 
L17-3 was prepared at 5mg/ml in 100% DMSO after which a ten-fold dilution was 














A volume of 200µl of this solution was administered by gastric gavage to five 
healthy mice.  Mice were closely observed for any signs of toxicity and were 
weighed on each day of testing.  A nick was made on the end of the tail vein at 
each time point and 10µl of blood collected and added to 50µl of pH9 Universal 
buffer.  Samples were taken before administration of the compound and after 1, 
3, 5, 8, 12, 24, 48, 72 and 96 hours.  The samples were frozen at -20°C until 
extraction as described in section 8.3.3 and analysis on an API 4000 mass 
spectrometer as described in sections 8.3.1 and 8.3.2. 
8.5.2 Subcutaneous dose 
L17-3 was prepared to 500µg/ml in 10% DMSO as described above and 200µl of 
this solution was administered subcutaneously to five healthy mice.  The mice 
were closely monitored for signs of toxicity and were weighed on each day of 
testing.  The blood samples were collected, stored, processed and analysed as 
described in the same manner as for the oral dosage. 
8.5.3 Intravenous dose 
The same stock of L17-3 as for the oral and subcutaneous doses was used for 
the intravenous administration.  Seven mice were used for this group to allow for 
any potential problems with the dosing procedure.  The animals were 
anaesthetized with a mixture of ketamine (120mg/kg) and xylazine (16mg/kg) 
after which 200µl of the test compound was injected under a microscope into the 
dorsal penis vain.  The mice were closely monitored for any signs of toxicity and 
were weighed on each day of the experiment.  The blood samples were 
collected, stored, processed and analysed as for the oral and subcutaneous 
doses. 
8.5.4 Data analysis 
WinNonlin® noncompartmental analysis (Version 5.2 Build 200701231637) was 
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A. Extract yields 
Table 33: The percentage yields of the acetone extracts of ten lichen species  
  Lichen 
Lichen mass  
(g) 




L1 Xanthoria parietina 0.761 0.014 1.827 
L8 Xanthoparmelia notata 2.644 0.223 8.424 
L11 Xanthoparmelia semiviridis (WC) 4.660 0.244 5.242 
L14 *Unkown1 (Parmotrema sp.) 2.036 0.423 20.786 
L15 Xanthoparmelia semiviridis (EC) 2.400 0.437 18.202 
L16 Flavoparmelia soredicans 1.217 0.225 18.488 
L17 Teloschistes chrysophthalmum 0.450 0.052 11.556 
L18 Unknown 2 (foliose soil lichen) 2.550 0.099 3.864 
L19 Thamnolia subuliforme 1.729 0.346 19.987 
L20 Usnea rubrotincta 1.602 0.091 5.686 
 
Table 34: The percentage yield of extracts of Xanthopharmelia semiviridis (L15) from the Eastern 
Cape  
Extract Sample mass (g) Percentage yield (%) 
Petroleum ether 0.592 0.311 
Dichloromethane 3.21 1.687 
Dichloromethane precipitate  0.996 0.523 
Ethyl acetate 3.754 1.973 
Ethyl acetate precipitate  1.343 0.706 
Methanol 26.085 13.707 
Methanol precipitate 2.736 1.438 
Water 1.254 0.659 























Table 35: The percentage yields of desiccation-tolerant plants 
Plant and mass Extractant Extract mass (g) Percentage yield (%) 
petroleum ether 3.421 3.421 
dichloromethane 7.504 7.504 




methanol 13.543 13.543 
petroleum ether 0.164 0.764 
dichloromethane 0.392 1.820 
acetone 0.346 1.607 
methanol 2.494 11.580 
Cheilanthes contracta 
21.5g 
water 0.235 1.090 
petroleum ether 0.280 0.135 
dichloromethane 0.992 0.479 
ethyl acetate 0.500 0.242 
methanol 1.877 0.907 
Selaginella dregei 
206.9g 
water 0.633 0.306 
petroleum ether 1.283 1.283 
dichloromethane 0.79 0.79 




methanol 2.025 2.025 
petroleum ether 0.390 0.537 
dichloromethane 0.803 1.108 
ethyl acetate 0.396 0.547 




water 4.084 5.633 
petroleum ether 1.400 1.186 
dichloromethane 0.682 0.578 
ethyl acetate 0.295 0.250 




















Table 36: The percentage yield of Warburgia salutaris dichloromethane and ethyl acetate 
extracts 
Plant part and mass  Extractant Extract mass (g) Percentage yield (%) 
dichlormethane 4.43 2.9 Bark  
151.2g ethyl acetate 0.36 0.2 
dichlormethane 34.05 6.8 Leaves  
497.4g ethyl acetate 2.98 0.6 
dichlormethane 4.21 2.7 Twigs  
153.0g ethyl acetate 0.76 0.5 
dichlormethane 2.47 1.2 Stem  
206.8g ethyl acetate 0.42 0.2 
 
B. HPLC chromatograms 
Figure 59: The HPLC chromatogram of the liquid-liquid petroleum ether fraction of W. salutaris 


































Figure 60: The HPLC chromatogram of the liquid-liquid petroleum ether fraction of W. salutaris 






































C. NMR spectra 
Lichen NMR 



















































































Figure 67: An expansion of the region from 2.25 to 2.7ppm on the 1H NMR spectrum of L17-3 
derived from T. chrysophthalmum obtained on a 900mHz instrument. 
 
 






















Figure 69: The 13C spectrum of L17-3 derived from T. chrysophthalmum  
 
 





















Figure 71: The 13C spectrum of L17-3 derived from T. chrysophthalmum  
 
 















Figure 73: The GCOSY correlations of L17-3 derived from T. chrysophthalmum  
 
 





















Figure 75: The GHMBC correlations of L17-3 derived from T. chrysophthalmum  
 
 




















Figure 77: The GHMQC correlations of L17-3 derived from T. chrysophthalmum  
 
 







































 Warburgia salutaris NMR 
Figure 80: The 1H NMR spectrum of muzigadial isolated from the dichloromethane extract of the 
bark of Warburgia salutaris. 
 
 
Figure 81: The 13C spectrum of muzigadial isolated from the dichloromethane extract of the bark 
















Figure 82: The 1H NMR spectrum of warburganal isolated from the dichloromethane extract of the 
bark of Warburgia salutaris 
 
 
Figure 83: The 13C NMR spectrum of warburganal isolated from the dichloromethane extract of 















Figure 84: The 1H NMR spectrum of ugandensidal isolated from the dichloromethane extract of 
the bark of Warburgia salutaris 
 
 
Figure 85: The 13C NMR spectrum of ugandensidial isolated from the dichloromethane extract of 
















D. In vivo bioavailability  
Figure 86: The in vivo concentration of L17-1 in each of three mice after oral administration at 































Figure 87: The in vivo concentration of L17-1 in each of three mice after subcutaneous 

















































Figure 88: The in vivo concentration of L17-3 in each of three mice after oral administration at 




























Mouse 1 Mouse 2 Mouse 3
 
 
Figure 89: The in vivo concentration of L17-3 in each of three mice after subcutaneous 



















































Table 37: The measured levels of L17-3 in five mice after oral administration at 5mg/kg.  Values 
are in µg/ml.  The LLOQ for L17-3 was determined to be 0.0244µg/ml. 
Hours Mouse 1 Mouse 2 Mouse 3 Mouse 4 Mouse 5 Ave Std Dev 
0 0 0 0 0 0 0 0 
1 2.29 2.61 2.47 1.25 1.99 2.122 0.5397 
3 2.85 3.02 3.22 N/A 3.26 3.0875 0.1900 
5 2.3 1.82 2.37 1.57 2.82 2.176 0.4903 
8 1.05 1.16 1.61 1.17 1.91 1.38 0.3658 
12 0.625 0.458 0.975 0.794 0.992 0.7688 0.2293 
24 0.00236 0 0.0288 0.0241 0.0151 0.014072 0.0128 
48 0 0 0 0.00363 0 0.000726 0.0016 
72 0 0 0 0 0 0 0 
96 0 0 0 0 0 0 0 
Abbreviations: N/A - not available; Std Dev – standard deviation; Ave - average 
 
Table 38: The measured levels of L17-3 in five mice after subcutaneous administration at 5mg/kg.  
Values are in µg/ml.  The LLOQ for L17-3 was determined to be 0.0244µg/ml. 
Hours Mouse 1 Mouse 2 Mouse 3 Mouse 4 Mouse 5 Ave  Std Dev 
0 0 0 0 0 0 0 0 
1 2.717 4.552 4.186 2.928 3.898 3.6562 0.7991 
3 3.652 4.695 5.017 4.074 4.303 4.3482 0.5314 
5 2.111 2.457 3.299 2.316 2.62 2.5606 0.4532 
8 1.466 0.833 1.239 0.628 0.91 1.0152 0.3345 
12 0.185 0.275 0.162 0.284 0.223 0.2258 0.0537 
24 0.003 0 0.007 0.003 0 0.0043333 0.0023 
48 0 0 0 0 0 0 0 
72 0 0 0 0 0 0 0 
96 0 0 0 0 0 0 0 
Abbreviations: Std Dev – standard deviation; Ave - average 
 
Table 39: The measured levels of L17-3 in five mice after intraveneous administration at 5mg/kg.  
Values are in µg/ml.  The LLOQ for L17-3 was determined to be 0.0244µg/ml. 
Hours Mouse 1 Mouse 2 Mouse 4 Mouse 5 Mouse 6 Ave Std Dev 
0 0 0 0 0 0 0 0 
1 7.341 7.228 3.856 2.811 4.412 5.1296 2.0497857 
3 7.452 4.515 5.191 5.856 7.081 6.019 1.2405142 
5 4.139 4.817 5.222 5.927 4.838 4.9886 0.6536469 
8 4.266 4.637 4.07 4.841 3.174 4.1976 0.6472544 
12 1.827 1.663 1.671 2.409 1.446 1.8032 0.3647893 
24 0.093 0 0.022 0.023 0.115 0.0506 0.0502125 
48 0 0 0 0 0 0 0 
72 0 0 0 0 0 0 0 
96 0 0 0 0 0 0 0 















E.  Lichen genetic sequences 





































































































































































Figure 99: The genetic sequence of Usnea rubrotincta (L20) 
 
CCGAGAGAGGGGCTTCGCGCTCCCGGGGGCTTCGGCCTCCACCTCTTCAC 
CCATTGCGTACTTACCGTTGTTGCTTTGGCGAGCCATAGGGTCCGCCTAC 
GCCGGCCTTGGGGCTGGTGAGCGCTCGTCAGGGGCCTTTCAAAACTCTGT 
TTTTAGTGACGTCCGAGTATAATACAAATCGTAAAAACTTTCAACAACGG 
ATCTCTTGGTTCCAGCATCGATGAAGAACGCAGCGAAATGCGATAAGTAA 
TGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGAACGCACATTGCG 
CCCCTCGGTATTCCGGGGGGCATGCCTGTTCGAGCGTCATTACACCCCTC 
AAGCGTAGCTTGGTATTGGGTCTCGCCCCTTGGGTGTGCCCGAAAAGCAG 
TGGCGGTCCGGAGCGACTTTGAGCGTAGTAAATTATCATCCCGCTTTGAA 
AGATCGGCTTTGGGCTAGCCAGAAACCCCAAATATTCTATAATNNACCTC 
GGATCAGGTAGGGANNCC 
 
 
 
 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 o
wn
